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Annotation
Doctoral thesis title: “Effects of retinoic acid on TGFβ2 protein and mRNA synthesis during early 
cardiovascular development in vivo and in vitro”.
 
 Clinical and basic research carried out during the last 50 years has established that vitamin A 
plays an important regulatory role in cell proliferation, differentiation as well as organogenesis in 
the developing embryo. Except for its role in vision, the functions of vitamin A are mediated by its 
physiologically active form, all-trans-retinoic acid (RA). 
 Vitamin A deficiency  as well as excess dramatically  influences the very early 
embryogenesis, especially cardiovascular development. Many genes, e.g. HoxB1, N-cadherin and 
transforming growth factor β2 (TGFβ2), that are involved in global regulation of embryonic 
development can be either up-regulated or down-regulated by vitamin A. 
 Heart is the first organ that develops during embryogenesis thus it is first  to be under 
influence of different regulatory factors, including deficiency or excess of vitamins. Numerous 
animal models have shown that vitamin A deficiency induces cardiovascular abnormalities and 
impaired development that leads to early embryo lethality.
 The use of the retinoid-deficient quail embryo in vivo model has revealed a time window at 
4/5 somite stage (ss) when RA is essential for further development. Studies presented as part of this 
thesis demonstrate a major role for TGFβ2 in posterior heart development in the inflow tract region. 
It was determined that: 1) complete vitamin A deficiency (VAD) in quail embryos in vivo is 
paralleled by  an extensive accumulation of TGFβ2; 2) the active form of vitamin A, RA, rescues 
heart development and down-regulates TGFβ2 mRNA synthesis as well as its protein production in 
the VAD quail embryo, and 3) suppression of TGFβ2 mRNA synthesis and protein activity in VAD 
embryos mimics the VAD rescue phenotype.
 Here we describe the development of an in vitro avian model that can be used to elucidate 
the molecular basis of the observations described above. In primary cell cultures from the heart 
forming regions (hfr) of 4-7 somite stage chick embryos RA, supplemented in 10 nM  and 100 nM 
concentration: 1) induces similar responses in the expression of TGFβ2 and HoxBI as were 
observed in vivo; 2) influences the expression of genes that  are regulated by  TGFβ2 through SMAD 
signaling pathway; and 3) induces the expression of the growth factor VEGF-A mRNA, one of the 
key factors for the differentiation of vascular endothelium. An antagonist  of RA, Ro 41 5253, 
induces an upregulation of TGFβ2. We conclude that primary cultures of chick embryo hfr cells can 
be used to elucidate the molecular mechanisms underlying the down-regulation of TGFβ2 gene 
expression by RA.
 Preliminary  results from human embryonic stem cell derived cardiac progenitor cell line 
suggest a response similar to that observed in the cultures of chick hfr cells, i.e. TGFβ2 transcripts 
being down-regulated in the presence of excess of RA; however, TGFβ2 protein level was not 
altered in these human cells.
 We conclude that there is an interaction between retinoic acid signaling and TGFβ2 
synthesis and signal transduction; more data are needed to understand the mechanisms involved. 
The interaction may be explored in several disease model systems that are characterized by  elevated 
levels of TGFβ2.
This work was conducted at Michigan State University (2003- 2005) and at the University  of Latvia 
(2008- 2010).
Key words: retinoic acid, cardiovascular morphogenesis, quail embryo, transforming growth factor 
beta2 (TGFβ2), primary embryonic cell culture
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Anotācija
Promocijas darba nosaukums: ”Retīnskābes ietekme uz TGFβ2 proteīna un mRNS sintēzi 
kardiovaskulārās sistēmas agrīnās attīstības stadijās in vivo un in vitro”
 Pēdējo 50 gadu pētījumi ir parādījuši, ka A vitamīns ir nozīmīgs šūnu dalīšanās, augšanas, 
diferencēšanās, kā arī orgānu veidošanās modulators/regulators mugurkaulnieku embrioģenēzes 
laikā. Fizioloģisko procesu regulācijā A vitamīna aktīvā forma ir retīnskābe (RA). 
 A vitamīna trūkums, kā arī pārdozēšana izsauc smagus embrioģenēzes traucējumus, īpaši 
ietekmējot kardiovaskulāro attīstību. RA regulē vairākos attīstības procesos iesaistītu gēnu, piem., 
HoxB1, N-kadherīns, transformējošais augšanas faktors β2 (TGFβ2) darbību. 
 Sirds ir pirmais orgāns, kas veidojas embrioģenēzē, tāpēc tās attīstībā var labi novērot 
dažādu attīstību regulējošo faktoru ietekmi. Izmantojot vitamīna A deficītus (VAD) dzīvnieku 
modeļus, parādīts, ka tā izarisītās sirds un kardiovaskulārās sistēmas anomālijas un attīstības 
traucējumi noved pie embrija bojāejas. 
 Izmantojot VAD paipalu embriju modeli (in vivo), ir noskaidrots, ka viens no kritiskajiem 
laika posmiem, kad RA klātbūtne ir nepieciešama embrija normālai attīstībai, ir tieši 4-5 somītu 
stadija (ss). Šajā pētījumā parādīts, ka TGFβ2 piedalās sirds apakšējās daļas attīstībā, īpaši 
ieplūšanas traktu morfoģenēzē. Pilnīgs A vitamīna trūkums VAD paipalu embrijos in vivo ir saistīts 
ar paaugstinātu TGFβ2 proteīna uzkrāšanos. RA pievienošana VAD sistēmā normalizē sirds attīstību 
un pazemina TGFβ2 mRNS sintēzi, kā arī proteīna produkciju. Inhibējot TGFβ2 mRNS un proteīna 
sintēzi VAD embrijos, var atjaunot normālu sirds morfoģenēzi arī bez RA klātbūtnes. 
 Mēs esam izveidojuši in vitro modeli, kuru var izmantot, lai noskaidrotu molekulāros 
mehānismus, kas ir atbildīgi par RA iedarbību uz TGFβ2 gēnu ekspresiju un sirds morfoģenēzi. 
Cāļa sirdi veidojošā rajona primāro šūnu kultūrās, kas iegūtas no 4-7 ss embrijiem, un kultivētas 
barotnēs ar RA novērots, ka RA (i) izraisa globālo regulatoro gēnu TGFβ2 un HoxB1 ekspresijas 
atbildi līdzīgi kā in vivo sistēmā, (ii) ietekmē TGFβ2/SMAD signālceļa mērķa gēnu ekspresiju, (iii) 
stimulē vaskulārā endotēlija augšanas faktora VEGF ekspresiju. RA antagonista (Ro 41 5253) 
klātbūtnē TGFβ2 mRNS un proteīna sintēze ir paaugstināta. Izmantojot cilvēka kardiovaskulārās 
sitēmas priekštečšūnas, noskaidrots, ka RA, līdzīgi, kā putnu in vivo un in vitro sistēmās, kavē 
TGFβ2 mRNS sintēzi. Pieaugušu cilvēku sirds šūnās šāda atbilde nav novērota. 
 Pētījumā noskaidrots, ka pastāv mijiedarbība starp RA un TGFβ2 signāla pārneses ceļiem un 
TGFβ2 sintēzi, tomēr dziļākai mijiedarbības analīzei nepieciešami vairāk datu. Ar paaugstinātu 
TGFβ2 līmeni saistītos slimību modeļos būtu vēlams pārbaudīt mūsu novēroto RA inhibējošo 
ietekmi uz TGFβ2 sintēzi. 
 Darbs izstrādāts Mičiganas Štata Universitātē (2003-2005) un Latvijas Universitātē 
(2008-2010).
Atslēgas vārdi: retīnskābe, kardiovaskulārās sistēmas morfoģenēze, paipalu embriji, 
transformējošais augšanas faktors-beta 2 (TGFβ2), primārās embrionālo šūnu kultūras 
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Abbreviations
ADH alcohol dehydorgenase
AKR aldo-keto-reductase
AO aorta
AP1 activating/activator protein 1
BCO-I β,β-carotene-15,15-monooxygenase
BMP bone morphogenic protein
cAMP cyclic adenosine monophosphate
cDNA complementary DNA
cM centimorgan
CNS central nervous system
co-SMAD common SMAD / SMAD4
CPCs cardiovascular progenitor cells
CRABP cellular retinoic acid binding protein
CRBP cellular retinol binding protein
CRE/ATF cAMP/activating transcription factor response element
CYP cytochrome
DMEM Dulbecco’s Modified Eagle Medium
DNA deoxyribonucleic acid
ECM extracellular matrix
EDTA ethylenediaminetetraacetic acid
EGF epidermal growth factor
EMT epithelial-mesenchymal transition/transformation
Endo endothelial cell growth medium Endo-Grow (Millipore/Chemicon)
Erk extracellular-signal-regulated  kinases / classical MAP kinases
FBS fetal bovine serum
FGF fibroblast growth factor
FN / FN1 fibronectin 
GTPase guanosine triphosphate hydrolase
hfr heart forming region
HH avian development stages according to Hamburger and Hamilton, 1951
HPLC high performance liquid chromatography
HUESC-24 human embryonic stem cell line 24
HUVEC human umbilical vein endothelial cels
IFT inflow tract
IGF insulin-like growth factor
IL interleukin 
INF interferon
JNK c-Jun N-terminal kinase
kb kilo base
KO-DMEM knock-out DMEM
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KO-SR knock-out serum replacement
LAP latency associated peptide
LRAT lecithin:retinol acetyltransferase
LTBP latent TGFβ binding protein
LTGFβ latent TGFβ
LV left ventricle
M-MuLV Moloney murine leukemia virus
MAPK mitogen-activated protein kinase
ME-OH methanol
MEFs mouse embryonic fibroblasts
MEKK1 MAPK/Erk kinase kinase 1
MH Mad-homology domains
mRNA messenger ribonucleic acid
MSC mesenchymal stem cells
NEO neogenin
OFT outflow tract
p/s penicillin/streptomycin
PAI-1 plasminogen activator inhibitor-1
PAR polarity protein 
PBS phosphate buffered saline
PCR polymerase chain reaction
PDGF platelet-derived growth factor
PFA paraformaldehyde
PPAR peroxisome proliferator-activated receptor
q long arm of a chromosome
R-SMAD receptor-regulated SMAD
RA / at-RA all-trans retinoic acid
RALDH/Aldh retinaldehyde dehydrogenase
RAR retinoic acid receptor
RARE retinoic acid response element
RBP retinol binding protein
RDH retinol dehydrogenase
REH retinyl ester hydrolase
Ro / Ro 41 5253 RA signaling antagonist
ROR retinoid-related orphan receptor
RORE retinoid-related orphan response elements
RPMI Roswell Park Memorial Institute medium
RV right ventricle
RXR retinoid X receptor
SA sinoatrial segment
SBE SMAD binding element
SDR short-chain dehydrogenase/reductase
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SHH Sonic Hedgehog signaling pathway
siRNA small interfering ribonucleic acid
Smurf SMAD-ubiquitination-regulatory factor
SP1 specificity protein 1
ss somite stage
STAT signal transducer and activator of transcription proteins
STRA6 Stimulated by Retinoic Acid gene 6
SV sinus venosus (inflow tract)
TAK1 TGFβ-activated kinase 1
TF transcription factor
TGFβ transforming growth factor β
TGFβR / TBRII transforming growth factor β receptor
THR thyroid hormone receptor
TNF tumor necrosis factor 
TRAF6 tumor necrosis factor α receptor-associated factor 6
TTR transthyretin
UTR untranslated region
VAD vitamin A deficient
VDR vitamin D receptor
VEGF vascular endothelial growth factor
VEGFR VEGF receptor
VSMC vascular smooth muscle cell
α-MEM α Minimal Essential Medium
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Introduction
 All multicellular organisms have the same basic cellular mechanisms of cell movement, 
induction, determination, pattern formation, expression of homeobox genes, and programmed cell 
death during their development. Vertebrate cardiovascular system is the first physiological organ 
system that develops and forms during embryogenesis. Many of underlaying mechanisms are 
considered to be developmentally and molecularly conserved. Two basic processes are involved in 
cardiovascular development: one that  drives morphogenesis (cell migration, proliferation and 
apoptosis), and one that is necessary  for functional development (cell differentiation and 
determination of cardiovascular tissue). Both processes are regulated by  the environment and 
signals within the embryo. These signals include vitamins, transcription factors, homeobox genes, 
cytokines, and different signaling molecules and pathways. 
 Vitamin A is crucial for vertebrate development and its insufficiency  has profound effects on 
early embryogenesis. The active form of vitamin A, retinoic acid, RA, regulates many  genes, 
including the ones involved in development. Animal models are an important tool to study early 
embryogenesis. Vitamin A deficient (VAD) animals develop various defects including an abnormal 
cardiovascular system that leads to embryo lethality. A cluster of RA regulated genes have been 
identified as participants in building the heart. RA regulation can be direct via binding to RARE 
sequences within target gene promoter or indirect through other unknown mechanisms.
 Transforming growth factors β make up a large multifunctional cytokine superfamily that 
are major regulators of normal growth and development in vertebrates. The expression of TGFβs 
and their cell surface receptors is universal and widespread throughout the development. Several 
VAD animal model studies have linked TGFβ2 to cardiovascular development. Targeted disruption 
of TGFβ2 in mouse leads to various abnormalities, mostly related to heart defects. The above 
considerations gives the rationale for testing the hypothesis that  RA is involved in the regulation of 
TGFβ2 synthesis and signaling during embryonic heart  development and that TGFβ2 is among 
downstream effectors in a RA signaling pathway for these processes.
 The aim of this study  was to identify the mediators of RA effects on inflow tract  formation 
during early cardiovascular development in vivo and in vitro. 
 To achieve this aim the following tasks were performed: 
- histological characterization of normal and VAD quail embryo sections;
- determination of the expression level of novel RA-regulated genes potentially involved in heart 
morphogenesis;
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- determination of the expression pattern and localization of TGFβ2 and TGFβRII in VAD quail 
embryos during early developmental stages;
- development of an in vitro system that could be used for further, detailed studies of the interaction 
mechanisms between RA and TGFβ2;
- determination of the effect of  RA on TGFβ2 protein production and mRNA levels;
- investigation into the effects of RA on TGFβ/SMAD signaling target genes and on genes involved 
in IFT formation;
- preliminary studies of the effects of RA on TGFβ2 in human cells from various developmental 
stages (adult heart cells, umbilical vein endothelial cells, early cardiovascular progenitor cells). 
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1. Literature Overview
1.1. Structure, metabolism and biological activity of vitamin A
 Vitamins are organic compounds required in small amounts by an organism and are involved 
in various fundamental body functions, including growth, maintenance of health and metabolism. 
Vitamins must be supplied by diet or as supplements because our bodies can not synthesize 
vitamins de novo (except for vitamin D). During 1900s, through experiments where animals were 
given different types of foods, scientists succeeded in isolating and identifying the various vitamins 
we know today. The fat-soluble vitamin A was discovered in 1913 by McCollum and Davis who fed 
purified diet with butter fat, egg yolk and lard or olive oil to a newly developed rat line (McCollum 
and Davis, 1913). Their subsequent findings demonstrated that fresh liver is rich in fat soluble-A 
(vitamin A) and water soluble-B and water soluble-C (McCollum et al., 1921). Soon it was 
discovered that yellow pigments of fruits and vegetables have similar nutritional effect. The first 
synthetic vitamin A (retinol) was made in 1947 by  the Dutch chemists van Dorp and Arens (Olson, 
1999).
 Research in mid 20’s and 30’s of the last century showed that any  imbalance, either 
deficiency or excess of vitamin A, dramatically changes differentiation of epithelial cells. Vitamin A 
plays an essential role in life of almost all chordates (invertebrate tunicates, lancelets and the 
vertebrates) in vision, in maintenance of epithelial surface, immune system, reproduction, 
embryonic growth and development. In humans the first  response to insufficient uptake of vitamin 
A is altered ocular features (xerophthalmia) as well as a generalized impaired resistance to 
infection. 
 Maternal insufficiency of vitamin A during pregnancy  in rats and pigs results in fetal death 
or offspring abnormalities with an obstructed development of cardiovascular and central nervous 
systems (Mason et al., 1935; Hale et  al., 1937; cit. from Zile, 2010). The critical early 
developmental stage for vitamin A requirement in the early avian embryo coincides with the first 
2-3 weeks of human pregnancy; heart formation may be severely compromised if maternal vitamin 
A intake is marginal or if there is interference with vitamin A function during pregnancy. While 
vitamin A deficiency is not prevalent in developed countries, the high incidence of vitamin A 
deficiency in developing countries may  account for the increased incidence of heart malformations 
in these populations (Zile, 2010).
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 Excessive intake of vitamin A is associated with reduced bone mineral density  and increased 
risk of hip fractures; excessive vitamin A intake during pregnancy is associated with embryonic 
malformations (Blomhoff and Blomhoff, 2006). The mechanism of action of retinoids is still poorly 
understood; many laboratories are working on different aspects of this important micronutrient.
 The term vitamin A is a general term for retinol, the alcohol form of the vitamin. It is stored 
in the ester form, most commonly as retinyl palmitate (Fig.1.1). The aldehyde form, retinal, is 
important for the function and maintenance of vision. The physiologically most important form of 
vitamin A is its acid form, retinoic acid that  functions at the gene level as a ligand for specific 
nuclear transcription factors that are involved in the regulation of fundamental biological activities 
of the cell. The term retinoids is currently used very broadly and includes both natural and synthetic 
compounds with vitamin A activity. 
1.1.1. Structure, chemistry and metabolism of vitamin A
 The body acquires vitamin A either as preformed vitamin A (usually as esters) from animal 
products (liver, kidney, egg, milk) or as provitamin A carotenoids (carrots, red peppers) that can be 
converted to vitamin A compounds in the body. All of these forms have beta-ionone ring (Fig.1.1) 
with an isoprenoid chain attached. The provitamin A, β-carotene, is the best source of vitamin A 
since it consists of two retinyl groups with β-ionone rings at  both ends of the molecule (Fig.1.1). It 
is cleaved by β-carotene-15,15-dioxygenase in human small intestine into two molecules of retinal 
(Nagao, 2004). More than 600 carotenoids have been characterized; only 50 of them are consumed 
in the human diet  and approximately  12 carotenoids account for most  of the dietary intake. They are 
found in measurable concentrations in human blood and tissues and include: α-, β-carotenes, 
lycopene, lutein and β-cryptoxanthin (Crews et al., 2001; Voutilainen et al., 2006). Some (α-, β-
carotenes), but not all (lycopene, lutein) carotenoids are able to produce vitamin A by an enzyme-
induced pathway in the intestine/or the liver. Retinal is formed by  central cleavage of the molecule 
and can be either reduced to retinol or oxidised to retinoic acid (Nagao, 2004). 
 Vitamin A as well as the provitamins A is fat-soluble; their absorption depends on the 
presence of adequate lipids and proteins in the meal. Deficiency of vitamin A can be due to 
intestinal disorders or disturbed lipid absorption. Only 3% of all carotenoids are absorbed and due 
to other metabolic reactions, only  a fraction of carotenoids is converted to vitamin A; thus 12 µg of 
β-carotene is needed to obtain 1 µg of vitamin A activity.
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Figure 1.1. Structures of natural retinoids and their metabolites. 
 There are three main points about the fate of carotenoids in human upper gastrointestinal 
tract. First, carotenoids can not be absorbed while they remain embedded in their original vegetable 
matrices, emphasizing the role of stomach in absorption and digestion process. Second, carotenoids 
have to be solubilized in mixed micelles to be absorbed. Third, carotenoids are mainly absorbed by 
duodenal mucosal cells and enterocytes within small intestine by  a mechanism involving passive 
diffusion, similar to that of cholesterol and the products of triglyceride lipolysis (Parker, 1996; 
Tyssandier et al., 2003). The rate of diffusion is likely determined by the concentration gradient 
between the micelle and the plasma membrane of enterocyte.
 β-carotene obtained from diet  in the enterocytes of the small intestine is first converted to 
the aldehyde form, retinal, that afterwards can be oxidized to retinoic acid or reduced to retinol (Fig.
1.2). Retinal is the major molecule after cleavage of β-carotene (Parker, 1996). Two types of 
cleavages are described in studies of β-carotene: central cleavage by β,β-carotene-15,15- 
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monooxygenase (BCO-I) and non-central cleavage (Napoli and Race, 1988; Parker, 1996). While 
central cleavage divides β-carotene molecule into half resulting in two all-trans-retinal molecules, 
non-central cleavage leads to the formation of two molecules of β-apo-carotenals with different 
chain length. The longer of the two molecules can subsequently  be shortened enzymatically into 
retinoic acid or retinal. The enzyme responsible for the asymmetric cleavage, β,β-carotene-9,10-
dioxygenase was cloned by  von Lintig and coworkers (Blomhoff and Blomhoff, 2006). Retinal in 
the intestine is reduced to retinol. In human intestine, retinol is almost  entirely  esterified with 16- 
and 18-carbon fatty acids for transport to the liver in chylomicrons.
Figure 1.2. Metabolism of vitamin A and provitamin A (Theodosiou et al.,  2010). BCO-I, β,β-carotene-15,15-
monooxygenase; CRBP, cellular retinol binding protein; LRAT, lecithin:retinol acetyltransferase; RBP, retinol binding 
protein; REH, retinyl ester hydrolase; TTR, transthyretin.
 Before the uptake by the enterocytes, dietary retinyl esters (e.g. retinyl palmitate) in the 
intestinal lumen are hydrolyzed to retinol by the pancreatic triglyceride lipase and intestinal brush 
border enzyme, phospholipase B (Harrison, 2005). The un-esterified retinol, when taken up by the 
enterocytes, is coupled with a specific binding protein, the cellular retinol-binding protein type II 
(CRBP-II). This complex serves as a substrate for re-esterification of retinol with long chain fatty 
acids (mainly palmitate) by lecithin:retinol acyltransferase (LRAT), while retinyl ester hydrolase 
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revert this process (Herr et  al., 1993; Parés et al., 2008). The role of CRBP-II is to protect retinol 
from degradation and to direct it to LRAT (Batten et al., 2004).
 Retinyl esters as well as uncleaved β-carotenes and small amounts of retinol are then 
incorporated into chylomicrons, the intestinal lipoproteins containing other dietary lipids, such as 
triglycerides, phospholipids, free and esterified cholesterol and apolipoprotein B (Roos et  al., 1998; 
Harrison, 2005; Blomhoff and Blomhoff, 2006). These large lipoprotein complexes (100-2000 nm 
in diameter) are then secreted from the enterocytes into the intestinal lymph and transported via 
circulation for storage to liver or delivered to other tissues (Blomhoff et al., 1990). Under normal 
dietary conditions much of dietary  vitamin A is absorbed via the chylomicron/lymphatic route. 
However, significant amounts of absorbed vitamin A are also secreted into portal circulation as 
unesterified retinol; it has been suggested that portal absorption is likely  important in pathological 
conditions affecting secretion of chylomicrons (Harrison, 2005; Blomhoff and Blomhoff, 2006). 
 After reaching the liver, chylomicron-retinyl ester complex is hydrolyzed in the 
parenchymal hepatocytes, but retinol is re-esterified by LRAT and stored in perisinusoidal stellate 
cells, called Ito cells (Fig.1.2, Hirosawa and Yamada, 1973; Hoover et al., 2008). These cells have 
high levels of cellular retinol binding protein type I (CRBP-I) and LRAT, which are important for 
the storage of retinyl esters. Fifty to 80% of total body vitamin A in humans is stored in the liver 
stellate cells as retinyl esters. Some retinyl esters are stored outside the liver as lipid droplets in 
lung, kidney and intestine. This extra-hepatic storage is important for extra supply of retinol to 
tissues with high and constant vitamin A demand. The cells in the pigment epithelium of eye require 
vitamin A to biosynthesize 11-cis-retinal (Fig.1.1) for normal visual functions (Blomhoff et al., 
1990; Blomhoff and Blomhoff, 2006).
 When required, stored retinyl esters in the liver are hydrolyzed, and the free retinol binds to 
its serum transport protein, the retinol binding protein (RBP). Most of retinol:RBP in circulation is 
associated with the thyroid hormone transport protein, transthyretin (TTR), and released into 
circulation to prevent elimination by kidney (Buxbaum and Reixach, 2009). This complex delivers 
retinol (together with thyroid hormone) to target tissues (Fig.1.2). Liver is the main site of RBP 
synthesis; RBP recycles extensively between the liver, plasma and extra-hepatic tissues (Blomhoff 
and Blomhoff, 2006). The normal reserve of retinyl esters in the liver ensures a steady blood plasma 
retinol level in spite of fluctuations in daily vitamin A intake. Retinol is released from stellate cells 
to maintain constant physiological concentration in the plasma of 2 µmol/L. In addition to retinol 
and retinyl esters, other retinoids are found in plasma at nanomolar concentrations, such as all-
17
trans-retinoic-acid (RA); the concentration of RA in plasma and other body fluids is 5-10 nmol/L 
(De Ruyter et al., 1979; Eckhoff and Nau, 1990; Roos et al., 1998). 
 Liganded RBP (holo-RBP) delivers retinol to target tissues, where retinol undergoes 
multiple enzymatic reactions. The existence of a specific cell surface receptor for RBP was 
demonstrated in studies from 1970s, but only  recently this receptor was identified and found to be 
regulated  by STimulated by Retinoic Acid gene 6, STRA6 (Kawaguchi et al., 2007). STRA6 binds 
specifically to RBP and mediates retinol uptake from holo-RBP. Interestingly, STRA6 is broadly 
expressed in the murine embryo, but in the adult its expression becomes more restricted to stellate 
cells, peritubular pigment epithelial cells and embryonic carcinoma cells (Redondo et al., 2008; 
Theodosiou et al., 2010).
 It is generally believed that active vitamin A metabolites are synthesized within target cells. 
Retinol from plasma serves as a major source for this synthesis. Other lipoproteins containing 
retinyl esters, retinol and carotenoids as well as locally stored retinyl esters in lipid droplets in target 
cells or their neighboring cells also contribute to synthesis of active metabolites (Blomhoff and 
Blomhoff, 2006). The most active form of vitamin A is RA (Kastner et al., 1995; Ross et al., 2000; 
Balmer and Blomhoff, 2002; Blomhoff and Blomhoff, 2006; Niederreither and Dollé, 2008). The 
synthesis of this metabolite occurs in a two step reaction: oxidation of retinol to retinal and 
oxidation of retinal to RA. Cells are able to catalyze the reverse reaction from retinal to retinol, but 
are not capable of retinoic acid conversion back to retinal (Napoli, 1993).
 The first step of vitamin A cellular metabolism is hydrolysis of retinyl esters to retinol, then 
the reversible oxidation of retinol to retinal, catalyzed by cytosolic alcohol dehydrogenases (ADHs) 
and microsomal retinol dehydrogenases (RDH) of the short-chain dehydrogenase/reductase (SDR) 
superfamily (Fig.1.3, Parés et al., 2008).
Figure 1.3. Schematic overview on cellular retinoid metabolism (Parés et al., 2008). ADH, alcohol dehydrogenase, 
AKR, aldo-keto-reductase, CRBPI, cellular retinol binding protein type I, CYP, cytochrome P450, LRAT, 
lecithin:retinol acyltransferase, RALDH, retinaldehyde dehydrogenase, REH, retinyl ester hydrolase, SDR, short-chain 
dehydrogenase/reductase.   
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These enzymes use only free retinol. Retinaldehyde reductase activity has been detected in 
members of the aldo-keto reductase (AKR) superfamily (Parés et al., 2008). Retinol metabolism is 
catalyzed by the widely expressed ADH3 as well as the tissue-restricted ADH1 and ADH4. ADH1 
and ADH3 function in liver to stimulate degradative retinol turnover to retinal which prevents 
retinol toxicity, whereas ADH4 and ADH3 in peripheral tissues oxidize retinol to retinal to generate 
RA for signaling to nearby cells (Parés et al., 2008). While ADHs are cytosolic, SDRs are 
microsomal. The oxidation of retinal to RA is a cytosolic process thus ADH functions in RA 
synthesis; the retinal produced by SDRs may also be required for processes other than RA synthesis 
(Theodosiou et al., 2010).
 Retinal is irreversibly oxidized (Fig.1.3) to RA by various retinaldehyde dehydrogenases. 
Vertebrates have three RALDHs of the Aldh1A class (called RALDH1 or Aldh1A1, RALDH2 or 
Aldh1A2, and RALDH3 or Aldh1A3) that are essential for embryonic development as 
demonstrated in knock-out studies (Niederreither et al., 2001). This oxidation is generally believed 
to be the rate-limiting step in the biosynthesis of RA (Perlmann, 2002; Blomhoff and Blomhoff, 
2006). Data from all RALDH knock-out studies indicate that different mechanisms are used for RA 
synthesis by  different cells (Niederreither et al., 2001). RALDH1 is expressed at high levels in the 
dorsal retina of embryos and in several adult epithelial tissues, but knock-out studies demonstrate 
only minor expression in dorsal retina suggesting that this enzyme is not essential for RA synthesis, 
but is instead involved in the catabolism of excess retinol (Duester et  al., 2003). RALDH2 on the 
other hand is essential for RA synthesis, especially during embryonic development. Animal studies 
demonstrate the localization of RALDH2 in mesenchymal cells including trunk mesoderm, 
proximal limb bud, lung bud mesoderm as well as heart (Ulven et al., 2000; Niederreither et al., 
2001; Duester et al., 2003). RALDH3 is expressed in mouse and chick retina, lens and olfactory pit, 
as well as in ureteric buds and surface ectoderm over the developing forebrain. Mice RALDH3 
knock-outs die within the first 10h after birth due to defects in nasal development (Dupé et al., 
2003).
 Retinoic acid can be synthesized directly from β-carotene in intestine, liver, kidney and 
lung. This process does not require prior oxidation of β-carotene to retinol (Napoli and Race, 1988; 
Nagao, 2004). Thus β-carotene and other carotenoids may be a source of RA, especially in humans 
who are capable of accumulating high concentrations of tissue carotenoids (Blomhoff and 
Blomhoff, 2006).
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 After biosynthesis, RA can bind to the cellular RA binding proteins (CRABP-I and CRABP-
II) and migrate to nucleus (autocrine signaling) for receptor binding, or be transported to a nearby 
cell (paracrine signaling). In the absence of ligand, CRABP-II is found in the cytosol, but in the 
presence of RA it translocates to the nucleus, where the complex associates directly  with retinoid 
receptor complex and mediates ligand transfer from the binding protein to the receptor (Dong et al., 
1999). 
 Since RA in higher doses is toxic, a balance between biosynthesis and degradation is 
necessary  for the control of its levels in cells and tissues. Catabolism occurs mainly through 
enzymes of the CYP26 family and is initiated by  hydroxylation of the C4 or C18 position of the β-
ionone ring of RA leading to oxidized metabolite forms of RA such as 4-hydroxy-RA and 4-oxo-
RA. The cytochrome P450 enzyme (CYP26A1) was first cloned in zebrafish showing the ability of 
degradation of RA (White et al., 1997). This enzyme was afterwards cloned in the human, mouse, 
rat and chicken (Blomhoff and Blomhoff, 2006). It is localized at high levels in liver, duodenum, 
colon and placenta as well as in some regions of brain (Lampen et al., 2001). The proximal 
upstream promoter region of CYP26A1 gene contains a functional RA response element (RARE) 
sequence, therefore transcripts are induced by RA, demonstrating the mechanism through which 
CYP26A1 gene can sense the elevated concentrations of RA and regulate the oxidative metabolism 
accordingly  (Lampen et al., 2001; Hernandez et al., 2007). Some of the degradation products, such 
as 4-hydroxy-RA, 4-oxo-RA, 18-hydroxy-RA and retinol- and retinoic acid -β-glucuronide are 
reported to be biologically active (Reijntjes et al., 2005; Barua and Sidell, 2004). The water-soluble 
RA metabolites are excreted in bile and urine (Blomhoff and Blomhoff, 2006). In several studies of 
catabolism of retinoids by  analyzing urinary, biliary and fecal metabolites other, more polar 
metabolites have been detected, including decarboxylation, epoxidation and isomerization products 
(Blomhoff and Blomhoff, 2006). 
1.1.2. Biological activity of vitamin A 
 The major biological functions of vitamin A are in cell growth and differentiation. The 
requirement of vitamin A for normal embryonic and fetal development is known from many 
nutritional studies (Zile, 2004; 2010). Vitamin A also is essential for the formation and maintenance 
of many body tissues, such as skin, bone and vasculature, as well as for vision and immune function 
(Collins and Mao, 1999). In humans, the role of vitamin A extends to adulthood regulating fertility, 
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maintaining normal vision and preventing neoplastic growth and neurodegenerative disease 
(Niederreither and Dollé, 2008).
 Deficiency  of vitamin A (VAD) leads to blindness and infectious diseases, whereas less 
severe VAD results in retarded growth and iron deficiency  anemia (Theodosiou et al., 2010). 
Conversely, excess dietary vitamin A can result in toxicity to the liver, central nervous system 
(CNS), the muscle-skeletal system, internal organs, and skin (Collins and Mao, 1999). 
Hypervitaminosis A can lead to reduced mineral bone density, and increased risk for hip fracture, 
and to malformations of the developing embryo.
 Vitamin A is converted to its most active compound, RA, through which it regulates 
embryonic development and organogenesis, tissue homeostasis, cell proliferation, differentiation 
and apoptosis at the gene level. The developmental roles of RA have been studied using a range of 
vertebrate models including zebrafish, amphibia, chickens, quail and mice, demonstrating RA 
morphogenic actions. RA is one of the first morphogens identified (Ide and Aono, 1988; Mitrani 
and Shimoni, 1989). Morphogen is a substance that is active in pattern formation, the spatial 
concentration or activity  of which varies and to which cells respond differently  at  different 
concentrations. RA is a rapidly diffusing signaling molecule that can control gene expression 
through the activation of specific nuclear receptors thus specifying cell identities.
 The best understood function of vitamin A is its non-genomic role in vision. The human 
retina has two distinct photoreceptor systems: the rods, containing rhodopsin, which can detect low-
intensity light, and the cones, containing iodopsin, which can detect different colors. In the retinal 
pigment epithelium retinol can be converted to 11-cis-retinal that is transferred to the photoreceptor 
cells and works more like co-factor. This aldehyde form of vitamin A, 11-cis-retinal, is the 
prosthetic group on both visual proteins. The mechanism of vitamin A action in vision is based on 
the ability of the vitamin A molecule to photoisomerize (change shape when exposed to light). 
Thus, in the dark, low-intensity light isomerizes the rhodopsin prosthetic group, 11-cis-retinal, to 
all-trans-retinal. The changes in shape lead to a change in electrical charge generating an electrical 
signal that is transmitted via the optic nerve to the brain, resulting in visual sensation as light 
perception.
 Reproduction includes many processes: oogenesis, ovulation, spermatogenesis, fertilization, 
implantation, embryonic development, placental functions and fetal development. In mammalian 
experimental models, retinol is required at the placental stage. Once it  is inside the cells, it is 
converted to the active form RA that can then regulate differentiation and growth processes at gene 
level. The function of vitamin A for all reproductive processes is not clear.
21
1.1.3. General classification of genes regulated by retinoic acid 
 The pleiotropic effects of vitamin A are attributable to a multitude of RA-linked 
transcriptional pathways involved in numerous cellular processes, including embryonic 
development. Retinoic acid is among the most important signaling molecules in vertebrate 
ontogenesis.
 Different studies throughout the decades have gathered important  information regarding 
vitamin A and its functions at  the genome and proteome level in organisms. More than 500 genes 
have been reported as regulatory targets for RA signaling. However, not all of them have RAREs 
that are necessary for direct ligand-receptor heterodimer binding within their promoter region. Thus 
it is clear that many genes can be regulated indirectly  by RA as the result  of interaction with 
intermediate transcription factors or via other mechanisms.
 The known RA-regulated genes have been categorized and a classification table constructed 
consisting of four major categories (i.e 0-4) of genes based on approximately 2000 papers covering 
532 genes (Balmer and Blomhoff, 2002). This table summarizes the experimental evidence 
available for each target  gene and gives the degree to which the evidence supports or disproves the 
fact of direct regulation, at least in the cellular context.
 RA can influence gene and protein functions through several pathways. The predominant, 
classical pathway is the one where RA, when liganded to the RAR/RXR hetereodimer, directly 
interacts with its RARE, its DNA response element in the target gene. It must be clarified that genes 
in category 3 are as much RA target genes as those in category 0. There are 27 genes in category 3 
that are unquestionably regulated directly by RA. Category 2 contains 105 genes which can be 
affected less than 6 h after administration of 1µM  or less RA, but indicators for direct regulation 
(i.e. RARE) are lacking. As for most of the 133 genes in category 0, there are no data that these 
genes are regulated directly through the classical RA pathway. Some of these genes are doubted to 
be regulated at the transcriptional level. The remaining category 1 contains 257 genes that are 
regulated by  RA, but it  is still not clear if their regulation is direct or indirect. The authors of this 
gene table conclude that most of the RA-regulated genes are up-regulated (approx. 300) while fewer 
genes are down-regulated (approx. 120). However, the direction of transcriptional regulation varies 
depending on cell type or developmental stage of the organisms. Furthermore, there are no 
observations on a systemic regulation of genes by RA and it is not possible to arrange the RA-
regulated genes in clusters (Balmer and Blomhoff, 2002; 2005).
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1.1.4. Mechanism of action of RA
 With the exception for its role in vision, the pleiotropic effects of vitamin A are mediated by 
its physiological active form, RA, which functions as the ligand for it specific nuclear receptors, 
retinoic acid receptors (RARs) that form heterodimers with the retinoid X receptors (RXRs). 
Almost all nuclear receptors have two binding domains: DNA binding domain in their N-terminal 
and ligand binding domain in the C-terminal (Mangelsdorf et al., 1995; Xiao et al., 1995).
 The RARs were discovered independently in 1987 by two groups, i.e. the Evans (Giguere et 
al., 1987) and Chambon (Petkovich et  al., 1987) laboratories. There are three subtypes of RARs, i.e. 
RARα, RARβ and RARγ. Their amino acid analysis has higher conservation among different 
species than within given species. Each subtype has at least two isoforms generated by different 
promoters (P1 and P2), that have RARE. These isoforms can be transcribed using P1 or P2, also 
alternative splicing can result in different isoform, but these isoforms differ only in their N-terminal 
region (Germain et al., 2006a; de Lera et al., 2007). There are two major isoforms for RARα (α1 
and α2) and for RARγ (γ1 and γ2) and four isoforms for RARβ (β1, β2, β3 and β4). RARβ1 and 
RARβ3 are initiated at the P1 promoter whereas RARβ2 and RARβ4 are initiated at the P2 
promoter (Germain et al., 2006a). Subsequently, in 1990’s, a new subfamily of receptors, the 
retinoid X receptors (RXRs) and their subtypes, RXRα, RXRβ and RXRγ were cloned 
(Mangelsdorf et al., 1990; 1992). There are two major isoforms for each RXR subtype, e.g. RXRα1 
and RXRα2 (Germain et al., 2006b). The RARs and RXRs are expressed differently  throughout the 
development and their separate roles still remain unclear (Xiao et al., 1995; Germain et al., 2006 
a,b).
 The RARs function mainly as heterodimers with RXRs, i.e. as RAR/RXR and act as ligand-
dependent transcriptional regulators by binding to the specific RARE DNA sequences found in the 
promoter region of retinoid target genes. The highest  affinity  ligand for RARs is all-trans-RA 
whereas for RXR another isoform, 9-cis-RA appears to be the best activator, but the physiological 
role of this RA isoform is still unclear (Germain et al., 2006b). RXRs also regulate transcription in 
heterodimeric complexes with the vitamin D receptor, VDR and the thyroid hormone receptor, 
THR, and are also necessary for efficient binding to DNA of the peroxisome proliferator-activated 
receptors (PPARs), that are involved in multiple aspects of fatty  acid metabolism, (Ziouzenkova and 
Plutzky, 2008). 
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 RAREs consist of two or more direct repeats of directly repeated hexameric degenerate 
copies of (A/G)G(G/T)TCA or more relaxed (A/G)G(G/T)(G/T)(G/C)A half-site motifs separated 
usually  by five or two nucleotides (Balmer and Blomhoff, 2005). RAR/RXR heterodimers are able 
to regulate transcription not only from DR5 (direct repeat with a five-nucleotide spacer), but also 
from DR2 and DR1 elements (Durand et al., 1992). RXR homodimers recognize RXREs that have 
only one nucleotide spacing in between direct repeats (De Luca, 1991; Xiao et al., 1995).
 RARs carry out their functions through the recruitment of different regulatory  proteins, i.e. 
the co-activators or co-repressors which are not exclusive for RARs but  are capable to bind with 
other DNA-binding proteins (Xiao et al., 1995). The binding of RA to its receptors releases the co-
repressors or results in the recruitment of co-activators. Receptor/co-activator complexes induce 
histone acetylation resulting in chromatin decompression and an increase in target gene expression. 
Opposite process takes place when the receptor associates with a co-repressor leading to histone 
deacetylation and chromatin compaction and a decreased gene expression (Jetten, 2009; Rochette-
Egly  and Germain, 2009). Deletion or silencing of the expression or of the production of RARs 
often results in an effect similar to that seen in vitamin A deficiency (Cui et al., 2003).
 Data about RA regulated genes have been summarized in a table (Balmer and Blomhoff, 
2002). Interestingly, more than 100 target genes are not regulated through the classical RAR/RXR 
binding to the RAREs. There is a wide range of genes that are regulated by RA and its receptors, 
but that lack the RARE sequence within the promoter. This has resulted in the search for potential 
different mechanisms, one of them suggesting protein-protein interaction. It has been well 
documented that an activated (liganded) RAR /RXR interacts with the activating protein 1, AP-1, a 
heterodimeric transcription factor composed of fos- and jun-related proteins involved in cell 
proliferation mechanisms (Pfahl, 1993; Zhou et al., 1999). This interaction leads to inhibition or 
alteration of the expression of genes that are regulated by AP-1, e.g. the transforming growth factor 
beta2 (TGFβ2) thus resulting in negative regulation (Noma et al., 1991; Blomhoff, 1997). For 
example, the anti-AP-1 activity  of RXRα as well as of RAR isoforms has been observed to inhibit 
three different AP-1 controlled promoters, i.e. in TGFβ1, collagenase and cFos (Salbert et al., 
1993). Moreover, the data from Evans lab (Schule et al., 1991) show that RA/RARα can form a 
non-productive complex with c-Jun providing the mechanism by which RA can limit cell growth 
and malignant progression (Schule et al., 1991; Rochette-Egly  and Germain, 2009). An example of 
such mechanism is the RA anti-cancer activity  in the treatment of acute promyelocytic leukemia 
patients. Since the addition of all-trans-retinoic acid to this therapy, approximately  72% of patients 
can achieve complete remission (Degos and Wang, 2001; Germain et al., 2006a,b). This number has 
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been increasing when all-trans-retinoic acid treatment was used together with arsenic trioxide, as up 
to 93% of these patients achieved 5-year overall survival rates; the survival rates are approaching 
100%. The question remains, why this treatment does not have such an effect in leukemia subtypes 
(Petrie et al., 2009).
 Another transcription factor, the specificity protein SP1, has been reported to associate with 
the RAR/RXR heterodimer and to bind to the SP1 specific site, called GC box element on target 
gene promoter sequences (Bouwman and Philipsen, 2002; Cheng et al., 2008).
 Ongoing research is devoted to discovering and describing other signaling mechanisms, 
especially those related to different isoforms of RARs. There are data that link RARs to RNA 
binding, as well as to translational regulation, phosphorylation and regulation of chromatin stability 
(see Rochette-Egly and Germain, 2009).
 The nuclear receptor discovery of the late 80’s lead to identifying many  so called “orphan 
receptors” that have a similar structure to other known receptors, but their endogenous ligands are 
unknown. The class of retinoid-related orphan receptors consists of three main isoforms, α, β, γ, that 
also regulate gene transcription by binding to DNA response elements (ROREs) consensus 
AGGTCA preceded by 6-bp A/T rich sequence in promoter region of target genes (Jetten, 2009). 
The data from non-denaturing mass spectrometry and scintillation proximity assays provide 
evidence that  RA and several other retinoids can bind to the RORβ and RORγ, but not to the RORα 
ligand binding domain, reducing RORβ-mediated transcriptional activity and inhibiting RORγ-
mediated transactivation (Stehlin-Gaon et  al., 2003; Wada et al., 2008; Jetten, 2009). However, 
other data show that RA can regulate RORs also through its classical signaling pathway involving 
binding with the RAR/RXR heterodimer and regulating ROR gene expression. Further studies are 
necessary  to determine whether RA is a genuine physiological ligand for these ROR receptors 
(Jetten, 2009). The RORs are involved in many developmental processes such as cerebral 
development and retina development, and are also critical regulators of thymopoiesis and 
development of several secondary lymphoid tissues (Jetten, 2009).
1.1.5. Role of RA in development
 Many nutritional studies with animals have shown the requirement of vitamin A for normal 
embryonic and fetal development as vitamin A deficiency or excess can lead to serious 
developmental abnormalities. Vitamin A in its active form as RA, can affect almost every organ and 
tissue if the embryo is treated with RA at critical time points during development (reviewed in Zile, 
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2001; 2004; 2010). Vertebrate embryos have the ability to metabolize vitamin A and generate at-RA 
but underlying cellular and molecular regulatory  mechanisms that  are affected by endogenous RA 
are not fully understood. It is important to understand the regulatory  mechanisms since RA is a 
strong morphogen and affects cell survival, proliferation, differentiation and organogenesis in 
developing embryos. Various developmental studies have been carried out in vivo (zebrafish, 
Xenopus laevis, chicken, quail and mice) to examine the role of vitamin A during embryogenesis 
and fetal development. These studies demonstrated that  RA and the RARs regulate the expression 
of many  developmental genes resulting in a wide range of functional alterations that include axial 
patterning, regional patterning of the central nervous system, neurogenesis, cardiovascular 
development, limb development and the formation of other organs (Niederreither and Dollé, 2008).
 Various strategies have been used to study retinoid signaling in early embryogenesis. One of 
the strategies is the gain-of-function approach and is used mostly to study the effects of RA excess 
in specific regions at specific developmental stages. Many  studies use concentrations significantly 
above endogenous levels, and thus they may  not reflect the physiological functions of vitamin A. 
Another strategy is the loss-of function approach involving the blocking of RA signaling, using 
antisense oligonucleotides to RA metabolism genes, or blocking the metabolisms of RA with 
monoclonal antibodies against RA (Romeih et al., 2003; Zhou et al., 1991).
 Among other approaches is the nutritional approach where retinoid signaling is switched off 
by the generation of vitamin A-deficient  embryos (Dersch and Zile, 1993), or the knock-out 
approach by the generation of transgenic mice via mutations or knock-outs of the RAR genes since 
their expression is widespread throughout different developmental stages (Luo et al., 1996; Ross et 
al., 2000; Rochette-Egly and Germain, 2009). Altering RA metabolism is another important and 
often used approach to examine the the physiological role of vitamin A in in vivo embryo models. 
This involves the interference with metabolism by knocking out genes of RA generating enzymes, 
such as Raldh2 (Niederreither et al., 2001; Ribes et al., 2005) and Raldh3 (Molotkova et al., 2007) 
or the genes of RA degrading enzyme Cyp26 (MacLean et al., 2007) or the generation of 
combination knock-outs of RAR/Cyp26 or Cyp26/Raldh2 (Niederreither and Dollé, 2008). 
However, there has always been a concern about incomplete silencing of RA signaling (discussed in 
Dupé and Lumsden, 2001), or in case of RARs, that they  do not provide a complete and clear VAD 
phenotype due to receptor redundancy (Iulianella and Lohnes, 2002) and the involvement of RXRs 
in other signaling pathways (Ross, 2000). Nevertheless, these studies have provided important 
insights into the various pleiotropic effects of vitamin A and have demonstrated the critical role of 
RARs in vertebrate development.
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 At this time, the only model showing the absolute essentiality of vitamin A for embryonic 
development is unambiguously  demonstrated in the vitamin A-deficient  (VAD) avian embryo. The 
completely VAD embryo develops gross abnormalities in the cardiovascular and central nervous 
systems and trunk that end with early  embryo lethality. Significantly, these embryos can be rescued 
leading to normal development by administration of the physiological ligand for RARs, all-trans- 
retinoic acid, or its precursor, retinol, at a certain time point during a critical stage in early 
development (Dersch and Zile, 1993; Zile, 2004; 2010).
 Crucial developmental decisions in the vertebrates take place during the neurulation stage 
(4-5 somite stage, ss), which is inaccesible to in vivo manipulations in mammals but easily 
accessible in the avian embryo. This developmental stage in the avian coincides with 2-3 weeks of 
human development. Although the RA synthesis system and its receptor transcripts are present 
before this crucial window, it is not until the time of initiation of RA requirement that the embryo 
first requires vitamin A (Kostetskii et al., 1998; Cui et al., 2003; Zile, 2004). Studies in the Zile lab 
have demonstrated that the RARα2, RARγ, and RXRα are the essential and required receptors to 
transfer RA signals at the 4-5 ss for avian embryonic development and survival (Romeih et al., 
2003).
 There are no master regulators in the heart development, but instead many signaling 
pathways are involved in the complex interactions to form the cardiovascular system from 
embryonic mesoderm and endoderm. Among the early signaling molecules are the superfamily  of 
transforming growth factors that include activins A and B, TGFβ2, TGFβ3, BMP2 and BMP4 
(Sporn and Roberts, 1992; Kingsley, 1994). This family of genes is also involved in cardiac left/
right determination as well as in pericardiac cell differentiation into cardiomyocyte lineage and 
vascular development. Strong evidence for TGFβ2 involvement in cardiac morphogenesis is 
provided by knock-out mice models that  develop multiple developmental defects including those in 
the heart  similar to those reported in the offspring of VAD rat (Wilson et al., 1953) and with the 
defects observed in RAR and RXR knock-out models (Mendelsohn et al., 1994; Sucov et al., 1994).
 Several transcription factors such as the GATAs-4/5/6, and the homeobox genes Nkx2.5, 
HoxB1 and Msx-1 have been linked to cardiac commitment and differentiation (Lyons, 1996). 
Interestingly, Nkx2.5 gene knock-outs have abnormal heart development and absence of heart 
looping, similar to the defects observed in VAD quail embryo. However, the expression of Nkx2.5 
is not altered in VAD quail embryos (Kostetskii et al., 1999).
 GATA genes regulate several cardiovascular developmental processes. GATA4 is required to 
allow cells to respond to cardio-inductive substances; it mediates BMP signaling by combined 
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action with Nkx2.5 (Pikkarainen et al., 2004). The posterior part of the heart tube has high levels of 
GATA4 transcripts (Jiang et al., 1998). This observation lead to the examination of the expression 
of GATA4 in VAD quail embryo, which does not form the inflow tract, the complex structure in 
posterior heart tube that links embryonic heart to the extra-embryonic vasculature. GATA4 is 
severely diminished in the heart-forming regions of the VAD embryo. In contrast, cardiac muscle-
specific gene expression involved in cardiomyocyte differentiation is not  regulated by RA signaling 
in vivo in VAD quail embryos (Kostetskii et al., 1999).
 Msx1 is known to be involved in heart  morphogenesis (Chen et al., 2007); it  has a RARE in 
its promoter region thus is sensitive to a direct regulation by  RA/RAR/RXR (Mangelsdorf et al., 
1995). The expression of Msx1 is down-regulated by  endogenous, physiological retinoids in vivo 
during early avian embryogenesis (Chen et al., 1995).
 N-cadherin, one of the cell adhesion molecules involved in cell assembly  and rearrangement 
during embryogenesis is crucial for cardiovascular development (Linask, 2003; Kostetskii et al., 
2005). Studies of N-cadherin expression in VAD quail embryos demonstrate its involvement in 
vascularization and heart  looping, but not in regulation of heart  asymmetry. Furthermore it  was 
shown that N-cadherin is negatively  regulated by RA; since its promoter region does not contain 
RARE, this regulation may be mediated by Msx1 (Romeih et al., 2009).
 RARs and RXRs are also important transcription factors linked to heart development as 
demonstrated in knock-out studies that report a wide spectrum of heart abnormalities (Ross et  al., 
2000). Studies with VAD quail embryos demonstrate that RARα2 has a distinct role in cardiac 
inflow tract formation, whereas RARγ regulates cardiac L/R asymmetry and looping (Romeih et  al., 
2003).
 In the VAD quail embryo, initially the embryonal and extra-embryonal vascular systems 
appear to develop normally; however, subsequently, the vascular networks are not maintained, the 
vitelline veins do not form and the endocardial tubes close, and thus there is no cardiac inflow tract 
(Zile, 2004; 2010). There is abnormal vasculogenesis in the VAD quail embryo correlated to 
diminished vascularization and this can be rescued by  administration of vitamin A to the VAD 
embryo (Dersch and Zile, 1993; Zile, 2004). Unpublished work (Zhou and Zile, 2010) suggests that 
the extracellular matrix protein fibronectin (FN) is regulated by  RA; this is of interest since 
treatment of embryos with an antibody to FN disrupts cell migration and causes abnormal heart 
development (Linask and Lash, 1988). Furthermore FN knock-out mice develop  abnormal but 
beating heart and defects in vasculogenesis (Watt and Hodivala, 1994).
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 While vitamin A via RA regulates many events during embryonic and fetal development, it 
has a crucial role during early embryonic development. There is a relatively limited time window 
when presence of the vitamin A active form, RA, is absolutely essential for normal cardiovascular 
development as well for initiating early developmental gene pathways that affect many aspects of 
the subsequent embryogenesis. Understanding how physiological levels of RA regulate different 
signaling pathways and target genes in various tissues at different time points is a challenge for 
further research.
1.2. Transforming growth factors
 The transforming growth factors betas (TGFβ) make up a large multifunctional extracellular 
cytokine superfamily of structurally similar proteins that  are major regulators of normal growth and 
development in vertebrates (Roberts and Sporn, 1992; Chang et al., 2002; Azhar et al., 2003; 2009; 
Hoover et al., 2008). There are more than 35 members of this superfamily in vertebrates; they 
include TGFβs, Activins, Inhibins, bone morphogenic proteins (BMPs), growth differentiation 
factors (GDFs), and the asymmetry molecules Nodal and Lefty (Kingsley, 1994; Hogan, 1996). The 
TGFβ superfamily  members as ligands can form homo- and hetero-dimers that bind to and activate 
two types of serine/threonine kinase receptors, which stimulate regulatory SMAD proteins to 
localize from cytoplasm to nucleus where they function as transcriptional regulators (Heldin et al., 
1997; Whitman and Raftery, 2005). TGFβs can signal through multiple pathways (to be described 
later in this section). TGFβ superfamily signaling is regulated at various levels, e.g. at extracellular 
binding and processing of TGFβs ligands and intracellular interactions of the receptors (Chang et 
al., 2002; Wu and Hill, 2009; Moustakas and Heldin, 2009). Abnormalities in TGFβ signaling lead 
to various defects and are linked to congenital heart disease, predisposition to cancer and 
cardiovascular pathogenesis (Euler-Taimor and Heger, 2006; Jiao et al., 2006; Gordon and Blobe, 
2008). The three isoforms of TGFβs 1, 2 and 3 exhibit a variety  of proliferative, inductive and 
regulatory functions (Sporn and Roberts, 1992) and have been linked to cardiovascular 
development (Azhar et al., 2003; Mercado-Pimentel and Runyan, 2007; Azhar et al., 2009). They 
have complex signaling patterns in the cardiovascular system (Euler-Taimor and Heger, 2006) and 
are potent  regulators of vascular development (Goumans et al., 2002; Bobik, 2006) and 
hematopoiesis (Larsson and Karlsson, 2005).
 In most of the scientific literature the term “TGFβ” is used loosely, without distinguishing 
between different isoforms, mainly to describe the functions of TGFβ1 since this isoform is the one 
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most studied. TGFβ2 is the isoform most strongly  linked to heart morphogenesis (McCormick, 
2001; Austin et  al., 2008). This is supported by observation in TGFβ2 knock-out mice that exhibit 
abnormalities in heart  development, which are the most prominent  among other defects as 
compared to those in lung, craniofacial, limb, eye and ear development (Dünker and Krieglstein, 
2000; Molin et al., 2004). TGFβ2 is also involved, in epithelial-mesenchymal cell transformation 
(EMT) during avian heart development (Romano and Runyan, 2000; Jiao et al., 2006; Mercado-
Pimentel and Runyan, 2007; Azhar et al., 2009).
 It is well known that in many cells RA regulates TGFβ signaling (Mahmood et al., 1992; 
Yoshizawa et al., 1998) with TGFβ2 being the most sensitive isoform to tissue retinoid levels (Glick 
et al., 1991). Inhibition of TGFβ signaling by endogenous RA is required for mouse lung 
development (Chen et al., 2007). On the other hand, RA-induced negative regulation of TGFβ2 
leads to altered EMT (described later), that is needed for septation in atrioventricular canal during 
heart morphogenesis (Romano and Runyan, 2000; Mercado-Pimentel and Runyan, 2007).
1.2.1. Molecular structure of TGFβs, LTBP and their receptors
 The three isoforms of TGFβ genes expressed in vertebrates are localized on different 
chromosomes. TGFβ1 occupies part of chromosome 19 (19q13.1) in human, chromosome 7 (7 
6.5cM) in mouse and chromosome 13 in chicken. TGFβ2 isoform lies within chromosome 1 (1q41) 
in humans, and in chromosome 1 (1 101.5cM) in mouse and chromosome 3 in chicken. The isoform 
TGFβ3 is located in chromosome 14 (14q24) in humans, chromosome 12 (12 41.0cM) in mouse 
and chromosome 5 in chicken. The chicken TGFβ2 gene consists of 7 exons and has several 
splicing variants (data from PubMed Entrez-Gene database).
 There are multiple TGFβ2 mRNA transcripts or approximately 3.0, 4.1, 5.1 and 6.5 kb in 
humans (Madisen et al., 1988) and mouse (Miller et al., 1989). In chicken there are three TGFβ2 
transcripts of size 3.9, 4.3 and 8 kb that are expressed differentially in developing chick embryos 
where 8-kb form is expressed at higher levels while in chicken chondrocytes and fibroblasts, 3.9 
and 4.3 kb forms are dominant (Jakowlew et al., 1990). Isolation and sequencing of human and 
mouse TGFβ2 cDNAs have revealed multiple potential poly-adenylation signals (Madisen et al., 
1988; Miller et al., 1989). It has been suggested that differential utilization of these signals in the 
3’-untranslated region (UTR) could generate the heterogeneity in transcript size (Webb et  al., 1988). 
Although it has been reported that RA increases the levels of TGFβ2 mRNA and protein in several 
cell types by a post-transcriptional mechanism (Glick et al., 1989), little is known of mechanisms 
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regulating transcription of TGFβ2 gene in vivo and in vitro. Collective studies of TGFβ2 gene 
structure in human and mouse cells suggest that  regulation of TGFβ2 expression occurs at multiple 
levels, including transcription, alternative exon splicing, and alternative utilization of poli A+ sites 
and post-transcriptional stabilization of mRNA (Noma et al., 1991).
 S1 nuclease protection analysis identified a transcriptional initiation site 1357 nucleotides 
(nt) 5’ of the methionine initiation codon (ATG) and TATA box was identified 30 base pairs (bp) 
from this transcriptional start site as is characteristic of many eukaryotic promoters (Noma et al., 
1991). Several AP1, AP2, CRE/ATF and SP-1 like DNA consensus sequence elements have been 
also identified surrounding the transcription initiation site (Noma et al., 1991). Studies with human 
TGFβ2 promoter demonstrate high levels of promoter activity within the DNA constructs 
containing nt between -508 to +63, whereas sequences between -778 and -508 nt modulated this 
promoter activity in a manner which was dependent upon the used cell line, suggesting the 
regulation of TGFβ2 being dependent of cellular background (Noma et al., 1991). The first study to 
identify a DNA element CRE/ATF necessary for transcription of TGFβ2 gene was conducted by 
O’Reilley and colleagues where they show that TGFβ2 promoter is regulated, in part; through a 
CRE/ATF binding site located 74 nt 5’ of the TATA box (O’Reilly et al., 1992). The consensus 
element of activating transcription factor (CRE/ATF) was originally identified as a segment of DNA 
that was able to confer cAMP responsiveness to the phosphoenolpyruvate carboxykinase (GTP) 
gene and has subsequently been shown to confer cAMP responsiveness to a variety  of genes 
(Roesler et al., 1988). This CRE/ATF sequence is necessary for basal gene expression. Comparison 
of TGFβ2 gene in human and in chicken revealed that although the coding regions are remarkably 
conserved between species, only the TAT and CRE/ATF elements are conserved in the promoter 
regions (Burt et al., 1991).
 The TGFβ family ligands, like typical secreted signaling molecules, are translated as pre-
proproteins that consist of signal peptide, pro-domain followed by the mature domain (Fig.1.4) 
(Padgett et al., 1997; Massagué, 1998). An amino-terminal signal peptide targets the precursor 
molecule to a secretory pathway whereas a pro-domain of variable length is involved for correct 
protein folding, dimerization of subunits and regulation of factor activity  (Kingsley, 1994; 
Massagué, 1998).
Figure 1.4. Structure of TGFβ family precursor molecules 
that are synthesized as pre-proproteins with signal peptide 
at N-terminal region targeting the molecules to the 
secretory pathway, followed by pro-domain and mature 
domain. Dibasic cleavage at RXXR motif leads to release of carboxy-terminal domain that homo- or hetero-dimerizes 
producing biologically active molecule (Böttner et al., 2000).
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Cleavage of pro-domain from the mature domain occurs at dibasic cleavage sites, RXXR motifs. 
During this process the carboxy-terminal fragment of 110-140 amino acids is released. Biologically 
active molecules are generated by homo- (characteristic for TGFβ2) or hetero-dimerization of these 
carboxy-terminal domains (Böttner et al., 2002). Six to nine conserved cysteine residues in the 
mature domain form intra-and intermolecular disulfide bonds characteristic of TGFβ family 
proteins (Padgett et al., 1997; Massagué, 1998). Eight cysteines in the TGFβ2 form four intrachain 
disulfide bonds. The dimer is stabilized by the ninth cysteine, which forms an interchain disulfide 
bond, and two identical hydrophobic interfaces (Daopin et al., 1992; Schlunegger and Grütter, 
1992).
 TGFβ is secreted as a biologically latent dimeric complex that contains the C-terminal 
mature domain and N-terminal pro-domain, LAP (latency associated peptide). The dimer is formed 
due to disulfide bond between two polypeptides of pro-domain. TGFβ is cleaved from its 
propeptide by furin-like endoproteinase during secretion (Koli et al., 2001; Kusakabe et al., 2008). 
Studies in cell cultures show the insensitivity of TGFβ2 to furin which is due to the tertiary 
structure of their LAP regions rather than their cleavage site (Kusakabe et al., 2008). The LAP 
propeptide remains associated with TGFβ dimer by non-covalent interactions. This complex is 
referred to as small latent TGFβ. The large latent TGFβ complex contains one of the four latent 
TGFβ binding proteins (LTBP) that is covalently linked to LAP (Fig.1.5). In most studied cell lines, 
it is found that TGFβs are secreted as large latent complexes (reviewed in Koli et al., 2001).
 LTBPs that belong to the LTBP/fibrillin-family of extracellular matrix (ECM) proteins are 
considered to have a central role in the processing, secretion and activation of TGFβs. There are 
four different LTBPs cloned (Koli et al., 2001). The structures of these glycoproteins are highly 
repetitive, mainly composed of epidermal growth factor (EGF)-like repeats, eight cysteine (8-Cys) 
repeats that are unique to this family, and also flanking regions containing proline-rich areas.
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Figure. 1.5. Schematic structure of the large latent 
TGFβ complex (Koli et al.,  2001). The small latent 
TGFβ complex contains the mature protein on the C-
terminal, and LAP (latency associated peptide) in its 
N-terminal. This structure is linked via disulfide bond 
to the third 8-Cys repeat of LTBP1 (Latent TGFβ 
binding protein 1). 
LTBPs are important for folding and secretion 
of TGFβ and they play a role in the 
localization of these complexes to the ECM 
and in the activation processes of TGFβs 
(Taipale et al., 1994). Additionally, LTBP1 
has functions as a chemo-attractant (Kanzaki 
et al., 1998) whereas LTBP2 has been reported as an anti-adhesive ECM  protein (Koli et al., 2001). 
The existence of four different LTBPs with only partial overlapping expression patterns suggests 
important functions in different tissues. LTBP1 is mainly  expressed in the heart, placenta, lung, 
spleen, kidney and stomach whereas LTBP2 is expressed in the lung, skeletal muscle, liver and 
placenta. LTBP3 and LTBP4 have similar expression patterns and are found in aorta, heart, small 
intestine and ovaries (Koli et al., 2001). Interestingly, in fetal tissues, LTBP1 and LTBP2 have 
higher expression than LTBP3 and LTBP4 (Saharinen et al., 1998).
 The central parts of all LTBPs are composed of a long stretch of 9 - 14 EGF-like repeats 
(Fig.1.5); this region is resistant to proteolysis (Taipale et  al., 1994; Saharinen et al., 1998). These 
repeats participate in protein-protein interactions and also provide stability  to protein structures via 
calcium binding (Koli et al., 2001). LTBPs mediate binding of all three TGFβ isoforms to 
fibroblast-like ECM matrices (Olofsson et al., 1992). The N-terminal parts and also parts of C-
terminus of LTBP are important in ECM/TGFβ association. The N-terminus contains 
transglutaminase substrate motifs. Transglutaminase is required for covalent ECM  association (Fig.
1.6; Nunes et al., 1997).
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Figure 1.6. Extracellular matrix and TGF-β (Gressner et al., 2007). Schematic presentation of intracellular TGF-β 
synthesis, secretion and extracellular immobilization via transglutaminase-dependent fixation of the large latent TGF-β 
binding protein (LTBP) to extracellular matrix,  release by proteases and activation of the latent TGF-β complex by 
reactive oxygen species (ROS), specific integrins,  thrombospondin-1 (TSP-1) or proteases with release of the active 
TGF-β homodimer, which binds to TGF-β receptors (TGFβR) III, II, and I to initiate the intracellular signaling cascade 
of Smad phosphorylation. Regulation of TGF-β occurs at the transcriptional level and, most importantly, by 
extracellular activation. LAP - latency associated peptide.
 LTBPs are produced in excess of TGFβ the secretion of which is inefficient in the absence of 
LTBP (Miyazono et al., 1991). Release of active TGFβ from the complex that is associated to the 
ECM, requires two steps, i.e. the release of complex from ECM  by proteolysis and an activation of 
TGFβ which can be achieved by different mechanisms. TGFβ regulates the cellular production of 
ECM components as well as the proteolytic balance thus maintaining the organization of 
extracellular structures (Koli et al., 2001).The major fraction of secreted LTBPs does not contain 
TGFβ (Miyazono et al., 1991). Cancer cells have often been found to produce abnormal amounts of 
TGFβ; they also fail to deposit  TGFβ complexes to the ECM, probably due to decreased fibronectin 
matrix in cancer cells and a decreased production of LTBP (Mizoi et al., 1993; Taipale et al., 1998). 
 The proteolytic release of TGFβ from ECM is driven by multiple proteinases of the serine 
protease family, including plasmin, mast cell chymase and leukocyte elastase (Taipale et al., 1995). 
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The released TGFβ is still in a biologically inactive form protected by  the domain consisting of 
EGF-like repeats forming well protected structure that can be activated by acidification or heat 
treatment (Taipale et al., 1994). Release from the ECM  involves the cleavage of the LTBP1 and 
LTBP2 at protease-sensitive sites (hinge region) whereas LTBP3 and LTBP4 are not cleaved at this 
region (Fig.1.6; Rifkin, 2004). Plasmin cleaves also LTBP2 thus releasing a large soluble protease-
resistant fragment (Hyytiäinen et al., 1998).
 Activation of latent TGFβ involves the disruption of the non-covalent interaction between 
the LAP and TGFβ, thus enabling TGFβ to bind its signaling receptors localized within the cellular 
surface. Two major mechanisms of activation of latent TGFβs are described in the literature; 
dissociation from LAP activates the TGFβs superfamily ligands and conformational changes such 
that the LAP is not released from its association with TGFβ complex but  exposes the TGFβ receptor 
binding site (Khali, 1999; Rifkin, 2004).
 The existence of different TGFβ isoforms, latent complexes, and LTBPs, suggests that there 
are multiple pathways for the activation of TGFβ. TGFβ can be activated in vitro by multiple 
physicochemical, enzymatic and drug-induced mechanisms (Koli et al., 2001). Physiochemical 
activation includes acidification of cellular microenvironment, changes in pH, irradiation and 
reactive oxygen species. From a physiological point of view, the acidic environment during wound 
healing could induce activation of TGFβ (Koli et al., 2001).
 Proteolysis targets the degradation of LAP pro-peptide and thus, the releases of active TGFβ. 
Mechanisms involving proteolysis are more diverse and more likely to operate in vivo. The 
proteolytic release of large, latent TGFβ from ECM may regulate local TGFβ activity either 
positively on negatively, depending on whether the substrate for activation is the soluble or matrix-
bound form of latent TGFβ (respectively) (Koli et  al., 2001). Also, LTBPs take a part  in proteolysis 
mediated TGFβ activation, since excess free LTBP or specific LTBP antibodies inhibit the 
activation process (Koli et al., 2001). Plasmin-mediated TGFβ activation can be neutralized through 
feedback inhibition, because TGFβ induces production of plasminogen activator inhibitor-1 (PAI-1) 
thus decreasing the formation of active plasmin (Laiho et al., 1986). Another ECM  protein, 
thrombospondin, a platelet  α-granule induced during wound healing, has been proposed to be 
involved in activation of TGFβ complexes via mechanisms that do not  involve cell surface 
proteases but induce changes in the conformation of LAP thus releasing active TGFβ (Ribeiro et  al., 
1999).
 Steroid hormone superfamily members are efficient regulators of the expression of TGFβ 
isoforms. TGFβs are likely to act as local mediators of the diverse actions of steroids, e.g. estrogens 
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and anti-estrogens can regulate TGFβ1 formation in different cells and tissues (Sporn and Roberts, 
1992). There have been reports of retinoid induced TGFβ activity (Glick et al, 1989; 1991). 
Retinoic acid and high calcium induce the expression of TGFβ2 in epidermal keratinocytes. Using 
neutralizing antibodies against TGFβ2, it has been shown that TGF β2 mediates the growth-
inhibitory effects of retinoic acid (Glick et al., 1991). However, recent reports show opposite 
retinoic-acid response of TGFβ2 in developing heart  in early embryogenesis of mouse (Li et al., 
2010) and chicken embryo (Romano and Runyan, 2000; Mercado-Pimentel and Runyan, 2007). 
High concentrations of vitamin D and its derivatives can induce the expression of the TGFβ in 
keratinocytes. Activity measurements indicate that a fraction of induced TGFβ is biologically  active 
without heat or acid treatments, but only  15% of the total, acid-activatable TGFβ was found to be 
active (Koli and Keski-Oja, 1993).
 The TGFβ superfamily  ligands signal through their receptors that belong to the family of 
transmembrane serine/threonine kinases. Based on their structural and functional properties, they 
are divided into three classes: TGFβRI, TGFβRII and TGFβRIII which include a ubiquitous 
extracellular β-glycan and the membrane glycoprotein endoglin (CD105) (Cheifetz et al., 1992; 
Kingsley, 1994). Beta-glycan binds to TGFβ2 with a greater affinity than other TGFβ isoforms and 
facilitates it interactions with TGFβRII/I complex, since TGFβ2 has lower affinity for TGFβRII 
than TGFβ1 and TGFβ3 (López-Casillas et  al., 1991; Wang et  al., 1991). In contrast, endoglin 
interacts with TGFβ1 and TGFβ3 isoforms, but has low affinity  for TGFβ2 (Cheifetz et al., 1992; 
Vincent et al., 1998). Beta-glycan belongs to the class of cell surface receptor molecules that 
regulate the access of ligands to the signaling receptors and contains heparan and chondroitin 
sulfate chains whose core protein binds to TGFβs (Cheifetz et al., 1992). Membrane-bound beta-
glycan positively  regulates TGFβ2 whereas a soluble form of beta-glycan found in serum and ECM 
(Andres et al., 1989) is capable of binding TGFβ2 with high affinity  thus inhibiting TGFβ2 
signaling (López-Casillas et al., 1994). Because of this dual action it has been suggested that beta-
glycan can be one of the TGFβ regulators in vivo (Esparza-López et  al., 2001). However there is 
evidence of TGFβ2 signaling in absence of TGFβRIII. A splice variant of the TGFβRII allows 
TGFβ2 ligand-receptor interaction in the absence of the TGFβRIII (Rotzer et al., 2001) as well as 
TGFβRII requires TGFβRI in order to bind the TGFβ2 (del Re et al., 2004).
 In mammals, only five type II receptors and seven type I receptors have been identified, 
whereas 29 ligands have been found (Heldin et al., 1997; Massagué, 1998; Derynck and Zhang, 
2003). TGFβ type I and type II receptors are glycoproteins and interact upon ligand binding. While 
TGFβRIII modulates ligand access to the signaling receptors, TGFβRI and TGFβRII are responsible 
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for signal transduction. Evidence from several studies led to the heterodimeric receptor model 
which postulates that TGFβRI requires TGFβRII for ligand binding and TGFβRI and the kinase 
activity of TGFβRII are required for signaling (Wrana et al., 1994). TGFβ1, TGFβ3 and activins 
bind type II receptor without requiring type I receptor, while BMP2, BMP4 and BMP7 bind 
primarily  to their type I receptors (Feng and Derynck, 2005). TGFβ2 interacts only  with the type II/
type I receptor combinations. Ligand binding to homomeric receptor dimers is not sufficient to 
activate signaling (Derynck and Zhang, 2003). Activation of TGFβRI and subsequent signaling 
requires phosphorylation of its Gly-Ser (GS) domain by TGFβRII in the heterodimeric complex. 
Ligand binding to the type II receptor can induce cytoplasmic domain autophosphorylation; 
however type II receptor signaling in the absence of type I receptors has not been reported (Derynck 
and Zhang, 2003). Phosphorylation provides the basis of downstream signaling (Wrana et al., 1994; 
Böttner et al., 2000).
1.2..2. SMAD dependent TGFβ signaling
 TGFβ/activin and BMP typically use different signal transduction pathways. TGFβ and 
activin must bind type II receptor that will phosphorylate type I receptor that will phosphorylate 
SMAD2 and SMAD3, allowing each to migrate to the nucleus, interact with SMAD4, and 
transcription factors or co-regulators, and stimulate TGFβ target genes. BMPs will bind to type I or 
type II receptor; signal transduction will be directed through SMAD1, SMAD5, or SMAD8 that 
will also interact with SMAD4 in the nucleus and regulate BMP target genes. SMAD proteins are 
intracellular components of the TGFβ signal transduction pathway. The first member of this family 
is MAD (mothers against decapentaplegic) which was identified in Drosophila melanogaster 
(Sekelsky et al., 1995). Other members of this family  were identified on the basis of their sequence 
homology  with MAD. Homologs in Caenorhabditis elegans have been named sma because the 
mutations in these genes resulted in smaller body size of larva. Vertebrate homologs of sma and 
MAD are called SMAD (Derynck et al., 1996). At least 10 vertebrate proteins have been identified. 
Members of this family play different roles in TGFβ superfamily  signaling. SMAD1, 2, 3, 5 and 8 
can be phosphorylated by TGFβRI after ligand-induced dimerization of TGFβRI and TGFβRII; 
therefore they are called receptor-regulated SMADS (R-SMAD) (Fig.1.7) (Massagué, 1998; 
Massagué and Chen, 2000). The phosphorylation of these SMADS leads to their localization from 
the cytoplasm to the nucleus, and enables them to interact with common SMAD4 (co-SMAD) that 
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form hetero-oligomers with R-SMADs and translocate into the nucleus upon the activation of 
signaling pathways (Fig.1.7, Massagué and Chen, 2000).
Figure 1.7. Schematic mechanism of TGFβ signal transduction through receptor and SMAD activation (Derynck and 
Zhang,  2003). Ligand binds to its receptors on cell surface, inducing the phosphorylation of receptor SMADs (R-
SMAD) that leads to oligomerization with common-SMAD (SMAD4) and translocation to the nucleus and binding to 
the promoter of target genes regulating its expression through physical interactions with other DNA binding 
transcription factors (X) and con-activators. Activation of R-SMADS is inhibited by SMAD6 or SMAD7. The R-
SMADs and SMAD4 shuttle between nucleus and cytoplasm. The E3 ubiquitin ligases Smurf1 and Smurf2 mediate the 
degradation of R-SMADs.
Interestingly, SMAD4 is not essential for TGFβ signaling as some TGFβ responses occur in the 
absence of SMAD4 and SMAD4 deficient cell lines have a limited responsiveness to TGFβ (Sirard 
et al., 2000). The R-SMADs and the co-SMAD consist  of conserved amino- and carboxy-terminal 
domains that form globular structures. Between these domains lies a linker region that interacts with 
prolyl-isomerases and ubiquitin ligases and that is enriched in prolines and phosphorylatable serines 
or threonines. With exception of SMAD2, the amino-terminal Mad-homology  1 (MH1) domains 
can interact  with other proteins and carries nuclear localization signals and a DNA-binding domain. 
The MH2 domain in C-terminus of R-SMADs can bind to type I receptors and can interact with 
other proteins, and it also mediates SMAD homo and hetero-oligomerization and mediates the 
transactivation potential of nuclear SMAD complexes receptor directed phosphorylation relieve 
these two domains (MH1 and MH2) from a mutually inhibitory interaction (Massagué and Chen, 
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2000; Derynck and Zhang, 2003; Moustakas and Heldin, 2009). R-SMADs and SMAD4 are 
expressed in most, if not all cell types; however they are differentially controlled during 
development. Since the C-terminal phosphorylation of R-SMADs allow them to associate with the 
co-SMAD, SMAD4, the resulting SMAD complex consist of a trimer of two R-SMADs and a 
single SMAD4 (e.g. SMAD2-SMAD-2-SMAD4 complex, a SMAD3-SMAD3-SMAD4 complex, 
or a SMAD2-SMAD3-SMAD4 complex), which then translocates to the nucleus where it bind to 
chromatin and regulate gene expression together with other transcription factors (Massagué et  al., 
2005). The SMAD-binding element (SBE) is defined as the sequence 5’-AGAC-3’or its reverse 
complement 5’-GTCT-3’ (Derynck and Zhang, 2003).
 The third class of SMADs includes inhibitory SMAD6 and SMAD7 and the only known 
function of them is to inhibit the signaling activity of R-SMADs. Inhibitory SMADs lack 
recognizable MH1 domain, but have MH2 domain (Derynck and Zhang, 2003). SMAD6 can inhibit 
BMP signaling, whereas SMAD7 inhibits both TGFβ and BMP signaling by occupying the TGFβRI 
for BMPs and TGFβs. SMAD6 inhibits signaling by  competing with co-SMAD for binding to 
receptor-activated SMAD1 and forms inactive SMAD1/SMAD6 complex (Massagué, 1998). 
SMAD6 and SMAD7 levels are elevated in response to BMP and TGFβ signaling thus these 
SMADs function as negative feedback controls for different pathways including TGFβ (Chang et 
al., 2000; Derynck and Zhang, 2003). Activation of the epidermal growth factor (EGF) receptor and 
possibly other tyrosine kinase receptors, interferon-γ signaling through STAT (signal transducer and 
activator of transcription) proteins, and activation of NF-κB by tumor necrosis factor α (TNFα), 
also induce SMAD7 expression, leading to inhibition of TGFβ signaling (Derynck and Zhang, 
2003). The Smurf1 (SMAD-ubiquitination-regulatory factor 1) and Smurf2, the HECT 
(homologous to the E6-AP carboxy terminus) family E3 ubiquitin ligases, also antagonize TGFβ 
signaling by interacting with R-SMADs and targeting them to degradation. Smurf1 interacts more 
with SMAD1 and SMAD5 which are BMP signal transducers, whereas Smurf2 interacts more 
broadly  with different R-SMADs, thus allowing interference with BMP and TGFβ signaling 
(reviewed in Derynck and Zhang, 2003).
 After ligand binding, the TGFβ receptors remain active for at least 3-4 h and continuous 
receptor activation maintains the SMAD complexes in the nucleus where they  regulate gene 
expression (Inman et al., 2002). Without ligand stimulation R-SMADS are localized in the 
cytoplasm, whereas SMAD4 is distributed in the nucleus and cytoplasm. In the nucleus, R-SMADs 
are constantly  dephosphorylated, resulting in disassociation of SMAD complexes and export 
inactive SMADs to the cytoplasm (Inman et al., 2002). In opposite to ligand dependent import of R-
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SMADs, SMAD4 continuously shuttles between nucleus and cytoplasm because of combined 
activities of a constitutively  active nuclear localization sequences in the MH1 domain and a nuclear 
export signal in the linker region whose activity depends on the nuclear transport receptor CRMI 
(Inman et al., 2002; Derynck and Zhang, 2003).
 SMAD phosphorylation of C-terminus of the type I receptor is the crucial point in SMAD-
dependent signaling, but other kinase pathways can further regulate SMAD signaling (Derynck and 
Zhang, 2003). The Erk mitogen-activated protein kinase (MAPK) pathway, stimulated by the 
activation of tyrosine kinase receptors and Ras can target R-SMADs. Erk MAPK phosphorylates 
the MH1 domain of SMAD2 and linker segments of SMAD1, SMAD2 and SMAD3 (Funaba et al., 
2002). Tyrosine kinase receptor activation and oncogenic Ras inhibit ligand-induced nuclear 
translocation of activated SMADs (Funaba et al., 2002). Phosphorylation of SMADs can also occur 
from the activation of MAPK/Erk kinase kinase 1 (MEKK1), which acts downstream from Ras and 
upstream from growth factor induced Erk MAPK and stress-activated SAP/JNK (c-Jun N-terminal 
kinase) pathways. MEKK1 activation enhances SMAD2 phosphorylation, heterodimerization with 
SMAD4, nuclear translocation and transcriptional activity  (reviewed in Derynck and Zhang, 2003). 
The induction of Erk MAPK and JNK signaling by  TGFβ itself may  regulate SMAD activation and 
signaling (Derynck and Zhang, 2003).
 Since the specificity between ligands and their receptors is only  partial, the functional 
specificity of TGFβs probably depends upon extracellular ligand activation, differences in 
intracellular SMAD interactions, interactions with other signaling pathways like Ras/MAPK, and 
interactions between SMADs and transcriptional co-activators and co-repressors (Ahzar, 2003).
1.2.3. SMAD-independent TGFβ signal transduction
 Other proteins mediate TGFβ signaling in addition to SMADs. In a breast epithelial cell 
culture model it has been demonstrated that  TGFβ activated TGFβRII phosphorylates the polarity 
protein PAR6, which regulates the local degradation of Rho, a small GTPase that controls assembly 
of intercellular tight junctions in mammalian cells and as these junctions dissemble, epithelial 
architecture disintegrates followed by EMT (epithelial-mesenchymal transition) that is regulated by 
TGFβ signaling (Moustakas and Heldin, 2009). While in the breast epithelial cell culture model 
TGFβ/PAR6 pathway  locally degrades Rho, other studies demonstrate positive activation of Rho 
GTPase signaling by TGFβ and BMP receptors in different cell types (Kardassis et al., 2009).
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Figure 1.8.  Schematic example of SMAD-independent TGFβ signaling (Xu et al., 2009). A, TGF-β activates p38 MAP 
K and JNK/MAPK signaling through the activation of TAK1 by receptor-associated TRAF6, and Erk MAP kinase 
signaling through recruitment and phosphorylation of Shc by the TβRI receptor. B,  activation of RhoA in response to 
TGF-β and induction of ubiquitin-mediated RhoA degradation at tight junctions.
Small GTPases control the early TGFβ signaling towards actin cytoskeleton reorganization via non-
SMAD pathways, whereas late cytoskeletal events are suggested to be directed by specific cross-
talk between SMAD-mediated transcriptional events involving up-regulation of Rho proteins or 
cytoskeletal proteins (Kardassis et al., 2009). This regulation is biologically  significant during the 
EMT process not only in embryonic development, but also in cancer cells.
 The TGFβRI directly  phosphorylates both serine and tyrosine residues in the ShcA adaptor 
protein thus inducing its association with adaptor protein (Grb2) and the Ras guanine exchange 
factor son of sevenless (Sos), that leads to activation of the Ras-Raf-MEK-Erk mitogen activated 
protein kinase (MAPK) signaling cascade, which can regulate cell proliferation and migration (Fig.
1.8) (Lee et  al., 2007). In addition, tyrosine kinase Src can phosphorylate Tyr2854 in the 
cytoplasmic domain of TGFβRII, leading to Grb2 and Shc recruitment and to activation of the p38 
MAPK pathway that promotes oncogenic signaling by TGFβ in malignant mammary epithelial cells 
(Galliher and Schiemann, 2007). Another example of non-SMAD signal transduction lies within the 
ubiquitin ligase tumor necrosis factor α receptor-associated factor 6 (TRAF6) recruitment to the 
TGFβRI cytoplasmic domain in mammalian cells. TRAF6 ubiquitylates and activates the catalytic 
activity of the TGFβ-activated kinase 1 (TAK1; MAP3K7), leading to activation of the p38 and c-
Jun N-terminal kinase (JNK) cascades, which regulate apoptosis or cell migration (Sorrentino et al., 
2008). The TGFβRI kinase activity is dispensable for this pathway (Sorrentino et al., 2008). The 
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interplay  between SMAD and JNK or p38 pathways could underlie diverse forms of integration and 
reciprocal regulation between TGFβ signaling and other pathways.
1.2.4. TGFβ and other pathway cross-talk
 Besides SMAD-mediated transcription, TGFβ activates other signaling cascades, including 
MAPK pathways. MAPKs, including Erk1/2, JNK1/2/3 and p38MAPKs are evolutionary 
conserved regulators that are essential for various cellular events. Many extracellular stimuli can 
induce the activation of serial phosphorylation from MAP kinase kinase kinase (MAPKKK) to 
MAP kinase kinase (MAPKK) and finally to MAPK which then phosphorylates many proteins 
(mostly  nuclear transcription factors) with diverse functions in regulating proliferation, cell growth, 
migration (Chang and Karin, 2001). One of the best characterized triggers for MAPK pathway is 
Ras activation which can propagate signals from various ligand or self-activated tyrosine kinases. A 
general notion from several studies have shown that HER2/Ras can antagonize TGFβ induced cell 
apoptosis and cell cycle arrest while allowing for the pro-migratory and pro-invasive functions of 
TGFβ (Seton-Rogers et al., 2004). The synergy  between the TGFβ and HER2/Ras/MAPK pathways 
often leads to the secretion of additional growth factors and cytokines, including TGFβ itself, which 
promotes epithelial-mesenchymal transition (EMT) and cell invasion, whereas JNK kinases 
negatively regulate the autocrine expression of TGFβ (Ventura et al., 2004).
 The SMAD linker region is loosely  organized and highly flexible in structure that makes it 
accessible for a number of kinases. Three residues in the linker region of SMAD3 were identified as 
Erk1/2 phosphorylation sites both in vivo and in vitro. Erk-mediated phosphorylation in these sites 
inhibits SMAD3 transcriptional activity (Matsuura et al., 2005). MAPKs also phosphorylate the 
linker region in SMAD1/5 thus blocking SMAD1/5 nuclear translocation, resulting in inhibition of 
BMP signaling by several signals that activate MAPK (e.g. EGF, FGF, IGF) (Guo and Wang, 2009). 
Erk, JNK, and p38 have all been implicated in the transcriptional regulation of SMAD7, whereas 
JNK and p38 phosphorylate tumor-derived SMAD4 and promote its degradation, thus indirectly 
regulating TGFβ signaling (Guo and Wang, 2009).
 MAPK phosphorylate number of nuclear transcription factors, including those that can 
interact with SMADs and regulate TGFβ/BMP responses. Best characterized are AP1 proteins 
including members of Jun, Fos, Maf and ATF subfamilies (Shaulian and Karin, 2002; Guo and 
Wang, 2009). Relationship  between Jun/Fos and SMAD functional interactions can be synergistic 
or antagonistic depending on their target genes and other binding proteins.
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 TGFβ and Wnt family members regulate various developmental processes; several 
differentiation and patterning processes require inputs from both pathways. In vertebrates, signaling 
of both pathways is important for establishing the basic body plan during gastrulation. It has been 
shown that mice lacking Wnt central signal transduction molecule, β-catenin, fail to form anterior-
posterior axis (Huelsken et al., 2000); the same effect is observed in mice lacking TGFβ 
superfamily signaling molecules, like SMAD2 and SMAD4 (Weinstein et al., 2000). Several studies 
in Drosophyla and Xenopus have shown that TGFβs and Wnt cooperate in regulating developmental 
and patterning events through a coordinate control of gene expression patterns (Attisano and Labbé, 
2004). In vertebrates, Wnts have been shown to cooperate with BMP-like ligands, by regulating 
graded Emx2 expression in dorsal telencephalon (Theil et al., 2002) and in embryonic carcinoma 
cells, Wnt and BMP have cooperative effect in several gene targets including Msx1 and Msx2 
(Willert et al., 2002). Studies with mouse models have revealed the cooperative involvement of 
TGFβ and Wnt signaling in cancer where disruption of TGFβ signaling in the context of activated 
Wnt signaling, promotes tumorigenesis (Cullingworth et al., 2002).
 The requirement of both pathways has been explained through an indirect  effect as shown in 
studies with chicken embryo where mis-expression of Vg1, a TGFβ-like ligand, causes induction of 
Wnt signaling pathway  transcription factor LEF-1 expression (Skromne and Stern, 2001). Analysis 
of specific target genes has revealed that members of both families can regulate gene expression 
through distinct but closely positioned enhancer elements, suggesting that  the synergism between 
TGFβ and Wnt might occur more directly (Attisano and Labbé, 2004). In studies with Xenopus, it 
has been shown that maximal activation of Xtwn gene requires presence of four components, R-
SMAD, SMAD4, LEF-1 and β-catenin suggesting that TGFβ and Wnt pathways synergistically 
activate specific target genes through direct interaction of SMADs and LEF-1 and this synergy can 
activate a specific gene expression program and thereby direct appropriate tissue patterning 
(Attisano and Labbé, 2004).
 Interactions of TGFβ/BMP pathway  with other pathways such as PI3K/Akt, Sonic 
Hedeghog (Shh), Notch, IL, TNFβ and INF-γ pathways have been described (reviewed in Guo and 
Wang, 2009). The core concept of TGFβ signaling cross-talk is the context dependency leading to 
conclusion that no simple role can be generalized to describe how TGFβ interacts with any other 
signaling pathway.
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1.2.5. TGFβ in vertebrate embryonic development
 Mouse models with targeted disruption of TGFβ gene expression reveal the role of each 
isoform during mouse development. TGFβ1 disruption results in diffuse and lethal inflammation in 
about three weeks after birth; also embryonal hematopoiesis is also defective (Shull et al., 1992; 
Kulkarni et  al., 1993; Dickson et al., 1995; Letterio and Roberts, 1996). Alterations in both TGFβ2 
and TGFβ3 genes lead to perinatal lethality. TGFβ2 null mice exhibit cardiac, lung, craniofacial, 
limb, eye, ear and urogenital developmental defects (Sanford et al., 1997) while TGFβ3 null mice 
have defective palatogenesis and arrested pulmonary  development (Kaartinen et al., 1995; Proetzel 
et al., 1995).
 During vertebrate embryogenesis, the heart is the first organ to form and function. The heart 
initially forms from two bilateral heart fields that  fuse at the ventral midline to form the primitive 
heart tube consisting of an inner endothelium surrounded by an outer layer of myocardium. 
Between these layers is extracellular matrix layer called cardiac jelly secreted mainly by the 
myocardium. Subsequently  loops and turns break the symmetry of the linear heart tube. In addition, 
endocardial cells undergo epithelial-mesenchymal transition (EMT) in response to signals from the 
overlying myocardium. As a result of this transition cells invade intervening ECM and form cardiac 
cushion. The mature heart valves and septa derived from the cardiac cushions ultimately divide the 
heart into four functional chambers (Harvey, 2002).
 Molecular studies have shown that TGFβ superfamily signaling is essential for heart 
development. For example, BMP2 is required for initial formation of the cardiac primordium, 
because Bmp2 null mice either do not have a heart or develop very  retarded and malformed heart 
(Zhang and Bradley, 1996). In addition, several TGFβ isoforms and receptors control EMT in the 
developing heart. In the chicken, TGFβ2 and TGFβRIII have roles in cell activation suggesting a 
direct and specific interaction. TGFβ3 and TGFβRII appear to have similar roles in cell invasion. In 
the mouse, TGFβ2 is the only ligand that has a demonstrated role in EMT. Fusion of the cardiac 
cushions fails in TGFβ2 knock-out mice, due to an increased number of mesenchymal cells that do 
not form cell-cell contacts to remodel the valves (Mercado-Pimentel and Runyan, 2007). TGFβ1 
knock-out mice do not seem to have any heart abnormalities, while TGFβ2 knock-out mice have 
specific defects in the development in valves and septa of the heart (Sanford et al., 1997). Recent 
studies with mice embryos demonstrate a role for TGFβ2 in early heart morphogenesis in the 
formation of the outflow tracts (Li et al., 2010). Vitamin A-deficient quail embryos develop severe 
heart abnormalities that lead to embryonic death at day  3.5-4. Some of these abnormalities manifest 
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as abnormal, un-looped, randomly oriented (left/right) but beating heart, sparse and abnormal extra-
embryonal blood vessels and the absence of linkages between the heart  and extra-embryonal blood 
supply; the inflow tracts are closed in the VAD embryos (Zile, 2004; 2010).
 Two type I receptors, Alk3 and Alk5, also have been shown to be involved in heart 
development. Alk3, also known as BMP type IA receptor, is essential for mesoderm formation as 
shown in conventional knock-out mice (Gaussin et al., 2002). It is interesting that TGFβ2 is 
downstream of Alk3 during cardiac cushion formation, as suggested from findings that  in Alk3 
knock-out mice the levels of TGFβ2 expression are greatly reduced when Alk3 is absent from the 
myocardium (Gaussin et al., 2002). These findings suggest that a cascade of TFGβ superfamily 
signaling is required for normal cardiac cushion formation. Alk5, a receptor for TGFβ isoforms may 
be required for heart looping during mouse embryonic development (Charng et al., 1998).
 In summary, heart development is regulated by both TGFβs and BMP isoforms at multiple 
developmental stages, including the time of formation of the heart  primordia, heart  looping and 
cushion formation, and later, at septum and valve formation. Findings from mouse knock-out 
models where TGFβ2 levels are decreased in absence of Alk3, suggest genetic connections among 
signaling pathways of different TGFβ superfamily members.
 During mouse development, morphological asymmetry of the left/right axis occurs at  about 
E8.0 (in chick it occurs at 10/11ss) when the embryonic heart tube loops toward the right. In chick, 
molecular determination of left/right axis is first initiated in Hensen’s node and then manifested by 
asymmetrical gene expression. Several TGFβ family ligands, such as Nodal, lefty-1, and lefty-2 are 
expressed asymmetrically  before or during the appearance of morphological asymmetry; they 
appear to be involved in normal left/right  axis formation (reviewed in Chang et al., 2002). In chick, 
it appears that the chick Cerberus (cCer), a member of Cerberus/Dan family that first was identified 
as BMP antagonist, is a BMP agonist  in Nodal induction in the chick left plate mesoderm. Thus 
BMP and cCer function synergistically to ensure the left-sided Nodal expression in the chick 
embryo during left/right axis development (Yu et al., 2008). TGFβ isoforms do not appear to be 
involved in this developmental process.
 Vasculogenesis and angiogenesis are two processes leading to the formation of blood 
vessels. Vasculogenesis is the de novo formation of blood vessels from endothelial precursors in 
mesoderm and their subsequent organization into primary capillary  plexus, whereas angiogenesis is 
the formation of blood vessels from pre-existing vessels through splitting and sprouting (Weinstein 
1999; LaRue et al., 2003). Morphological observations in TGFβ1 knock-out mice demonstrate the 
role of TGFβ1 in vasculogenesis and hematopoiesis (Dickson et al., 1995). The disruption of 
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TGFβ1 in mice leads to midgestation lethality  in half of the homozygotes and about half of 
heterozygotes, where the primary causes are defects in the yolk sack vasculature and the 
hematopoietic system (Dickson et  al., 1995). Initial differentiation of mesodermal precursors 
occurs, but subsequent differentiation of endothelial cells into capillary  like tubules is disturbed 
leading to vessels with decreased wall integrity. Interestingly, TGFβRII-deficient mice also develop 
a similar phenotype. However, recent studies where in cell cultures OP9 stroma cell co-cultures 
with mouse embryonic stem cells do induce vascular smooth muscle cell (VSMC) and pericyte 
differentiation, but TGFβ1 together with platelet-derived growth factor (PDGF) are dispensable for 
the induction of VSMC/pericyte genes in that system (Lindskog et al., 2008). There is no evidence 
of other TGFβ isoform involvement in vasculogenesis or angiogenesis.
 Another important process during embryogenesis that appears almost simultaneously with 
the development of the cardiovascular system is the development of the nervous system. Studies 
carried out in the central and peripheral nervous system of mouse, rat, and chicken embryos showed 
the widespread expression of TGFβ2 and TGFβ3 with slight immunostaining for TGFβ1 (Böttner et 
al., 2000). Later studies show that TGFβ1 is also present in the central nervous system at 
neurulation stages as well as at the initial steps of spinal cord and brain development (Mecha et al., 
2008). However, knock-out models of all three TGFβ isoforms do not show disruption in the central 
nervous system (Chang et al., 2002).
 Targeted disruption of TGFβ2 in mouse leads to perinatal lethality  due to various 
abnormalities, mostly related to heart defects (Sanford et al., 1997). However, various craniofacial 
defects, axial and appendicular skeletal defects, retinal hyperplasia and renal defects in majority of 
female mice were also observed (Sanford et al., 1997). Both TGFβ2 and TGFβ3 isoforms are 
related to cleft  palate development, while BMP4 and activin βA have been shown to play  important 
roles in tooth development (reviewed in Chang et al., 2002). BMP4 and BMP7 are involved in early 
eye development; however there is some evidence that  TGFβ2 is also necessary  for normal eye 
remodeling (Saika, 2006). TGFβ2 null mice also have abnormally large fontanels (spaces that occur 
between the skull bones before fusion), defects in bone growth in the occipital region of the skull 
and variable jaw bone defects (Sanford et  al., 1997) which are consistent with the proposed roles of 
TGFβ2 in osteoblast differentiation and in osteoclast functioning (reviewed in Chang et al., 2002).
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1.2.6. TGFβ and vitamin A
 The functions of TGFβ and RA are known to merge in a variety of biological processes 
including embryogenesis, organ development and carcinogenesis (Roberts and Sporn, 1992). 
Interestingly, TG-interaction factor (TGIF) is a transcriptional repressor common to both TGFβ (as 
a co-repressor for TGFβ activated SMADs) and RA signaling pathways, by binding to the ligand-
binding domain in RXRs and preventing transcription activation from the retinoid response 
elements in the promoter sequences (Bartholin et al., 2006). Developmental events linked to RA-
regulated TGFβ signaling include the inner ear (Butts et al., 2005) and pancreas (Colakoglu et al., 
2006). Inhibition of TGFβ signaling by endogenous RA is required for mouse lung development 
(Chen et al., 2007).
 The data from most of the research in cell cultures relates to bi-directional cross-talk 
between RA and TGFβ signaling. Regulation of expression of cellular RA binding proteins I and II 
(CRABP-I, -II) and the expression of TGFβ3 were examined in mouse embryonic palate 
mesenchymal cells and demonstrated that all three TGFβ isoforms and RA down-regulated the 
expression of CRABP-I; TGFβ1 stimulated the expression of CRAPB-II and the expression of 
TGFβ3 within 24 h of treatment (Nugent and Greene, 1994). Furthermore, using the same model 
system, Nugent et al., (1995) showed the ability  of TGFβ, including the endogenous forms, to 
modulate the expression of nuclear RARβ (Nugent et al., 1995). In contrast, RA had little or no 
effect on TGFβ1 mRNA, whereas TGFβ2 mRNA levels were stimulated. It was also shown that RA 
increased TGFβ2 and TGFβ3 protein release in the medium, protein being mostly in the latent or 
inactive form. The amount of active TGFβ released was increased relative to the total increase in 
TGFβ released, suggesting that RA treatment stimulated activation of latent TGFβ (Nugent et al., 
1998). The elevated retinoid-induced TGFβ activity  may  be by the up-regulation of TGFβ receptors 
by RA (Yoshizawa et al., 1998). In contrast, findings from a vitamin A-deficient in vivo system 
clearly  demonstrate that endogenous RA has a negative regulatory role on TGFβ1 and TGFβ2 (Li et 
al., 2010).
1.3. Early development of the cardiovascular system
 Vertebrate cardiovascular system is the first physiological organ system that develops and 
forms during embryogenesis. Completion of development continues throughout all prenatal 
development. Many of the underlaying mechanisms are considered to be developmentally  and 
molecularly conserved, but the subsequent septation of the chambers and the formation of the 
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outflow tract, varies among species depending upon the utilization of lungs (Fishman and Chien, 
1997). Morphogenesis of the heart begins with the initial patterning of the embryo that determines 
the three axes of the embryo: anterior-posterior, dorsal-ventral and left-right. These axes are 
imprinted into the cellular program as cell populations expand to form the embryo and extra-
embryonal tissues (Keller et al., 2000). Two basic processes are involved in cardiovascular 
development: one that drives morphogenesis (cell migration, proliferation and apoptosis), and one 
that is necessary  for functional development (cell differentiation and determination of 
cardiovascular tissue). Both processes are regulated by  the environment and signals within the 
embryo (Zile, 2004).
1.3.1. Early embryogenesis and the role of epithelial-mesenchymal transition
 Epithelial-mesenchymal transition (EMT) is a concept proposed in cell biology studies of 
tissue morphogenesis during embryonic development (Hay, 2005). EMT is a highly conserved 
cellular program that allows polarized, immobile epithelial cells to convert to mobile mesenchymal 
cells. This process was initially recognized during several critical stages of embryonic development, 
but more recently it has been linked to promotion, carcinoma invasion and metastasis (Yang and 
Weinberg, 2008). The earliest EMT in vertebrate development appears during gastrulation, a 
process that forms mesoderm and endoderm tissue from the ectoderm in which the cells are 
organized as an epithelial sheet. Before gastrulation chick embryo is composed of two layers, i.e. 
epiblast and hypoblast (Fig.1.9) in area pellucida from which all embryonic tissues develop.
Figure 1.9. Germ layers in 24-h (4 ss) chick embryo. Somites are induced from primitive streak mesenchyme (Hay, 
2005). Inset illustrates the EMT of the epiblast. 
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During gastrulation, the epiblast is stretched tight  as a result of adhesion and cellular migration. 
Epiblast integrity is maintained by tight junctions between epiblast  cells. Mesoderm cells form 
through a de-epitelialization process, i.e. EMT, from the epiblast. The primitive streak, the site of 
EMT, is a dynamic structure. Elongation of streak towards anterior part occurs during pre-somatic 
stage (HH2 to HH4) and is regulated by global tissue morphogenic movement within epiblast plane. 
A number of developmental factors, not related directly  to EMT, influence the time and place for 
EMT process to generate mesoderm and endoderm (Hay, 2005; Nakaya and Sheng, 2009).
 During EMT, epithelial cells undergo dramatic phenotype changes, loose expression of E-
cadherin and other components of epithelial cell junction (Fig.1.10). They  adopt a phenotype of 
mesenchymal cells and acquire mobility  and invasive properties that allow them to migrate through 
the extracellular matrix.
Figure 1.10. Overview of cellular changes and molecular markers during epithelial-mesenchymal transition (EMT) 
(Ouyang et al., 2010).
 The basic types of tissue in vertebrates are epithelium and mesenchyme. There are three 
types of epithelium: simple, stratified and gland epithelium. Embryonic epithelium mainly is the 
simple type; mesenchyme develops simultaneously with epithelium (Hay, 2005). Epithelium is the 
earliest embryonic tissue that  forms sheets of cells with tight junctions. This sheet of adjacent cells 
are attached tightly to the underlaying extracellular matrix consisting of collagen type IV and 
laminin, and is called basal lamina. Epithelial cells under tension develop  very strong junctions 
called desmosomes which contain specialized adherence molecules (cadherins and catenins) that 
dissociate during EMT. These specialized cadherins are found in later stages of development, i.e. in 
endothelium (VE-cadherin) and in fibroblasts (N-cadherin). One of the features that separates 
epithelial cells from mesenchymal cells is the polarity  of epithelial cells: their apical side is free and 
unattached, whereas the posterior side through basal actin cortex is attached to the ECM by means 
of integrins, the receptors for ECM.
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 EMT is necessary during heart development for the formation of valves, the process that 
occurs at 16-22 ss (HH12 to HH14) (at about 69 h of incubation) (Runyan and Markwald, 1983). 
The valve forming region includes atrioventricular canal and the outflow tract region that gives rise 
to the aortic and pulmonary valves. Prior to EMT, myocardium and endothelium are separated by a 
cell-free space filled with ECM, called cardiac jelly (Krug et al., 1987). In the chick, TGFβ2 and 
TGFβRIII have roles in cell activation that  suggest direct and specific interactions, while in mice 
TGFβ2 is the only  ligand that has a demonstrated role in EMT (Mercado-Pimentel and Runyan, 
2007).
1.3.2.Early development of the heart
 Heart develops from one of the three germ layers established in the early embryo. The early 
vertebrate embryo is an oval disk consisting of endodermal and ectodermal cell layers, between 
which the mesoderm is situated. Mesoderm is the germ layer that gives rise to heart muscle. The 
cardiovascular progenitor cells as a dense mass of mesodermal mesenchyme, move from their 
original midline primitive streak (under the Hensen’s node) (Fig.1.11) towards forming heart fields 
(Pérez-Pomares et al., 2009).
Figure 1.11. Localization of heart precursors in the primary heart field during gastrulation and tubular heart formation in 
avian embryo (Brand, 2003). Blue label, atrium; red label, ventricle; yellow label, conus/ outflow tract; RV, right 
ventricle; LV, left ventricle; SA, sinoatrial segment/inflow tract/sinus venosus.
 Current theory  suggests that there are two heart fields forming within anterior lateral 
mesoderm during early embryogenesis (Abu-Issa and Kirby, 2004, 2008; Cui et  al., 2009). Primary 
heart field will give rise to the left ventricle and inflow tract, and the secondary heart field will 
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become right ventricle and the outflow tract (Black, 2007). Both heart fields are starting to form at 
primitive streak stage/pre-somite stage, (HH3-HH5; approximately 15h after gastrulation) in avian 
embryos (Fig.1.11); in the mouse it  is at approximately  E6-7.25 (day of embryonic development); 
in human it takes place at approximtely  day  15 of embryogenesis. These cells will contribute to all 
cell layers of the heart: myocardium, endocardium and parietal pericardium, as well as to 
endothelial cells in the heart area (Fishman and Chien, 1997). At 1-4ss (HH7) in chicken (E7.5-
E8.25 in mouse), when the lateral plate mesoderm splits into the splanchnic and somatic mesoderm, 
cardiovascular precursor cells and the myocardial progenitors (restricted to the splanchnic 
mesoderm) migrate and form the cardiac crest (horseshoe-shaped area located cranially to the 
prechordal plate) after which they differentiate and assemble into two bilateral heart tubes (Fig.
1.12). 
Figure 1.12. Position and 
movement of primary (red) 
and secondary (blue) heart 
fields from cardiac crescent 
through the looping stages of 
heart development in the 
mouse. Compass indicates 
body axes.  E, approximate 
stages in embryonic days of 
development. Ca, caudal; Cr, 
cranial; L, left; R, right. 
(Harvey, 2002).
Splanchnic mesoderm (cardiogenic mesoderm) will later contribute to the most cranial portion of 
the heart tube (outflow tract) and the most lateral part of this mesoderm will contribute to the caudal 
heart tube (inflow tract) (Fig.1.13) (Abu-Issa and Kirby, 2008). The primordia of the consecutive 
heart chambers are definable before the appearance of myosin-type filaments and primitive Z 
bands, which occurs simultaneously with the first  spontaneous action potentials in the 7 ss avian 
embryo. The bilateral heart fields move medially and fuse at the ventral midline to form the heart 
tube (Harvey, 2002; Abu-Issa and Kirby, 2008; Pérez-Pomares et al., 2009).
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Figure 1.13. An overview of the development of the vertebrate 
heart. Equivalent of mouse E7.5 (A),  E8.5 (B), E9.5 (C), and 
E11.5 (D). OFT, outflow tract; RV, right ventricle; LV, left 
ventricle; A, atria; AO, aorta; SV, sinus venosus (inflow tract); 
RA, right atrium; LA, left atrium. (Goetz and Conlon, 2007). 
The bilateral heart  fields initiate their differentiation 
into the endocardial and myocardial lineages while 
moving to the midline and forming the cardiac crest as 
the result of the forces generated by the general 
folding of the embryo. This process happens faster in 
mouse embryos than in chicken embryos (Abu-Issa et al., 2004). At the 8-9 ss in avian embryo 
(E8.5 in mouse), fusion of the lateral heart primordia proceeds to include the outflow tract and atrial 
primordia; the pacemaker site migrates into the atrial wall and subsequently into the sinus venosus 
(inflow tract) (Fig.1.13), this process occurring simultaneously with the progressive transformation 
of mesenchymal cells into cardiomyocytes (Virảgh et al., 1989). The process of fusion and 
formation of a single heart  tube begins towards moving anteriorly and proceeds caudally. By  the 
7-10 ss (HH9-10), the heart begins to move to the right (Fig.1.14).
Figure 1.14. Chick heart tube at 9-10ss 
(HH10), shown in cross-section (left 
panel) and in ventral view (adapted 
from Fishman and Chien, 1997). 
The primitive bilaminar heart 
tube is composed of an outer 
myocardial (myocardium) layer 
which will form the beating 
heart muscle, and an inner endocardial (endocardium) layer, which will form the endothelial layer 
of the heart contiguous with the vasculature (Fig.1.14) (Harvey, 2002; Goetz and Conlon, 2007). 
Endocardium has several other functions, e.g. it  plays an important role in signaling to 
cardiomyocytes and is required for proper formation of trabecular myocardium (Wagner and 
Siddiqui, 2007,b). Endocardium is involved in the signaling required for transdifferentiation of 
myocytes into the Purkinje fiber cells that comprise much of the cardiac conduction system 
(Mikawa and Hurtado, 2007). At a later stage in heart development the cells from specific 
endocardium region will undergo EMT to form endocardial cushions (Harris and Black, 2010).
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 The heart tube is polarized along cranio-caudal axis with the dominant pacemaking activity 
located at the inflow tract, ensuring unidirectional peristaltic-like contraction and a sinusoidal 
electrocardiogram (Christoffels et al., 2004).
 Differentiation of cells begins in upper regions of the cardiac mesoderm plate at HH7, even 
prior to fusion, and proceeds caudally. At 9-10 ss (HH10), the cardiac cells continue to stream 
together and form presumptive atrial tissue as well as the future sinus venosus (inflow tract) tissue 
which is located caudally  of the heart tube. Similarly, outlet  tissue (outflow tract) is recruited from 
the cephalic mesoderm. Thus the heart tube extends in both cranial and caudal directions (Fig.1.14) 
(Ciu et al., 2009). By 24-27 ss (HH15), the two chambers, atrium and ventricle, are morphologically 
different, and the ventricle is beginning to thicken by the growth of the wall. Cardiac jelly separates 
the myocardium from endocardium and becomes thicker especially  in the regions where cushions 
and valves will form, i.e. the outflow tract and the atrio-ventricular junction (Keller et al., 2000; 
Wagner and Siddiqui, 2007a).
 Mammalian and avian hearts are comprised of two atria and two ventricles. The formation 
of the atria and ventricles involves different regulatory events (Christoffels et al., 2004) which take 
place at a later stage of heart development and will not be discussed in this work.
1.3.3. Genes involved in early  cardiovascular development
 Commitment to a cardiac fate is the result of many signals from underlaying ectoderm, 
which include bone morphogenic proteins (BMPs), basic fibroblast growth factors (FGFs), Wnt 
proteins as well as several of the TGFβ superfamily cytokines (Nemer, 2008). The mechanisms that 
underly  cardiovascular development is still not fully  understood. Several transcription factors (TFs) 
required for normal heart development are well described and include the GATAs. GATA family of 
TFs consists of six proteins. GATAs 1, 2, 3 are important regulators of hematopoietic stem cells and 
their derivatives, while GATA 4, 5, and 6 are expressed in various mesodermal and ectodermal 
derived tissues (Pikkarainen et al., 2004). GATA4 is required to allow cells to respond to cardio-
inductive substances; it mediates BMP signaling by combined action with the TF Nkx2.5. During in 
vitro cardiogenesis, GATA4 expression precedes that of Nkx2.5 and is essential for survival of 
cardioblasts (Grépin et al., 1997). Synergistically with SMAD proteins, the intracellular signal 
effectors of TGFβ/BMP signaling, GATA4 activates Nkx2.5 transcription (Benchabane et al., 2003).
 The homeobox gene Nkx2.5 is one of three transcription factor genes (Nkx2.5, GATA4 and 
MEF2C) that are expressed in murine and chicken cardiogenic mesoderm and that encode candidate 
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regulators of cardiac myogenesis (Lints et al., 1993). In the chick, Nkx2.5 expression is first seen at 
HH5 in antero-lateral mesoderm, and along with GATA4, requires the continuous presence of BMP 
and FGF8 signals until myocardial differentiation becomes independent of BMP2 at 5-7 ss (HH8) 
(Schlange et al., 2000; Wagner and Siddiqui, 2007). However, the Nkx2.5 null mice exhibit heart 
abnormalities only at the stage of looping morphogenesis (Lyons et  al., 1996). Studies of Nkx2.5 
expression patterns in chick and mouse models support a hypothesis of Nkx2.5 role in modulating 
the unique patterns of gene expression involved in the conduction system of the developing heart at 
11-12 days of development (HH41 to HH42) (Thomas et al., 2001).
 The cell adhesion molecules cadherins are important  for tissue organization during 
embryonic development. N-cadherin is involved in cell assembly and rearrangement during 
embryogenesis and is crucial for cardiovascular development (Linask, 2003; Kostetskii et  al., 
2005). N-cadherin is expressed in mesodermal tissues that differentiate into heart and is localized 
within heart forming regions (Linask, 1992). Blocking of N-cadherin in chick embryo at early  pre-
somatic stages (HH5) resulted in interrupted fusion of bilateral epimyocardial layers, thus not 
forming a single cardiac tube (Nakagawa and Takeichi, 1997). At the cellular level, large gaps 
between cells were observed where antibody against N-cadherin was injected. However some 
beating in these disorganized myocardial layers was observed suggesting that differentiation to 
cardiomyocytes was not altered but their contraction was not coordinated (Nakagawa and Takeichi, 
1997). Also studies with targeted silencing of GATA4 revealed that N-cadherin expression in the 
middle part of the cardiac crescent is crucial for subsequent fusion of pericardiac cells and 
formation of a single heart tube (Zhang et al., 2003). Studies in vitro demonstrate that Msx1 and 
Msx2 (Hox8) regulate N-cadherin mediated adhesion and Msx1 is involved in cell sorting and 
proliferation (Lincecum et al., 1998). Msx1 is a transcription factor involved in heart 
morphogenesis (Chan-Thomas et  al., 1993; Chen et al., 2007); it  has not been described as a heart 
specific gene for the avian embryo, but it  is expressed ectopically in the heart forming regions of 
the VAD quail embryo (Chen et al., 1995). Moreover, mutant Msx1-/- mice do not have any cardiac 
defects (Satokata and Maas, 1994) but Msx1-/-; Msx2-/- double mutant mice display a broad range 
of outflow tract malformations (Chen et al., 2007).
 Fibronectin is one of the ECM proteins which along with other ECM compounds assembles 
already at early  morphogenesis (reviewed in Rozario and DeSimone, 2010). The loss-of-function 
phenotype of fibronectin has been studied in mouse (George et al., 1993), Xenopus laevis (Davidson 
et al., 2006), zebrafish (Trinh and Stainier, 2004) and chick embryos (Linask and Lash, 1988a,b); it 
leads to embryonic lethality  and,along with other defects, results in cardia bifida, defects in 
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mesoderm specification, myocardial precursor migration and yolk sack vasculature. Similar effects 
are obtained from studies where embryos are treated with exogenous RA (Osmond et al., 1991).
 Retinoic acid receptors and retinoid X receptors are the key molecules in RA signaling 
essential throughout the development and for the maintenance various body  functions. RARs and 
RXRs each have three subtypes. Studies with the VAD quail model demonstrate the critical time 
window at 4-5 ss when RA presence is crucial (Kostetskii et  al., 1998) and RARα2, RARγ and 
RXRα are essential for RA signal transduction (Cui et  al., 2003). The absence of RA signaling at 
that time leads to death of the avian embryo at 3.5 days as a result of multiple gross abnormalities 
that include retarded growth, abnormalities in central nervous system and the skeletal structure, the 
lack of circulatory system, and an abnormal, non-compartmentalized and dilated heart that lacks the 
inflow tracts and is oriented randomly (Zile et al., 2000; Zile, 2004).
 An important part of cardiac morphogenesis is the establishment of the correct asymmetry  
because the subsequent process of looping (when the heart tube begins to form an S-shaped 
structure) is altered. The asymmetry molecular pathways are set up early in development and are 
regulated by a balance between transient stimulatory and inhibitory signals involving many genes at 
specific stages. The chick homolog of the mouse gene Nodal is expressed asymmetrically  along the 
left side of the axis during and after gastrulation of the chick embryo (Levin et al., 1995; Zile et al., 
2000). The transcription factor Pitx2 is also expressed in the left lateral plate mesoderm during 
early heart development and it has been linked to the regulation of L/R asymmetry  pathway for 
heart and viscera. Pitx2 appears to be regulated by Nodal (St. Amand et al., 1998). Among many 
asymmetry genes is also the fibroblast growth factor 8, FGF8, which has been suggested to be a 
determinant for right-side asymmetry; one of its functions is to repress Nodal and Pitx2 on the right 
side of the embryo (Schlueter and Brand, 2009).
 The molecular mechanisms that regulate early cardiac morphogenesis, however, are still not 
completely elucidated. In contrast, the use of knock-out mice has allowed the identification of 
proteins involved in events after the primary heart tube has developed, i.e. heart looping, epithelial-
mesenchymal transition, heart segmentation into chambers, chamber maturation as well as the 
subsequent events leading to the development of a mature cardiovascular system (Nemer, 2008). 
The genes discussed in this section are only a small part of the molecular regulators of early heart 
development. Various interactions among transcription factors, signaling pathways, morphogens 
and other molecules are involved in the complex development of the cardiovascular system.
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1.3.4. Early development of the vascular system
 The principal components of the cardiovascular system include the blood, blood vessels, 
heart and the lymphatic system. Early  heart morphogenesis has been described in the previous 
chapter. It does not take place without  development of vascular system which is responsible for the 
distribution of primary blood cells and later for the distribution of oxygen and nutrients as well as 
removal of carbon dioxide and other metabolic waste products (LaRue et al., 2003; Eichmann et al., 
2005). Development of a rich vascular network also ensures that every cell in the growing organism 
will receive adequate levels of oxygen and metabolites to meet its energy and structural 
requirements. Morphologically  the structure of blood vessels is relatively  simple. The largest 
surface of the vascular system is capillary bed (tunica intima), composed only  of endothelial cells 
which are first to form during development. These capillary tubes are surrounded by a basement 
membrane; the larger vessels have additional layers that form the vessel wall that consists of a 
muscular layer (tunica media) and outer connective tissues (tunica adventitia) containing a network 
of small blood vessels (vasa vasorum) and nerves (Griendling et al., 2000).
 Given the complex nature of the vascular system and variety of biological processes that are 
required for its formation and maintenance, it is no surprise that a large number of signaling 
pathways are involve in this process. Mutations in these pathways often manifest in phenotypes that 
result in embryonic lethality at mid gestation. Some of those mutation phenotypes have been 
described in mouse model systems. Notch, TGFβ, Sonic Hedgehog (SHH), VEGF and angiopoietin 
pathways are just  some that if affected can lead to abnormal vascular development between E8.0 
and E10.0 in mice, and ultimate embryonic lethality  (Walls et  al., 2008). The vascular activities of 
these pathways are not restricted and limited to this developmental window, they extend to 
organogenesis, maintenance of vascular homeostasis in adulthood and states of pathological 
angiogenesis. Some of the genes, e.g. Notch, TGFβ and SHH, are involved also in other 
developmental processes and are not restricted to vascular development.
 The vascular system in any organ and tissue must be established early  during development, 
since the diffusion distance of molecules is limited (for O2 it  is 100-200µm). The early  development 
of the vascular system consists of vasculogenesis and angiogenesis. Angiogenesis is the formation 
of blood vessels from endothelial cells of pre-existing vessels, while vasculogenesis is the de novo 
formation of blood vessels from mesoderm (Weinstein, 1999; LaRue et al., 2003; Eichmann et al.,
2005). Vasculogenesis is tightly correlated with heart development and it occurs simultaneously 
with formation of  primary  and secondary heart fields at the time when somites begin to form 
(Weinstein, 1999; Patan, 2000). Endothelial cell differentiation starts during gastrulation when cells 
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move through the primitive streak to form the mesoderm. Newly formed mesodermal cells organize 
into axial mesoderm (will give rise to the notochord) (Fig.1.15), paraxial mesoderm (somites) and 
intermediate mesoderm (kidney  and gonads). The lateral plate mesoderm lies on both sides of the 
intermediate mesoderm.
Figure 1.15. Origin of endothelial cells and distribution of mesodermal tissues in the chick embryo (gastrulation at stage 
HH4). The presumptive extra-embryonic and lateral mesoderm expresses VEGF receptor 2 (VEGFR2). Slightly 
modified from Eichmann et al., 2005.
The dorsal part of lateral mesoderm will develop contact with ectoderm and will form the body wall 
and limbs while the ventral part in contact  with ectoderm will form visceral organs. The posterior 
part of mesoderm occupies half of the embryo during gastrulation and will give rise to the extra-
embryonic mesoderm (Eichmann et al., 2005).
 The peripheral cells in these mesodermal layers acquire the morphology of endothelial cells. 
The clumps of primitive mesodermal cells remaining adherent to the newly formed vascular 
endothelium, called blood islands, are the site of origin of extra-embryonic hematopoiesis. An 
ancestral progenitor common for both endothelial and hematopoietic cell lineages was postulated as 
angioblast and later renamed hemangioblast (see Tavian and Peault, 2005), suggesting it develops in 
yolk sac. The angioblasts contributing to the dorsal aorta arise by an EMT of cells originating from 
splanchnic mesoderm later in development. The endocardium arises from angioblasts that migrate 
some distance before assembly  (vasculogenesis); the intersomitic arteries are the first vessels that 
form by angiogenesis and sprout off of the patent dorsal aorta (Poole et al., 2001). The vascular 
endothelial growth factor (VEGF), a heparin-binding, endothelial cell specific mitogen, is involved 
in vascular patterning and appears to be critical for migration, growth and morphogenesis of 
angioblasts into initial vascular patterns (Poole et al., 2001).
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 Hemangioblasts differentiate within the mesoderm partially in response to the signaling of 
fibroblast growth factor (FGF) family, but  the mechanisms still are not clear, since they are involved 
in many  other cell fate decisions. It has been reported that  vascular endothelial growth factor 
receptor type 2, VEGFR2 (Flk1), plays a crucial role in differentiation of mesoderm exclusively  to 
endothelial and hematopoietic lineages (Shalaby et al., 1997). VEGFR2 deficient  cells are unable to 
contribute to the vascular network when placed in wild-type hosts, and accumulate in ectopic 
locations; this suggests that VEGFR2 is required for reception of signals that  direct hemangioblasts 
towards their proper positions within embryo (Shalaby et al.,1997). The VEGF receptor 1, VEGFR1 
(Flt-1) is also expressed exclusively in endothelial cells, but its disruption results in an increased 
number of mesodermal cells that become differentiated angioblasts; this increased density prevents 
cells from forming normal vascular channels (Fong et al., 1999; Patan, 2000). The functional 
differences between these receptors may reflect activation by  different ligands within the VEGF 
family, i.e. VEGF-A and VEGF-B bind to VEGFR1, while VEGF-C and VEGF-D bind to VEGFR2 
(Roman and Weinstein, 2000). In mice, an inactivation of a single VEGF allele causes embryonic 
death between days 11 and 12 due to malformation of the heart, undeveloped dorsal aorta and 
reduced number of primitive blood cells in the yolk sac, demonstrating that  VEGF is required to 
maintain angioblast differentiation (Patan, 2000). TGFβ as well as FGF, VE-cadherin (vascular-
endothelial cadherin) and N-cadherin have been linked to yolk sac hematopoiesis and/or 
vasculogenesis or angiogenesis, as is the case with cadherin molecules (Pepper, 1999; Bohnsack 
and Hirschi, 2004; Montero-Balaguer et al., 2009).
 Hemangioblasts give rise to the blood islands which form the primary vascular plexus when 
fused (Fig.1.16). Blood islands consist of an internal core (hematopoietic precursors) and an 
external ring (endothelial cells).
Figure 1.16. Schematic representation of differentiation of yolk sac blood islands (adapted from Eichmann et al., 2005).
58
 Yolk sac hematopoiesis disappears after the 60th day of human development. Blood cells 
produced in the yolk sac are predominantly  nucleated erythrocytes, which synthesize embryonic 
hemoglobin. This first pool of erythrocytes produced is known as primitive erythrocytes, and the 
blood cells produced later during development in liver are called definitive erythrocytes. Primitive 
erythrocytes have also been detected in the cardiac area as early as 3 ss (21 days of human 
development) indicating that vascular connections between the yolk sac and embryo are initiated at 
this early  stage (Tavian and Peault, 2005). Inside the embryo, cells of the lateral mesoderm 
assemble symmetrically at  the lateral sides of the embryo forming the pre-endocardial tubes, and 
then later fuse at the anterior intestinal portal. The fused region forms the endocardium of the heart. 
The formation of two ventral and two dorsal aortas is closely related to heart   morphogenesis. The 
two dorsal aortas fuse later in development giving rise to one single vessel. The distal part of dorsal 
aortas gives rise to the vitelline or omphalomesentric arteries which fuse with the yolk sac vessels, 
similar to the two vitelline veins that form by splitting of the sinus venosus area (also called inflow 
tract) of the developing heart. Mesodermal cells of the extra-embryonic area give rise to the 
umbilical vessels (Patan, 2000).
 Vasculogenesis results in the formation of major embryonic blood vessels and primary 
vascular plexus in the yolk sac. In the chick embryo, this takes place before 14 ss. The time when 
vascular plexus remodels into a system with arteries and veins is critical for embryo survival. Many 
mouse mutants for genes involved in vascular development die during this remodeling phase at the 
14 ss (Roman and Weinstein, 2000).
 Another event of vascular development is angiogenesis, the formation of blood vessels from 
pre-existing vessels. It consists of two processes: the sprouting of endothelial cells and the splitting 
of vessel lumens by intussusceptive microvascular growth (IMG). Organs that are derived from 
ectoderm-mesoderm, e.g. the brain and neuroectoderm, are vascularized by angiogenesis (Patan, 
2000).
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2. Materials and Methods
2.1. in vivo experiments
2.1.1. Quail embryo model
 The generation of the vitamin A-deficient  (VAD) quail embryo model and the criteria for 
normal and VAD quail embryonic development in vivo have been described (Dersch and Zile, 1993; 
Twal, et al., 1995). Briefly, normal embryos were obtained from eggs of quail (Coturnix coturnix 
japonica) raised on the Michigan State University Poultry Research and Teaching Farm and fed 
game bird chow (Purina Mills Inc., St. Louis, MO). VAD eggs were obtained from quail fed a semi-
purified diet adequate in all nutrients except that vitamin A in the diet was replaced by  all-trans-
retinoic acid, which is not transferred to the egg (Dong and Zile, 1995). Eggs were collected daily 
and stored at 15°C until used. After incubation, the embryos were staged according to somite pair 
count and Hamburger & Hamilton (1951), using the standard avian HH stages to characterize the 
somite developmental stages (ss), as follows: pre-somite (HH4-6), 1 ss (HH7), 2-5 ss (HH8), 6-8 ss 
(HH9), 9-11 ss (HH10), 12-14 ss (HH11), and 15-17 ss (HH12, about 48 hr of incubation).
2.1.2.Treatment of embryos with all-trans-RA, or with antisense oligonucleotides to TGFβ2
 Eggs were incubated horizontally for 26-34 h at 38.5°C and 60% humidity, windowed as 
described by Selleck (1996), and embryos at pre-somite (HH4) or 1-5 ss (HH7-8) were subjected to 
various treatments. VAD quail embryos were sub-blastodermally  injected with 10-50 µl of Tyrode`s 
solution containing 10% VAD egg homogenate, 5% filter-sterilized Pelikan Fount India ink and a 
treatment substance, as described previously (Kostetskii, et al., 1998; 1999). In rescue experiments, 
10 ng of RA were administered to the VAD embryos. This RA concentration had been demonstrated 
to be effective in the induction of normal cardiovascular development in the VAD embryo, without 
any teratogenic effects (Kostetskii, et al., 1998). Controls received the vehicle without RA.
 For TGFβ2 gene blocking experiments, VAD embryos at 1-4ss were injected with 0.7 
nmoles of TGFβ2 antisense oligonucleotides (AS). The chicken TGFβ2 AS sequence (GeneBank 
Accession no. X59080) is as follows: 5'-GCA CAG AAA TTG GCA TGA TAT CCT TTA GGT 
TC-3'. The oligonucleotides were synthesized with phosphorothioate modification at the 
Macromolecular Structure Facility  at  Michigan State University. Control embryos received either 
the vehicle alone or a non-specific oligonucleotide. After the various above treatments, the embryos 
(visible above the ink background) were staged, the eggs sealed and incubated for additional 6 to 40 
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h, the length of time dependent on the experimental design. Embryos were examined either for 
morphology, or analyzed for the expression of TGFβ2 and TGFβRII (TBRII) by in situ 
hybridization.
2.1.3. Whole-mount in situ hybridization
 Normal and VAD embryos were dissected from extra-embryonal membranes, washed in 
cold PBS, and fixed in 4% paraformaldehyde (PFA) overnight at 4ºC. Embryos were dehydrated in 
a graded methanol series and stored at –20ºC until analysis. In situ hybridization was performed 
according to standard protocols using digoxigenin-tagged probes from available plasmids. 
Antisense riboprobes were prepared from chicken TGFβ2 (gift  of the late Dr. Anita Roberts) and 
from chicken TBRII (gift of Dr. Joey  Barnett). Synthesis of digoxigenin-tagged riboprobes was 
carried out with an in vitro transcription kit (Ambion) following the manufacturer`s protocol. The 
expression patterns of TGFβ2 and TBRII genes were examined at various early  stages of 
development.
 In situ hybridization was performed as described previously (Kostetskii et  al., 1993). All 
embryos were re-hydrated before in situ hybridization. Hybridization was carried out at 60ºC 
overnight in standard hybridization solution containing 1 µg/ml dig-oxygenin-tagged cRNA probe. 
After NBT/BCIP reactions the stained embryos were examined either under microscope or 
embedded in paraffin and sectioned at 10 µm.
 
2.1.4. Immunolocalization of endothelial cells
 Immunolocalization of endothelial cells was with the monoclonal antibody against QH-1 
(Developmental Studies Hybridoma Bank, University of Iowa), a presumptive quail endothelial cell 
marker. Stage-dependent changes in endothelial cells surrounding the heart forming region were 
examined in normal and VAD quail embryos by peroxidase-biotin-streptavidin immuno-
histochemistry. Embryos were fixed in 4% PFA, dehydrated, embedded in paraffin and sectioned at 
10 µm. Deparaffinized and rehydrated sections were heated in citrate buffer (10 mM  citric acid, pH 
6.0) at 92–95ºC for 25 min for epitope retrieval. After cooling to RT, sections were treated with 3% 
H2O2 for 10 min to inhibit endogenous peroxidase activity. Sections were next incubated in 1% 
bovine serum albumin (BSA)/10 mmol/l tris-(hydroxymethyl)-aminomethanebuffered saline (TBS), 
pH 7.4 blocking solution for one h to reduce non-specific binding of antibody, followed by 
incubation overnight at 4ºC with monoclonal antibody against QH-1, 1:100. Next, sections were 
incubated with horseradish peroxidase (HRP)-conjugated goat-anti-mouse IgG, 1:500 (Sigma) for 2 
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h at 4ºC. Antigen-linked peroxidase was detected with the chromagen 3-3’-diaminobenzidine 
(DAB) diluted in 10 m mol/l PBS, pH 7.2, containing 0.015% H2O2. Subsequently, the sections 
were lightly  stained in Gill’s hematoxylin, blued in 0.3% ammonium water, then dehydrated in 
ethanol-xylene and mounted with Permount. Antibody incubations were performed in Shandon 
racks; between steps the sections were rinsed with 10 mM TBS, pH 7.4.
2.1.5. Expression analysis by real-time PCR
 To confirm the data obtained from whole-mount in situ hybridization, the expression of 
TGFβ2 was analyzed by quantitative (real-time) reverse transcription polymerase chain reaction 
(qRT- PCR) at the Center for Animal Functional Genomics at Michigaan State University. Primer 
sequences are shown in Appendix 1. The primers were designed using the Primer Express 2.0 
program (Applied Biosystems). Total RNA was isolated from 4-7 ss normal and VAD quail 
embryos using TRIzol reagent according to manufacturer’s protocol (Gibco) and subsequently 
cleaned using RNeasy kit (Qiagen). RNA was quantified using a UV spectrophotometer (A260/A280), 
and the quality of RNA assessed by agarose-formaldehyde gel electrophoresis. Total RNA (2.5µg) 
was reverse transcribed using oligo (dT)12-18 primers and SuperScriptII-reverse transcriptase 
(Invitrogen), according to the manufacturer’s protocol. Gene expression levels were quantified on 
an ABI Prism7000 (Perkin Elmer Corp., Applied Biosystems) using the Syber Green Universal 
Master Mix (Applied Biosystems). In brief, the reactions mixture (25 µl total volume) contained 20 
ng single stranded cDNA, gene-specific forward and reverse primers (0.3 µM final concentration), 
12.5 µl Syber Green RT-PCR Master Mix, and 10 µl ddH2O, RNAse free. The real-time cycler 
conditions were as follows: PCR initial activation step at 95ºC for 15 min, 40 cycles each of 
melting at  95ºC for 15 sec and annealing/extension at 60ºC for one min. Assays were performed in 
duplicate using pooled RNA representative of 30 normal and 30 VAD embryos (30/each 
experiment). Relative fold-changes were quantified using the comparative CT (ΔΔCT) method 
(Winer et al., 1999). Data were normalized to the housekeeping gene β-actin and analyzed using the 
General Linear Model procedure in SAS statistical software (SAS Institute, Inc. Cary, NC; Version 
7.0).
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2.2. in vitro experiments
2.2.1. Cell cultures
Table 2.1. Overview on the cell cultures used in this work
Source Description Abbreviation Reference
Chicken early stage 
embryos
heart forming region 
cell population
hfr this work
Apical part of 42-day old 
chicken heart
heart mesenchymal 
cells
avian heart cells this work
Human heart biopsy heart mesenchymal 
stem cells
human heart 
MSC
kind gift of Dr.M. Hoogduijn 
Riekstina et al., 2009
Human umbilical cord Human umbilical vein 
endothelial cells
HUVEC Chemicon/Millipore
Human embryonic stem 
cell-derived cardiac 
progenitor cels
human cardiac 
progenitor cells
CPCs kind gift of Dr.M.Puceat 
Blin et al., 2010
Mouse embryonic 
fibroblasts
Mouse embryonic 
fibroblasts
MEFs kind gift of Dr.M.Puceat
 Blin et al., 2010
Table 2.2. Media used for the various cells
Name Description Cells cultured
DMEM DMEM/10%FBS/1%p/s avian hfr, heart cells, 
human MSC, MEFs
Endo Endo-GRO LS (Chemicon/
Millipore)
avian hfr, HUVEC
α-MEM α-MEM/10%FBS/1%p/s human heart MSC
KO-DMEM KO-DMEM/15%KO-SR CPCs, MEFs
Avian heart forming region (primary) cell cultures 
 Freshly hatched normal chicken eggs were incubated for 36-42 h at 37°C. The embryos were 
dissected under microscope in cold phosphate buffered saline (PBS) and staged by  their somite 
stage. Heart forming regions (hfr) from pre-somatic stage-2 ss, 3-5 ss and 7-14 ss were separated 
from the rest of embryonic tissue and kept in cold sterile DMEM  with 1% penicillin/streptomycin 
and 2% fungizone (all from Invitrogen).
After dissection chicken hfr were washed with sterile PBS and treated with 0.25% trypsin-
EDTA (Invitrogen) for 2-4 minutes. The primary cultures of 3-5 ss hfr cells were prepared from 
combined 10-15 explants treated with trypsin. One explant yielded ca. 50 000 cells. Trypsinized 
cells were counted and plated in 24-well plates, 20 000-30 000 cells/well and thereafter grown in 
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different media for three days at 37°C, 5% CO2 in dark. Cardiac crest and underlying neural tube 
cells from the 3-5 ss embryo hfr explant produced a heterogenous cell population in culture. 
Explant cells developed adherent monolayer within three days in culture; the confluence of the 
samples cultivated in Endo medium was 30-40% , and in DMEM, 10-15%. 
 Standard DMEM base for hfr cell cultivation was supplemented with 10% Fetal Bovine Serum 
(FBS) and 1% penicillin/streptomycin (all from Invitrogen). Endothelial cell growth media base, 
Endo-GRO (Endo, Chemicon/Millipore), according to the manufacturer’s protocol was 
supplemented with 2% FBS, 5 ng/ml Endothelial Growth Factor (EGF), 5 ng/ml basic Fibroblast 
Growth Factor (FGF), 15 ng/ml Insulin-like Growth Factor (IGF1), 50 µg/ml ascorbic acid, 1 µg/ml 
hydrocortisone hemisuccinate, 0.75 U/ml heparin sulfate, 10 mM  L-glutamine (Chemicon/
MIllipore) and 1% penicillin/streptomycin (Invitrogen). Both media were supplemented with all-
trans-RA (Sigma) to 10 nM  (3 ng/ml) or100 nM  (30 ng/ml) final concentration or with RA 
antagonist Ro 41 5253 (a kind gift from Hoffmann/LaRoche Co) to 0.5 µM, 1.5 µM or 3 µM final 
concentration. Control cells were grown without RA or Ro. All manipulations with RA were made 
in dark. Experiments were replicated five times with each concentration of RA and media.
Avian heart cells
 Avian heart cells were obtained from apical part of 42-day old chicken heart. In brief, the 
apical part of the heart was minced and digested with 0.5 mg/ml sterile filtered collagenase type IV 
(Sigma). After two washes in RPMI media, dissociated tissue and cells were cultured in α-MEM 
supplemented with 10% FBS and 1% penicillin/streptomycin (all from Invitrogen). Medium was 
supplemented with all-trans-RA (Sigma) to 66 nM  (20 ng/ml) or 133 nM (40 ng/ml) final 
concentration and incubated at 37°C, 5% CO2 for three, five and seven days. Control cells were 
grown without additional RA.
Human cells
 α-MEM base for human heart mesenchymal stem cell (kind gift of Dr. Martin Hoogduijn) 
cultivation was supplemented with 10% FBS and 1% penicillin/streptomycin (all from Invitrogen). 
Human umbilical vein endothelial cells were grown in endothelial cell growth media base, Endo-
GRO (Endo, Chemicon/Millipore), according to the manufacturer’s protocol and was supplemented 
with 2% FBS, 5 ng/ml EGF, 5 ng/ml basic FGF, 15 ng/ml IGF1, 50 µg/ml ascorbic acid, 1 µg/ml 
hydrocortisone hemisuccinate, 0.75 U/ml heparin sulfate, 10 mM  L-glutamine (Chemicon/
Millipore) and 1% penicillin/streptomycin (Invitrogen). Both media were supplemented with all-
trans-RA (Sigma) to 66 nM  (20 ng/ml) or 133 nM (40 ng/ml) final concentration and incubated at 
37°C, 5% CO2 for three, five and seven days. Control cells were grown without additional RA.
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 Human embryonic stem cell-derived early cardiovascular progenitor cells (CPCP) line has 
been recently characterized (Blin et al., 2010) and was used in these studies. In brief, human ESC 
were cultured in the presence of BMP2, then sorted after the SSEA-1 (CD15) and grown in defined 
media with certain supplements that result in the generation of endothelial cells, cardiomyocytes 
and smooth muscle cells. Human CD15+ cells and CD15- cells (kind gift of Dr. Michele Puceat) 
generated from HUESC-24 were cultured in 15% KO-SR in KO-DMEM (all from Invitrogen) 
cultured up to 7 days. The concentrations of all-trans-RA (Sigma) were as previously  described for 
the avian cell cultures, respectively, 3 ng/ml (10 nM) and 30 ng/ml (100 nM). Control cells were 
grown without RA. All manipulations with RA were made in dark. Experiments were replicated 
five times with each concentration of RA and media.
2.2.2. Analysis of secreted TGFβ2 by ELISA
 The amount of total secreted TGFβ2 protein in medium was quantified by TGFβ2 DuoSet 
ELISA (R&D Systems, Cat. #DY302; the antibodies in this kit react with avian proteins). In brief, 
medium was collected from incubated cells, and immediately used for ELISA. Media samples were 
incubated with 1 N HCl at RT for 10 min to activate TGFβ2 and neutralized with 1.2 N NaOH in 
0.5 M HEPES. Assays were repeated five times with triplicate samples. The changes in secreted 
TGFβ2 in RA supplemented media were expressed as percent of secreted TGFβ2 from internal 
control (cells cultured in media without RA supplement). The mean values, standard deviation and 
statistical significance P values were calculated using GraphPadPrism v 5.0 software.
2.2.3. Expression analysis by PCR and real-time PCR
 RNA from chicken hfr and heart cell cultures as well as from human cell lines was extracted 
using TRIzol reagent (Invitrogen) according to the manufacturer’s recommendations. First strand 
cDNA synthesis was performed on 0.5-1 µg total RNA using RevertAid™ M-MuLV Reverse 
Transcriptase (Fermentas). The quality of cDNA was tested in PCR reaction (25 cycles) with 
chicken housekeeping gene β-actin or human housekeeping genes β-actin, GAPDH, and PGK1. 
Chicken gene VEGF-A, GATA4 and Nkx2.5 mRNA expression was tested in obtained cDNA by 
standard PCR reaction (Veriti, Applied Biosystems): initial activation at 95°C 5 min, followed by  30 
to 35 cycles of melting at 95°C for 15 sec, annealing at 58 to 60°C for 20 sec and elongation at 
72°C for 20 sec. All primer sequences and reference numbers are shown in table 3. Gene expression 
levels were quantified by real-time PCR on an ABI Prism 7300 (Applied Biosystems) using 
Maxima SYBR Green/ROX qPCR Master mix (Fermentas). In brief, the reaction mixture in 20 µl 
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total volume contained 10 - 15 ng single stranded cDNA, gene specific forward and reverse primers 
(0.4 µM  final concentration), 10 µl SYBR Green Master mix. PCR conditions: initial activation step 
at 95°C 4 min, 40 cycles each of melting at  95°C for 15 sec and annealing/extension at 60°C for 40 
sec. Primer sequences are shown in Appendix 1. Assays were performed in duplicate. Relative fold-
changes were quantified using the comparative CT (ΔΔCT) method (Winer et al., 1999). Data were 
normalized to the housekeeping gene β-actin or PGK1 or GAPDH. All products were resolved on 
1.8% agarose gel with 100 bp DNA ladder (Fermentas).
2.2.4. HPLC analysis
 RA samples for HPLC were prepared essentially as described (Miyagi et al., 2001). Briefly, 
ca. 700 000 cells from combined explant tissue in 500 µl of phosphate buffered saline pH 7.4 were 
vortexed for 60 seconds with 500 µl ethanol, 225 µl 2 M  KOH and 600 µl n-hexane. After 
centrifugation at 15 000 rpm for 5 min, upper phase and lower phase were collected separately. 
Lower (water) phase was vortexed with 450 µl 2 M HCl, 600 µl of n-hexane, centrifuged as 
previously  and upper phase was collected. The fractions were evaporated; each residue was 
dissolved in 200 µl of n-hexane and subjected to analysis on Agilent 1100 HPLC system (Agilent 
Technologies).
 All-trans-RA solution in DMEM with 10% FBS was used for calibration. RA was analysed 
with UV detector at 351 nm in 100 µl samples using a reverse-phase Zorbax Eclipse XDB-C18 
column 4.6x150 mm, 5 µm with MeOH-0.3 % acetic acid (80/20 v/v) mobile phase or at λ 350 nm 
using Zorbax SIL column 4.6x250 mm, 5 µm with n-hexane : 2-propanol : acetic acid (1000 / 43 / 
0.675 v/v/v) mobile phase at  flow rate 1.0 ml/min at 25°C. Results were evaluated by a 
ChemStation Plus.
 Eukaryotic cells are cultured in different media, which contain defined composition of salts, 
amino acids, vitamins and sugars (media base), supplemented most frequently with FBS to 10% 
final concentration and antimicrobial substances. Since defined media base, DMEM from 
Invitrogen or Endo from Chemicon/Millipore, does not contain any retinoids, the only unmonitored 
source of RA in hfr cultivation experiments could be FBS or chick embryo cells themselves. We 
analyzed the presence of RA in FBS lots, which were obtained from Invitrogen and Chemicon/
Millipore as well as in the chick embryo explants cells.
 HPLC analysis demonstrated that in 10% solution of the FBS purchased from Invitrogen 
preparation there was 0.99 ± 0.02 nM  RA, while FBS purchased from Chemicon/Millipore 
contained 0.92 ± 0.02 nM RA (Table 2.3).
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 Table 2.3. The analysis of all-trans-RA in media
all-trans-RA
reverse phase direct phase 
DMEM (10%FBS) 0.96 nM 0.95 nM
after extraction n/a 0.70 nM
Endo (2%FBS) - -
10% FBS (Invitrogen) 0.99 nM 0.94 nM
after extraction n/a 0.64 nM
10% FBS (ChemiconMillipore) 0.92 nM 0.90 nM
after extraction n/a 0.77 nM
All values are compared using standards of 10 nM and 100 nM RA
Recalculation of the measured RA concentrations to 100% FBS, gives values close to 10 nM, which 
corresponds to the average RA concentration of human serum, i.e. 1.5–3.0 ng/ml or ca. 5-10 nM. 
No detectable RA was found in chick embryo explant tissues. 
 Control media used in all experiments without extra RA supplement, contained FBS at 
concentration of 10% (in DMEM) and 2% (in Endo) and therefore had base levels of 0.96 nM  RA 
and 0.1 nM  RA, respectively. These levels are below the normal RA concentration in human plasma 
(De Ruyter et  al., 1979; Eckhoff and Nau, 1990), thus the addition of 10 nM RA would be closer to 
its physiological levels.
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3. Results
3.1. TGFβ2 is negatively regulated by RA during early heart morphogenesis in 
VAD quail embryo
3.1.1. Abnormal heart inflow tract development in the vitamin A-deficient quail embryo
	
 Several morphological abnormalities caused by deficiency of vitamin A have been 
described in the vitamin A-deficient (VAD) quail model. Embryos lacking any form of vitamin A 
die by the day 4 of embryogenesis (Dersch and Zile, 1993; Kostetskii et al., 1999; Cui et al., 2003). 
The earliest gross developmental changes are evident at the time of formation of the cardiovascular 
system. These changes manifest as an abnormal, un-looped, randomly oriented (left/right) but 
beating heart. Extra-embryonal blood vessels and the central nervous system (CNS) are abnormal. 
These studies have provided strong evidence that the presence of vitamin A is essential for posterior 
heart (primary heart field) to form its linkages between heart and the extra-embryonal blood supply, 
i.e. the inflow tracts, which are closed in VAD embryos. Dersch and Zile (1993) showed that 
administration of endogenous retinoic acid (the active form of vitamin A) at a specific time of 
embryonic development, the 4-5 somite stage of HH8, can rescue the development of the VAD 
avian embryo and normalizes the development of the cardiovascular system.
 The progression of the gradual morphological changes in the cardiac region between the 
heart forming regions of normal and VAD embryos is shown in Figure 3.1. In order to determine if 
the closing of the inflow tracts (IFT) is due to decrease of endodermal cells, we evaluated the 
morphology  and endothelial contribution to the posterior heart forming regions using QH1 
immunostaining of transverse sections throughout the developmental stages 6-7 ss, 8-9 ss and 10-11 
ss. First, the immunostaining between N and VAD samples in all stages is of similar intensity 
suggesting that proliferation and differentiation are not altered in the epimyocardial and endodermal 
layers at the posterior heart forming sites of the VAD embryos. Instead, the defects in 
morphogenesis at this site may involve disturbances in other cellular events, e.g. a lack of the 
certain components required for building the inflow tracts or cell migration. Second, transverse 
sectioning gave a better insight into the abnormalities of cell layer positions. At the 6-7 ss, the 
developing heart of the VAD embryo (Fig.3.1 B) is similar to that of the normal embryo (Fig.3.1 A). 
Any differences, if visible in the whole-mounts, are due to individual differences between embryos. 
Normal heart development at 8-9 ss is shown in Fig.3.1 C. The primitive heart tube is localized 
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slightly to the right, but the two parts of the primary  heart field (primordia) are almost completely 
fused (Fig.3.1 c1), and will form a normal heart tube later in development. Inflow tracts are wide 
open but still pointed more posteriorly.
Figure 3.1. Morphology and QH-1 immunostaining of the posterior heart forming regions of normal and VAD quail 
embryos at 6/7 ss through 10/11 ss of development. Normal (A) and VAD (B) quail embryos at 6/7 ss are shown in 
whole-mounts and sequential transverse sections through the posterior heart forming region. QH-1 localization is 
associated with the endodermal cell layers. Normal development of 8/9 ss embryo is shown in (C); in the VAD embryo 
shown in (D) the inflow tracts (arrows) are abnormally expanded anteriorly but are beginning to narrow caudally (d3). 
At the 10/11ss, the normal embryo (E and e1) has a single heart tube (ht), positioned to the right, the inflow tracts 
(arrows) are open, linking the heart via the vitelline veins to the extra-embryonal circulation. The same stage VAD 
embryo is shown in panels F, f1, f2 and f3, revealing that the endodermal cell layers continue to be a part of the 
abnormally developing  inflow tract structures in these embryos.
ss, somite stage; nt, neural  tube; da,dorsal aorta; ht, heart; en, endocardium; ep, epimyocardium.
Arrows point to inflow tracts.  Brown HRP staining localizes QH-1 in the cross sections. Scale bar in A applies also to 
B, C,  D, E, and F; scale bar in G, 1mm, applies to all cross sections. Dotted lines in the whole-mounts indicate the sites 
of sectioning at approximately the same level in normal and VAD embryos. All views are ventral.
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In the VAD embryo the inflow tracts are large and abnormal and beginning to narrow towards 
caudal ends at the 8-9 ss (Fig.3.1 D,d3). The heart  is still in the middle, but primordia fusion is 
interrupted and epimyocardium is bulging ventrally (Fig.3.1 d1). At 10-11 ss the heart of a normal 
embryo is a single tube positioned to the right with a slight looping, the inflow tracts are wide open, 
positioned more distal from the midline and linked to the extra-embryonal circulation via vitelline 
(omphalomesentheric) veins (not visualized/marked in Fig.17). The heart of the VAD embryo 
shows visible morphological abnormalities. In addition to the previously shown morphological 
disturbances, i.e. the heart  in the middle and bulging ventrally, we now clearly see that even at this 
stage the two endocardia are still not fused (Fig.3.1 f1). This is because the fusion of the heart tubes 
in the VAD embryos takes place later and eventually results in the formation of a single, ballooned, 
chamber-less heart (Dersch and Zile, 1993; Kostetskii et al., 1998; Zile, 2004). The IFTs in the VAD 
embryo are oriented caudally  and  more parallel to the midline. The endodermal cell layers continue 
to be a part of the abnormally  developing IFT structures in the VAD embryo (Fig.3.1 f1,f2,f3). 
However, the endocardial and epimyocardial cell layers in these abnormally developing IFT 
structures of the VAD quail embryo are comparable to the normal. The structural deviation of the 
IFT from the normal, clearly  manifested at the 10-11 ss, is likely due to differences in the 
architecture of the developing heart tube and foregut, affecting the morphogenesis of the IFTs, but 
not the differentiation of cardiomyocytes, since the heart is still capable of beating in VAD embryos, 
although weakly.
 At this time it appears that the closing of the IFTs is due to the cellular layers from the 
opposite sides having moved together, resulting in the narrowing and subsequent total closure of the 
open spaces, thus cutting off the entry for the vascular links, i.e. the vitelline veins.
3.1.2. Over-expression of N-cadherin, TGFβ2 and its receptor TGFβRII in the absence of RA
 N-cadherin is an important cell adhesion molecule that has been linked to heart 
morphogenesis (Kostetskii et al., 2005). It is expressed in the mesodermal tissue that differentiates 
into heart (Hatta et al., 1987) and is localized within heart forming regions (Linask, 1992).
 Studies with 1-5 ss mice have provided descriptive analysis of TGFβ2 expression during 
early cardiac morphogenesis and show this gene to be expressed in the promyocardium of the sinus 
venosus of the inflow tract as well as in the foregut endoderm (Dickson et al., 1993). Earlier studies 
of Kostetskii and Zile (1993), suggested that if the early embryo lacks vitamin A, transforming 
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growth factor TGFβ expression is altered. TGFβ2 in the heart forming region (hfr) was the most 
altered isoform in VAD embryos. TGFβ2 in the avian embryo is expressed as early as pre-somite 
stages (HH4) and is localized in most tissues and in all cell layers (Jakowlew et al., 1994).
 Here we examined the changes in N-cadherin and TGFβ2 gene expression using real-time 
PCR (Fig.3.2).
Figure 3.2. Quantification of differences in the expression levels of N-cadherin (A) and TGFβ2 (B) between normal and 
VAD embryos using real-time PCR, illustrating N-cadherin and TGFβ2 abundance in VAD embryos.
Quantification of the expression of both genes by real-time PCR indicates a significant (p  = 0.0002) 
3.7-fold change of N-cadherin and 1.7-fold change of TGFβ2 in 4-7 ss VAD embryos compared to 
the same stage normal embryos (Fig.3.2 A, B). A more detailed analysis of N-cadherin is described 
in Romeih et al. (2009).
 The spatiotemporal expression of TGFβ2 in quail embryos was examined by  in situ 
hybridization. At the 6-7 ss, there is an intense over-expression of TGFβ2 in the VAD embryos 
when compared to normal (Ghatpande et al., 2010). Cross-sectioning at  the posterior level of the 
heart-forming region reveals that in both normal and VAD embryo TGFβ2 is expressed in all cell 
layers, but is over-expressed in the VAD embryo. At the 10-11 ss the intensity  of the TGFβ2 in the 
VAD embryo is beginning to decrease, but still having abnormal morphology, suggesting that after 
10 ss the presence of RA is not critical for TGFβ2 expression.
 The expression of TGFβ2 and one of its receptor TBRII, a component of the TGFβ signaling 
complex (López-Casillas et al., 1991; Massagué et al., 1998), is shown in quail embryos at 7 ss in 
Figure 3.3. The expression of TBRII and TGFβ2 at various stages was examined and demonstrated 
that the expression of TBRII mimics the expression of TGFβ2, and that their expression intensity 
and localization are similar. At the 7 ss, there is an intense over-expression of TGFβ2 in the VAD 
embryo (Fig.3.3 B) in comparison to normal embryo (Fig.3.3 A). Similar over-expression is 
observed in the case of TBRII (Fig.3.3 D and E).
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Figure 3.3. Expression of TGFβ2 and its receptor TBRII in whole-mounts of normal (N) and vitamin A-deficient (VAD) 
quail embryos at 7 ss (HH9) and blocking TGFβ2 and TBRII expression with anti-sense TGFβ2, assessed by in situ 
hybridization. The elevated levels of TGFβ2 between N and VAD embryos (panels A and B) and TBRII (panels D and 
E) are illustrated. Arrow points the posterior heart forming region. Treatment of VAD embryos at 1ss with TGFβ2 
antisense oligonucleotide (0.7 nmol) normalizes both TGFβ2 (C) and TBRII (F) expression. G - negative control with 
non-specific oligonucleotides. All views are ventral.
This TGFβ2 over-expression in the VAD embryos continues at least until the 11 ss. This observation 
supports the involvement of the TGFβ2 signaling pathway in the RA-regulated heart 
morphogenesis. As shown by  Ghatpande et al. (2010), cross-sectioning at the posterior level of the 
heart-forming region reveals that in both normal and VAD embryos TGFβRII (similarly  to TGFβ2) 
is expressed in all cell layers; this is in general agreement with the data reported earlier (Jakowlew 
et al., 1994). This TGFβ2 over-expression in the VAD embryos continues at least  until the 11 ss. 
This observation supports the involvement of the TGFβ2 signaling pathway in the RA-regulated 
heart morphogenesis. As shown by Ghatpande et al. (2010), cross-sectioning at the posterior level 
of the heart-forming region reveals that in both normal and VAD embryos TBRII (similarly to 
TGFβ2) is expressed in all cell layers; this is in general agreement with the data reported earlier 
(Jakowlew et al., 1994).
 Additional support of TGFβ2 signaling pathway involvement in the RA-regulated heart 
morphogenesis comes from the finding that blocking the over-expression of the TGFβ2 in the VAD 
embryos normalizes not only the expression of TGFβ2 but also that of the TBRII. The 
administration of TGFβ2 antisense oligonucleotide to VAD embryos at 1 ss normalized the 
expression of both TGFβ2 (in 70% cases; n = 15) and TBRII (in 70% cases; n = 15) (Fig.3.3 C and 
F). The 7 ss was chosen for comparative evaluation of expression because at this developmental 
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time the differences in the expression in the TGFβ2 and TBRII genes between normal and VAD 
embryos are most pronounced, indicating peak transcriptional activity. Further results are described 
in greater detail in Ghatpande et al. (2010) (see attached copy of article) where it is shown that 
blocking excess TGFβ2 active protein rescues VAD cardiovascular phenotype whereas addition of 
active TGFβ2 protein induces the VAD phenotype in normal embryos.
3.2. Effect of RA on TGFβ2 and selected potential TGFβ2 target genes on chick 
heart forming region cells in culture
3.2.1. Development of cell culture model
 My research and that of others in the lab of Zile (Ghatpande et al., 2010) suggested a role of 
RA as a negative in vivo regulator of TGFβ2 during early  heart development of the avian embryo. 
To develop a model system for accessing the molecular mechanisms of regulation that are 
influenced by RA/TGFβ2 interplay during avian early embryogenesis, we established an in vitro 
system of chick heart forming region (hfr) cells.
 To ascertain the functionality  of the hfr ,we tested the viability of the explants from chick 
embryos in DMEM  and Endo media. Chicken hfr explants were obtained after incubation of freshly 
hatched eggs. Eggs were opened and embryos dissected and staged according to somite stages 
(according to the somite count). The heart forming regions from 1-9 ss were obtained by dissection 
(Fig.3.4 A) and placed in separate wells on 24-well plate containing DMEM or Endo media and 
cultured for 24 h (Fig.3.4 B). Contractile cardiomyocytes were observed after a one day of 
cultivation in both DMEM and Endo medium.
Figure 3.4. Chick embryo at 4 ss (A, left) and dissected heart forming region explant (A, right) after one day cultivation 
cultured in Endo medium (B). Red line marks the borders of contractile tissue developed within a day in culture.
73
Explants from all tested development stages developed contractile cardiomyocyte tissue aggregates 
when cultured in Endo media, however the yield of such tissue diminished at  later stage explants, 
i.e. only one out of four at 7-10 ss. The development of contractile tissue in DMEM  in comparison 
to Endo medium was poor at 1-2 and 3-5 ss; no contractile explants were obtained in DMEM at 
7-10 ss (Table 3.1).
Table 3.1. Chick hfr explants from various embryonic development stages that were forming 
contractile tissue aggregates in cultivation media 
1/2ss 3/5ss 7/10ss
DMEM 1 (8) 1 (7) 0 (4)
Endo 3 (8) 7 (9) 1 (4)
Total number of explants placed in culture are shown in brackets.
All of the 7-10 ss explants cultured in Endo medium developed an adherent cell monolayer, while 
the same stage explants cultured in DMEM did not develop adherent cell monolayers. However, the 
media and culture conditions were not optimal for structural development.
 VEFG-A, GATA4 and Nkx2.5 gene mRNA expression was determined to test the presence 
of cardiovascular cell population within hfr cell cultures.
Figure 3.5. PCR analysis of chick hfr cell population cultured in two 
media. DMEM,DMEM, normal adherent cell growth media, Endo, 
Endo-Grow, endothelial cell media. β-actin was internal control. 
Samples from Endo media gave stronger intensity bands for 
VEGF-A, GATA4 and Nkx2.5 gene mRNA transcripts in comparison to those from DMEM  where 
VEGF-A and Nkx2.5 bands were very weak; no transcripts were observed for GATA4 (Fig.3.5).
 Next, we tested the responsiveness of cultivated hfr cells to RA treatment. Homeobox gene 
HoxB1 is involved in early  development of vertebrate embryos, and known to be regulated by RA 
both in vitro (Boncinelli et al., 1991) and in vivo (Wood et al., 1994; Maden et  al., 1996). The 
accumulation of HoxB1 gene mRNA transcript amplification product from hfr cells grown in media 
with or without added RA at the end point of 40 cycle real time PCR is shown in Fig.3.6.
Figure 3.6. PCR analysis of the expression of HoxB1 gene 
mRNA in avian hfr cells grown in Endo media with RA 
supplement. β-actin was used as a reference in control (no RNA 
supplemented) and exogenous RA supplied cells.
The expression of HoxB1 was very weak in the control 
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samples of chick hfr cells that were grown in media without RA supplement. These results clearly 
demonstrate the stimulation of the HoxB1 gene mRNA synthesis by RA. Quantification of the 
differences of the concentration of the HoxB1 gene specific product revealed ca. 400-1000-fold 
increase of HoxB1 gene mRNA expression after RA stimulation.
3.2.2. Effect of exogenous RA on the secretion of TGFβ2 protein and the expression of TGFβ2 
gene mRNA
 Chick hfr cells were grown in DMEM  and Endo media supplemented with exogenous RA at 
10 nM concentration which corresponds to the average concentration of RA in human blood 
plasma, 5-10 nM (De Ruyter et al., 1979; Eckhoff and Nau, 1990) and at the elevated level of RA, 
100 nM. Cell growth medium was collected after three day  cultivation and used for TGFβ2 ELISA 
assay on the same day. Media without RA supplement was used as a control for each experiment.
 Chick hfr primary cell cultivation experiments in RA-supplemented media were replicated 
five times.
Figure 3.7. Influence of exogenous RA on TGFβ2 protein and mRNA synthesis in primary hfr cells grown in DMEM 
and Endo media for three days in culture. (A) Relative quantification of TGFβ2 total protein in the cultivation media 
(+/- per cent) in comparison to the control cells with no RA added (100%). (B) Relative quantification of TGFβ2 
mRNA (+/- per cent) in comparison to the control cells with no RA added (100%). Standard deviation is indicated by 
error bars. The differences in comparison to the control at significance level p<0.05 are marked by (*), at p<0.005 by 
(**); at p<0.0001 by (***).
 
 In comparison to the control without added RA, both added RA concentrations in a dose-
dependent manner suppressed the accumulation of total TGFβ2 protein: protein concentration was 
decreased by ca. 50% in DMEM and by 60% and 80% in Endo medium (Fig.3.7 A).
 TGFβ2 mRNA synthesis was also decreased in the presence of exogenous RA. The 
accumulation of TGFβ2 transcripts was reduced to ca. 65% in comparison to the control cells in 
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DMEM, and in dose-dependent manner to 60% and 40% level in comparison to the control cells in 
Endo medium (Fig.3.7 B).
3.2.3. Effect of exogenous RA on TGFβ/SMAD regulated gene and VEGF-A mRNA synthesis
 To assess if the altered TGFβ2 mRNA synthesis and protein secretion in the presence of 
exogenous RA in hfr cells affects the expression of the mRNA of proteins that are regulated through 
the classical TGFβ/SMAD signaling pathway, we selected target genes according to previous 
studies in human fibroblast cultures (Verrecchia et al., 2001). The genes, which were identified in 
the above study, have been grouped in six clusters. We selected randomly  one gene from each 
cluster (e.g. Fibornectin (FN1), c-myc, lamininB1, neogenin (NEO), CD44 and β-catenin). Since 
the decrease of the levels of TGFβ2 is observed using highest added RA concentration (100 nM), 
the genes were screened for their mRNA expression in chick hfr cell cultures grown in the presence 
of 100 nM RA (Fig.3.8).
Figure 3.8.  Relative quantification of TGFβ2 and TGFβ/SMAD target genes in DMEM and Endo media supplemented 
with 100 nM RA for three days. 
TGFβ2 gene expression was greatly suppressed in the presence of 100nM RA; a significant 
decrease was also observed in the expression of laminin B1 (laminB1), neogenin (NEO), while 
decrease in c-myc and β-catenin (b-caten) expression was less pronounced and CD44 expression 
was not altered. In contrast, exogenous RA resulted in an greatly elevated expression of fibronectin 
(FN1) in the cultured primary hfr cells.
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 Next, it  was of interest to examine the expression of FN1 and NEO in the primary  hfr cell 
culture in response to different levels of exogenous RA. We choose FN1 because of its different 
from TGFβ2 response to RA, and NEO since its response to added RA was most pronounced.
 FN1 encodes an extracellular matrix protein (Hay, 1981). In human cells it is significantly  
up-regulated by  TGFβ2 through SMAD signaling pathway  already at 30 min (Verrecchia et al., 
2010). NEO gene encodes a multifunctional receptor that regulates many developmental processes, 
especially neural tube and mammary  gland formation, myogenesis and angiogenesis (Cole et al., 
2007). It is significantly  up-regulated by TGFβ2 through SMAD signaling pathway in the human 2 
h after TGFβ2 signal comes (Verrecchia et al., 2010).
Figure 3.9.  Influence of exogenous RA in primary hfr cells grown in DMEM and Endo media for three days in culture 
on the accumulation of mRNA of the genes that are regulated by TGFβ2 protein through SMAD signaling pathway. (A) 
Relative quantification of FN1 mRNA (+/- per cent) in comparison to control cells with no RA added (100%). (B) 
Relative quantification of NEO mRNA (+/- per cent) in comparison to control cells with no RA added (100%). Standard 
deviation is indicated by error bars. Differences in comparison to the control at significance level p<0.05 are marked by 
(*), at p<0.005 by (**); at p<0.0001 by (***).
FN1 gene transcript  accumulation was stimulated by exogenous RA in both media. Cells from 
DMEM  showed statistically significant, 84% and 68% RA dose independent increase of FN1 gene 
mRNA synthesis at  both RA concentrations. Cells cultured in Endo medium showed statistically 
significant 63% increase of FN1 mRNA accumulation only at 100 nM RA, while the 46% increase 
at 10 nM RA in medium was not statistically significant (Fig.3.9 A).
 Changes of NEO mRNA expression in the presence of exogenous RA paralleled those 
observed with TGFβ2 mRNA accumulation. mRNA expression levels of NEO decreased in the 
presence of exogenous RA. Changes of NEO gene expression in DMEM with supplemented RA 
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showed a tendency to decrease, which was impossible to confirm by  statistical analysis due to high 
standard deviation of the data. More robust changes in the expression of NEO mRNA were 
observed in the hfr cells grown in Endo media, where expression was decreasing in RA dose-
dependent manner to 51% and 34% level in comparison to the cells cultured without RA 
supplements (Fig.3.9 B).
 Previous studies in the in vivo VAD quail embryo demonstrated impaired vasculogenesis 
along with other cardiovascular abnormalities in early  development. VEGF plays a specific role in 
the maintenance and induction of growth of vascular endothelial cells (Ferrara et al., 1991) and also 
is a strong mitogen (Ferrara, 2000). Since the absence of RA results in a decrease of endothelial cell 
population and impaired vasculogenesis at 5-10 ss in the VAD quail embryo in vivo (LaRue et al., 
2004), it was important  to examine chicken Vascular Endothelial Growth Factor VEGF-A 
expression in the mixed hfr cell population in vitro.
Figure 3.10. Influence of exogenous RA in primary hfr cells grown in DMEM and Endo media for three days in culture 
on the expression of the VEGF gene mRNA. Standard deviation is indicated by error bars. Differences in comparison to 
the control at significance level p<0.05 are marked by (*), at p<0.005 by (**); at p<0.0001 by (***).
 Cells cultured in DMEM  and Endo medium show an elevated, RA dose- dependent VEGF-
A mRNA transcript accumulation (Fig.3.10). Hfr cells in DMEM with 10 nM  RA supplement 
produced 42% and with 100 nM RA supplement,78% more VEGF-A mRNA expression in 
comparison to the control without added RA; the effect was even more pronounced in Endo 
medium, i.e. the increase was 135% at 10 nM RA and 235% at 100 nM RA.
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3.3. Effect of RA deficiency on TGFβ2 and selected potential TGFβ2 target genes 
studied in chick heart forming region cells in culture
 The RA antagonist Ro 41 5253 (Ro; Apfel et al., 1992) at 2-10 fold excess over 
physiological RA levels is known to block the binding of RA to RARα by inducing conformational 
change in the receptor (Keidel et al., 1994). At a 50-100 fold excess of Ro over RA also blocked is 
RARα mediated signaling. Ro has been used to mimic VAD status in studies of chick 
embryogenesis (López et al., 1995; Stuckmann et al., 2003).
Figure 3.11. Influence of Ro on protein and mRNA synthesis in primary hfr cells grown three days in Endo media. (A) 
Relative quantification of TGFβ2 total protein in the cultivation media (+/- per cent) in comparison to the control cells 
with no Ro added (100%). (B) Relative quantification of TGFβ2 mRNA (+/- per cent) in comparison to the control cells 
with no Ro added (100%). (C) Relative quantification of FN1 (left) and NEO (right) mRNA (+/- per cent) in 
comparison to the control cells with no Ro added (100%). (D) Relative quantification of VEGF-A mRNA (+/- per cent) 
in comparison to the control cells with no Ro added (100%). Standard deviation is indicated by error bars. The 
differences in comparison to the control at significance level p<0.05 are marked by (*), at p<0.005 by (**); at p<0.0001 
by (***).
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FBS, which we used in our experiments, contained a typical concentration of plasma RA, which 
was correspondingly diluted by adding 10% or 2% of the serum to the cell growth medium. We 
tested the effectiveness of Ro in chick hfr cell primary culture to assess if the changes in protein 
expression will parallel those that are observed in VAD quail embryos in vivo (Ghatpande et al., 
2010). Experiments were done in Endo medium only, since in the previous assays we found more 
clear-cut responses to RA in Endo medium as compared to DMEM. 
 All mRNA relative quantification experiments were repeated twice with 0.5 µM Ro 
concentration, three times, with 1.5 µM  and 3.0 µM  Ro concentrations. In the presence of RA 
antagonist Ro at 0.5 µM concentration the accumulation of TGFβ2 protein is increased by 54.9% in 
comparison to the control without  antagonist. The increase tends to diminish when higher 
concentrations of antagonist are added: +35.7% at 1.5 µM Ro and 10% at 3.0 µM Ro (Fig.3.11 A). 
 TGFβ2 mRNA synthesis in response to the Ro treatment parallels the pattern of protein 
accumulation. At 0.5 µM Ro, TGFβ2 transcript accumulation is 60% higher, at  1.5 µM  Ro, it  is 
45% higher and at 3.0 µM Ro it is 33% higher than in control cells without antagonist (Fig.3.11 B). 
 The antagonist does not have any influence on the expression of FN1 mRNA synthesis, 
while NEO transcript level is 80% elevated at 0.5 µM  Ro concentration, 125% elevated at 1.5 µM 
Ro concentration and 140% elevated at 3.0 µM  Ro, in comparison to control cells without 
antagonist (Fig.3.11 C). No changes in VEGF-A mRNA synthesis in response to RA antagonist 
were detected. At 3.0 µM  Ro concentration the level of the VEGF-A expression is 69% higher than 
in the control cells, but the differences are not statistically significant (Fig.3.11 D).
3.4. Effect of excess RA on TGFβ2 and selected potential TGFβ/SMAD regulated 
genes in human cell cultures
3.4.1. Characterization of human heart mesenchymal stem cells
 Recent data (Ghatpande et al., 2010; Li et al., 2010) and this work demonstrates that RA-
regulated TGFβ2 expression and synthesis are elevated in absence of RA and decreased in presence 
of the exogenous RA in avian cells. The same interplay  between RA and TGFβ isoforms have been 
shown previously in mouse embryogenesis (Mahmood et  al., 1992; 1995). We next wanted to see 
whether RA elicits the same response on TGFβ2 signaling in human cells.
 Adult stem cells are capable of self-renewal, and can give rise to different cell types. These 
cells are responsible for maintenance of homeostasis of our body tissue (Freitas and Dalmau, 2006). 
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Human heart mesenchymal stem cells were characterized by immunocytochemistry, flow cytometry 
and PCR methods using well described mesenchymal and embryonal stem cell markers (for details 
see attached copy of Riekstina et  al., 2009) and the mesenchymal stem cells (MSC) from the heart 
were compared with other MSC derived from different tissues (Fig.3.12).
Figure 3.12. Semi-quantitative two-step PCR analysis of 
embryonic stem cell marker Oct4, Nanog,  Sox2, and germ layer 
markers Nestin, GATA4, Pdx1 and TGFβ1, as well as 
mesenchymal stem cell marker Thy-1 (CD90) and Endoglin 
(CD105) expression in bone marrow (BM), adipose tissue (AT), 
dermal (D) and heart (H) mesenchymal stem cells.  β-actin was 
used as internal control in all experiments.
Human heart  cell samples express all the embryonic stem cell markers as well as germ layer 
markers that were chosen according to manufacturer’s suggestions (RnD System’s), where Nestin is 
used as ectodermal, GATA4 and Pdx1 as endodermal and TGFβ1 as mesodermal lineage markers. 
GATA4 is a cardiac specific marker expressed only in heart mesenchymal stem cells (Fig.3.12).
3.4.2. Effect of excess RA on the secretion and expression of TGFβ2 and its target genes in 
human heart mesenchymal stem cells and in avian heart cells
 Cultured human heart MSC expresses all embryonic stem cell markers, and cardiac specific 
marker at the same time suggesting their “stemness”. We next looked at the response of TGFβ2 to 
the presence of exogenous excess RA (66 nM  and 133 nM) in cultured human heart  mesenchymal 
stem cells (MSC) (Fig.3.13). The concentrations were chosen to be slightly above (40 ng/ml; 133 
nM) and below (20 ng/ml; 66 nM) the concentration that is necessary for induction of atrial sub-
lineage development (100 nM) in embryonic stem cells (Gassanov et al., 2009).
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Figure 3.13. Total TGFβ2 protein in human heart MSC (A) and in 42-day avian heart cells cultured for 3, 7 and 14 days 
in media supplemented with 66 nM and 133 nM RA (X- axis).  Total amount of TGFβ2 is compared to an internal 
control and given in percent. Bars indicate the standard deviation. Statistical significance,  p<0.05.
  
Five human heart MSC lines were cultured in the presence of excess RA. In all of these cell lines 
there was a 39.8% and 44.5% increase of the total TGFβ2 in the 7-day cultures; this increase was 
highest when cells were cultured for 14 days, i.e. 79.2% and 93.3%, respectively (Fig.3.13 A).
Figure 3.14. Relative quantification of expression levels of TGFβ2 in human heart MSC cultured for 3, 7 and 14 days in 
media supplemented with RA (66 nM and 133 nM ,on X- axis). Samples from RA–supplement-free media were used as 
controls (Control).
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 These results are not in line with the those obtained from in vitro experiments with chicken 
hfr cells cultured for 3 days, where in the presence of RA, the levels of total TGFβ2 are 
significantly decreased. To explore the observed differences, two adult chicken heart cell lines were 
tested for TGFβ2 response to the presence of exogenous RA (Fig.3.13 B). The results from 3-day 
and 7-day cultures demonstrate a 20% and 50% decrease of total TGFβ2 protein levels, 
respectively. In the 14-day cultures there were  elevated levels of TGFβ2 protein, but these data are 
not statistically significant. 
 Data from real-time PCR (Fig.3.14) demonstrate 1.3-fold and 1.6-fold elevation in TGFβ2 
expression levels in human heart MSC 3-day cultures, while the increases of 1.37-fold and 1.47-
fold in 7-day cultures are not statistically significant.
 In the previous chapter (3.2.4.) we described data from Verrecchia et al. (2001) of TGFβ/
SMAD regulated genes in human fibroblast cell cultures. The same genes from each cluster used 
for avian hfr cell screening were used for screening of five human MSC cell lines cultured in the 
presence of exogenous RA for 3 days (Fig.3.15 A), 7 days (Fig.3.15 B) and 14 days (Fig.3.15 C).
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Figure 3.15. Mean fold changes in TGFβ/SMAD regulated gene expression in human MSC lines cultured for 3 days 
(A), 7 days (B), and 14 days (C) in the presence of excess RA. Bars indicate standard deviation. 
In most of the results obtained from real-time PCR screening it was difficult  to determine the effects 
of RA on gene expression due to the high standard deviations. Slight similarities between human 
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MSC and avian hfr cell culture results could be observed in the expression mean fold changes 
between TGFβ2 and FN1, the expression levels of which are decreased in the presence of RA. The 
expression of other genes is either down-regulated or not affected and mostly are statistically 
insignificant (Fig.3.15).
3.4.3. Effect of excess RA on the secretion of TGFβ2 protein in human umbilical vein 
endothelial cells
 We next looked for vertebrate endothelial cells that would be closer in their developmental 
stages to those used from the avian embryos. To further examine the interaction between RA and 
TGFβ2, we obtained human umbilical vein endothelial cells (HUVEC) from Chemicon/Millipore 
and cultured these cells for up  to 15 days in defined endothelial cell media (Endo), supplemented 
with 66 nM and 133 nM RA.
Figure 3.16. Total TGFβ2 protein in HUVEC cultured in Endo-Grow media supplemented with 66 nM and 133 nM RA 
and compared to control media without RA (100%). Cell media samples were taken every 2 to 3 days.  Days of cells in 
culture are shown on X- axis.
The results show a slight increase in total TGFβ2 protein level at day  3 (Fig.3.16); the strongest 
response to the presence of excess RA is in the sample from day 5 in media with 133 nM RA (50% 
increase above control). By day 7 the levels of TGFβ2 protein are elevated in the presence of 66 nM 
RA but not in the presence of 133 nM RA, whereas at  the day 15 there is approx. 35% elevation in 
total TGFβ2 protein.
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3.4.4. Effect of exogenous RA on the secretion and expression of TGFβ2 in human cardiac 
progenitor cells derived from embryonic stem cells
 In the studies described here we examined the role of RA in the regulation on TGFβ2 
expression and protein level in various cells to determine if the responses to RA are similar between 
species (chicken and human) and cell types (heart MSC and endothelial cells). We have observed 
that RA can be either a positive or a negative regulator in the examined embryonic and adult cells. It 
was of interest next to examine human cells from  early cardiovascular development, i.e. embryonic 
stem cells.
 Fig.3.17 illustrates the results when CD15+ cells (CPCs), were tested for their response on 
TGFβ2 in the presence of added RA. While total TGFβ2 protein concentration was very low (299 
pg/ml) in the cells grown in control media, total protein was elevated in cells grown in media 
supplemented with 100 nM RA (Fig.3.17).
Figure 3.17. Total TGFβ2 protein concentration in CPCs (dark bars) and MEFs (light bars) cultured in media 
supplemented with RA (concentrations shown on X axis) for 6 days.
Next, we tested the mRNA expression levels of TGFβ2 and FN1 (Fig.3.18). RNA from MEF feeder 
layer grown in media without RA supplement was used as control for species-specific primers; no 
transcripts were detected in real-time PCR analysis; thus the data from this analysis show human 
CPC-specific response to the presence of excess RA. Expression analysis of TGFβ2 transcripts (Fig.
3.18) demonstrate a 0.23-fold decrease of the TGFβ2 transcription in presence of RA at 
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physiological concentrations (Roos et al., 1998) and only 0.6-fold decrease in the presence of 
excess RA.
Figure 3.18. Relative quantification of TGFβ2 and FN1 expression in CPCs cultured in media supplemented with RA 
and cultured for 6 days.
 The mean fold change data from samples of media with 10 nM  RA show a 0.00072-fold 
decrease in FN1 expression, the presence of 100 nM RA results in a 0.7-fold decrease. The data 
presented here represent only  one experiment; clearly, more CPC lines must be tested to obtain 
statistically significant data.
4. Discussion
4.1. Vitamin A deficiency leads to severe cardiovascular defects in VAD quail 
embryos
 Retinoid deficiency during embryonic development causes abnormalities in organs of 
epithelial and mesodermal origin preventing the normal formation of cardiovascular system in the 
avian and mouse embryo (Heine et al., 1985; Dersch and Zile, 1993; 2004; 2010; Niederreither et 
al., 2001). It was discovered that in the avian embryo, at  the 4-5 ss during neurulation, the presence 
of RA is essential for subsequent normal development (Kostetskii et al., 1998). If RA is 
administered to the VAD embryo during this time window, the embryo is rescued and develops 
normally. The cardiovascular system abnormalities caused by a complete lack of RA are 
characterized by an absence of vascular networks and by  a ballooned, non-compartmentalized, 
randomly-positioned heart without an open inflow tract (IFT) at its posterior part (Heine et  al., 
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1985; Dersch and Zile, 1993; Zile, 2010). In vivo studies show that the basis for later cardiovascular 
defects is the failure of the  primitive heart tube to stay  open at its posterior end (inflow tract), thus 
preventing the formation of vitelline (omphalomesenteric) veins normally connecting the embryo 
with the extra-embryonal circulation (Dersch and Zile, 1993; Zile, 2004; see also Fig.3.1). The data 
from sequential steps in the formation of IFT (Fig.3.1) revealed that  in the VAD embryo 
epimyocardial and endodermal cell layers are similar to those of normal embryos and that 
endothelial cells (marked with QH1 Fig.3.1) are present within their appropriate structures. There 
is study on the effects of vitamin A deficiency  on numbers of endothelial cells and angiobalsts 
demonstrating the 40% decrease in numbers of endothelial cells within sinus venosus (IFT) area in 
VAD quail embryo at 10 ss (LaRue et al., 2004). Our data confirm the narrowing and closure of  the 
IFT in VAD embryos by stage of 10 ss, which cut off the entry for vascular links.
 Since the proliferation and differentiation in endodermal cell layers seems not to be altered, 
the defects in morphogenesis at these sites may be due to disturbances in other cellular events, e.g. a 
lack of certain molecules necessary for building the IFT. Our studies implicate an excessive N-
cadherin expression (Fig.3.2.A) in the VAD quail embryos as a likely contributor to the abnormal 
IFT formation, since the over-expression of this molecule results in abnormal vascularization 
(Romeih et al., 2009). It is also possible that an excess of N-cadherin interferes with the 
organization of IFT. It appears, that only a strictly limited physiological amount of this molecule is 
required for normal development of IFT.
 Various growth factors (TGFβ, VEGF, FGF) and and their signaling pathways are involved 
in early vasculogenesis and heart development; their interplay as well as RA regulation is essential 
for normal cardiovascular development (Poole et al., 2001; Wagner and Siddiqui, 2007a; Nemer, 
2008). 
4.2. Expression of TGFβ2 and TGFβRII is increased in the absence of RA
 In mice, at days 6.5-9 post implantation (coincides with 1-5 ss in avian embryogenesis) the 
TGFβ2 isoform is mainly  expressed in the promyocardium of the sinus venosus of the IFT  and in 
the foregut endoderm (Dickson et al., 1993). Our work demonstrates that the expression patterns of 
TGFβ2 and its receptor TGFβRII in the normal and VAD quail embryos at the neurulation stage are 
similar; and transcripts are mainly restricted to the anterior part of the embryo, including the neural 
folds and the heart forming regions (Fig.3.3); expression is present in all embryonic cell layers. 
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These observations are consistent with the data of TGFβ2 mRNA and protein localization in 
chicken embryos (Jakowlew et al., 1994). 
Our data demonstrate the over-expression of these genes due to absence of RA. The global 
expression of TGFβ2 gene is 1.7-fold increased in VAD embryos at 4-7 ss (Fig.3.2 B) suggesting 
that RA can regulate its expression. However, TGFβRII, an important component of the TGFβ 
signaling pathway (López-Casillas et al., 1991), is also over-expressed in absence of RA. This 
observation supports the hypothesis that TGFβ2 signaling is involved in RA-regulated 
cardiovascular development. The addition of antisense TGFβ2 to VAD embryo in vivo decreases 
and normalizes the levels of TGFβ2, and also normalizes the expression of TGFβRII (Fig.3.3). 
However, this finding does not prove that TGFβ2 and TGFβRII are an obligate receptor-ligand pair. 
Our data of TGFβ2 and its receptor response to the absence of RA differ from previously described 
data when the opposite process to deficiency is mimiced by addition of exogenous RA to cell 
cultures, where TGFβ2 expression is increased (Glick et al., 1989; Yoshizawa et al., 1998). There is 
also evidence of differential cell type-specific RA effect on TGFβ2 levels (Glick et al., 1991). These 
contradictory observations emphasize the complexity of the regulatory mechanisms at the pre-
receptor level of TGFβ signaling, since activation and regulation of this signaling can occur at 
various levels. The localization of TGFβ2 and TGFβRII transcripts is also in the same cardiogenic 
cell layers as the localization of the transcripts of the RA receptors RARα2, RARγ and RXRα 
(Kostetskii et al., 1998; Cui et al., 2003), strengthening the hypothesis of an interaction between 
TGFβ2 and RA signaling during early cardiovascular development.
 Our findings suggest that a negative regulation by RA of TGFb2 signaling protects the 
embryo from excessive TGFβ2 activity during critical developmental periods. While there is 
evidence that RA signaling is a negative regulator for certain malignant processes (Sun and Lotan, 
2002), the role of RA as a negative regulator of TGFβ2 in the context of normal embryonic 
development was first demonstrated only recently (Ghatpande et al., 2010; this work).
 In studies on potential downstream signaling pathways by TGFb2,we discovered that 
protein levels of pSMAD2 or pSMAD3 4 are not altered in VAD embryos, whereas Erk1/2 levels 
are increased (Ghatpande et al., 2010). Erk1/2 is a signal transduction molecule on the Ras/MAPK 
pathway. This observation suggests that TGFβ2 when elevated (as in the absence of RA), could 
transfer its signals through the MAPK pathway. In support of these observations are reports of 
TGFβ signal transduction through other than the canonical SMAD pathway, e.g. the MAPK 
pathway (Derynck and Zhang, 2003) or cross-talk between these two pathways (Lee et al., 2007; 
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Guo and Wang, 2009). However, the link between overactive TGFβ2 and overactive pErk2 during 
RA-regulated embryonic development remains to be unambiguously verified.
 In addition, preliminary work from Zile lab (unpublished) identifies other genes that may be 
involved in heart  formation and are differentially  expressed in VAD embryos. Some of the genes 
have been suggested to be linked to TGFβ signaling, e.g. the EMT process-related extracellular 
matrix protein fibronectin (Mercado-Pimentel and Runyan, 2007), which is significantly  up-
regulated in VAD embryos during 6-10 ss, the time of IFT closure, suggesting a role for ECM in 
IFT formation. Another molecule, intersectin, is also elevated in VAD quail embryos in heart 
forming region (unpublished data from Zile lab). Intersectin is a multi domain adaptor protein and 
is involved in several signal transduction pathways, especially  in the regulation of Ras induced 
activation of MAPK kinases (Adams et al., 2000).
 In summary, in our in vivo studies we have made the following observations: 1) endogenous 
RA is a critical negative regulator of TGFβ2 in vivo during early avian embryogenesis; this 
regulation occurs at the transcriptional level; 2) the elevated levels of TGFβ2 due to an absence of 
RA result  in closed heart inflow tracts thus making it impossible for extra-embryonal vasculature to 
link to the the heart tube; this demonstrates that strictly regulated TGFβ2 levels by  physiological 
levels of RA are essential for normal IFT formation which is followed by the positioning of the 
heart tube to the right side and the subsequent looping of the heart.
4.3. Effect of RA on TGFβ2, VEGF and on TGFβ/SMAD target genes in avian 
heart forming region cells in vitro
 Vitamin A deficiency and excess have profound effects on the development of the vertebrate 
embryo. These effects differ and are related to tissue-specific sensitivity to presence or absence of 
RA (Zile, 2004; Campo-Paysaa et al., 2008).
 The abnormalities observed in studies with excess RA showed remarkable similarities to 
those generated by  a lack of vitamin A, thus identifying common development pathways that are 
disrupted by an imbalance of vitamin A (Ross et al., 2000; Maden, 2001).
 In our studies of effects of exogenous RA on chick heart forming region cells (primary cell 
culture) we use two concentrations: 10 nM  RA that is close to physiological levels in plasma (De 
Ruyter et al., 1979; Eckhoff and Nau, 1990) and 100 nM that is slight excess and have been 
reported to cause some adverse effects on cardiac cell development in zebrafish (Waxman and 
Yelon, 2009). Furthermore, in our present studies other important experimental conditions must be 
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taken in account, i.e. the basic media with FBS always had a background level of RA that was near 
normal for embryonic cells (10% FBS had 0.96 nM RA and 2% FBS - 0.2 nM RA). We did not 
observe any morphological changes in cell cultures among different treatments. The experiments 
with RA antagonist  were conducted to mimic complete RA deficiency in chick heart forming region 
primary cell cultures.
 TGFβ2 is essential for the movements and formation of heart fields and cardiac crest in vivo 
during the very early embryogenesis (until 3 ss) and again later on, i.e. after 20 ss, during EMT and 
endocardial cushion formation (Table 4.1). The interplay between RA and TGFβ2 involves different 
cell types during avian embryonic heart morphogenesis. RA is required for many early 
developmental events, including vascular development regulating endothelial cells (LaRue et al, 
2004; Zile, 2004); regulation of heart asymmetry  (Zile et al., 2000; Zile, 2010); and during heart 
inflow tract formation where it appears to act  as a negative regulator of N-cadherin and TGFβ2 
(Romeih et al., 2009; Ghatpande et al., 2010; Zile, 2010).
 To address the molecular mechanisms of the interplay between TGFβ2 and RA, an in vitro 
cell culture model was needed. Such a model would enable propagation of defined subsets of cells, 
diminishing individual differences among individual developing embryos and facilitating the use of 
standard methods for evaluation of gene expression and for characterization of interactions among 
regulatory proteins. The cardiovascular marker gene expression and observation of functional 
cardiomyocyte formation in chick heart  forming region tissue and cell cultures showed that these 
explants are capable to develop and sustain the differentiation process in vitro most efficiently  when 
isolated at 3-5 ss and cultured in endothelial cell media, that promoted endothelial cell 
development.
 Addition of exogenous RA in physiological (10 nM) and excess (100 nM) concentrations 
down-regulated TGFβ2 mRNA and protein expression; this effect was more pronounced in Endo 
medium than in DMEM. Since RA dose-dependent down-regulation of TGFβ2 was paralleled at 
protein and mRNA expression level, we conclude that RA blocks TGFβ2 gene transcription.
 The TGFβ2 promoter does not contain any RA response elements (Chang et al., 2002), that 
are needed for a direct regulation of RA of its RAR/RXR complexes, thus the regulation of TGFβ2 
by RA should proceed through an indirect mechanism, involving interplay of the growth factors or 
endocrine effectors at crossroads of cell signaling and regulatory  pathways. TGFβ2 expression is 
governed by two AP-1 binding sites, two AP-2, two Sp1 and four CRE binding sites located in the 
promoter of this gene (Noma et al., 1991). It is known that RA/RAR/RXR complex can bind to 
AP-1 thus antagonizing its activity, that is necessary for induction of TGFβ2 expression (Schule et 
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al., 1991; Dhandapani et al., 2003). Recent studies of amniotic cell membrane explants reveal that 
Sp1 and liganded RAR/RXR interact physically preventing the Sp1 factor binding to promoter 
sequence (Borel et al., 2010). Further analysis of TGFβ2 promoter and DNA binding proteins are 
needed to gather specific data.
 The blocking experiments were done with Ro 41 5253 (Ro), a RA antagonist, which was 
added to the medium in >1000 fold excess over RA. These culture conditions should mimic 
complete VAD situation observed in the in vivo model. Similar to the in vivo VAD model, TGFβ2 
expression in Ro-blocked primary cell cultures was up-regulated. Due to the great excess of Ro 
over RA the maximum level of TGFβ2 up-regulation was achieved already at 0.5 µM concentration 
of the antagonist, while higher Ro doses proved to be less effective for TGFβ2 mRNA and protein 
synthesis due to possible unspecific side effects on other gene expression.
 In the studies with selected genes, that are regulated at mRNA expression level by the 
presence of TGFβ2 through conventional SMAD signaling pathway  in human cell culture 
(Verrechia et al., 2001), we observed various responses towards exogenous RA, which is down 
regulating TGFβ2 in chick embryonic cells.
 Fibronectin gene FN1 encodes an ECM protein. FN1 gene expression is down-regulated by  
RA in VAD quail embryo model (Zhou and Zile, unpublished data), in pre-somatic stage - 1 ss 
(HH3-7) chick embryo explants (Osmond et al., 1991) and in mouse embryonic fibroblast cells 
NIH-3T3 (Scita et  al., 1996). Unlike these models, FN1 mRNA production increased in presence of 
RA in in vitro avian embryonic cell culture, but  RA blocking experiments did not affect the 
expression of FN1. Undoubtedly, ECM formation in vivo ad in vitro differs substantially and further 
studies on RA/FN1 interactions should be conducted either in vivo or in 3D culture model. Since 
FN1 gene promoter does not have RARE sequences (Dean et al., 1987), its RA-dependent 
regulation is likely indirect and may proceed through pathways other than TGFβ2/SMAD signaling.
 Neogenin (NEO) is a multifunctional receptor that is related to neural tube development 
(Cole et al., 2007). Its expression in cultured chick embryo hfr cells indicates the presence of 
neuronal cell subpopulation, that may be derived from the early neuronal tube region located 
underneath the hfr of the embryo and were not dissected out during the preparation of explants used 
for our hfr cell cultures. In human cells the expression of NEO gene is regulated through TGFβ/
SMAD signaling pathway in a time-delayed manner (Verrecchia et al., 2001). We demonstrated that 
NEO gene mRNA expression in response to RA in chick primary hfr culture parallels the response 
of TGFβ2 gene mRNA expression; this effect is best seen in the cells grown in Endo medium. NEO 
is mostly related with neuronal cell lineage, therefore this response could come from neural cells 
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within hfr primary cell mixture and is not specifically related to heart  morphogenesis. The data 
from VAD quail embryo sections demonstrate that TGFβ2 is expressed in all cell layers, thus the 
elevated TGFβ2 levels could affect its target genes within other than cardiovascular cell layers. We 
suggest that in the cultured chick hfr cells NEO may be regulated by RA through a TGFβ2 and 
SMAD signaling pathway, but this regulation may not be related to heart morphogenesis. More 
detailed analysis must be done to draw conclusions, because in VAD quail embryos in vivo there 
are no changes in the levels of pSMAD2/3 protein. This must be unambiguously verified in in vitro 
system.
 The mRNA expression of the vascular endothelial growth factor VEGF-A is significantly 
elevated when exogenous RA is present in chick embryonic hfr cell cultures grown in Endo 
medium, while blocking of RA does not  alter the expression of VEGF-A in these cells 
demonstrating ambiguous mechanisms of RA actions, e.g. presence and absence. RA can induce 
VEGF mRNA expression through a mechanism that involves SP1 binding sites in the VEGF gene 
promoter (Akiyama et al., 2002; Maeno et al., 2002). RA-regulated VEGF expression involving 
TGFβ signaling is reported also in human embryonic stem cells (Sidell et al., 2010). Our data on 
RA regulation of VEGF-A gene expression in embryonic hfr cell culture corroborate previous 
assumptions that the regulation of the endothelium growth factor production by exogenous RA may 
be the molecular mechanism that ameliorates the decrease in endothelial cell numbers associated 
with vitamin A deficiency (LaRue et al., 2004). Insensitivity  of VEGF-A mRNA production to the 
blocking of RA by  its antagonist indicates that RA is not the ultimate regulator of the basal level 
production of this growth factor, although it may exert considerable regulatory  effect, at least at 
specific stages of the development.
 We have developed an in vitro model, which can be used to understand the molecular basis 
of the observed phenomena of TGFβ2 down-regulation in presence of RA. In primary cell cultures 
from the heart  forming regions of 4-7 ss chick embryos, RA supplemented in 10 nM and 100 nM 
concentration, (i) induces responses in the expression of global regulators TGFβ2 (down-regulated) 
and HoxBI (up-regulated) opposite to those observed in vivo (TGFβ2 up-regulated and HoxB1 
being down-regulated in absence of vitamin A) (Maden et al., 1996; Ghatpande et al., 2010) 
(ii) influences the expression of certain genes, that are regulated by TGFβ2 through SMAD 
signaling pathway in human cells, although not always in the same way as it is anticipated either 
from in vivo VAD models or considering other in vitro models and from the down regulation of 
TGFβ2 in our hfr cell culture; (iii) induces expression of growth factor VEGF-A mRNA, which is 
one of the key factors for differentiation of vascular endothelium; (iv) Ro 41 5253, an antagonist of 
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RA, induces up-regulation of the TGFβ2 and NEO genes, that are down regulated by  RA, but  exerts 
no statistically  significant influence on the expression of FN1 and VEGF-A genes, that  are up-
regulated by RA. Research at the molecular level is required to elucidate the mechanism.
 In summary, a cell culture model of chick embryo 3-5 ss primary  heart-forming region (hfr) 
cells was developed in Endo media in which it was determined that that this model mimics the 
effect of the negative regulation of TGFβ2 mRNA and protein expression by RA observed in the in 
vivo VAD quail embryo model. TGFβ2 down-regulation by RA takes place at the gene transcription 
level; it is indirect due to the absence of RAREs in TGFβ2 promoter region. The developed primary 
cell culture model can be used to elucidate molecular mechanisms that lead to the down-regulation 
of TGFβ2 gene mRNA expression by RA.
4.4. Effect of exogenous RA on human heart MSC, endothelial cells and early 
cardiovascular progenitor cells
 Most of the research in the field of developmental biology has been conducted using animal 
models for studying different molecular interaction mechanisms. The data from our research in 
VAD quail embryos (Ghatpande et  al., 2010) where RA acts as a negative regulator for TGFβ2, is 
similar to the data from mouse embryogenesis (Mahmood et al., 1992; 1995). Furthermore, our 
present in vitro avian cell culture data of TGFβ2 response to RA are similar to those observed in the 
avian in vivo model.
 Here we present the results obtained from in vitro cultures of human heart mesenchymal 
stem cells (MSC), umbilical vein endothelial cells (HUVEC) and early  cardiovascular progenitor 
cells (CPC).
 Elevated TGFβ2 protein and gene expression in human heart MSCs in presence of excess 
RA (66 nM and 133 nM) is not in line with the results chicken hfr cells cultured for 3 days, where 
in the presence of excess RA (100 nM), the levels of total TGFβ2 are significantly decreased. This 
discrepancy may be because the developmental stages of the cells are not similar, since the human 
cells are from adult heart, whereas chicken hfr cells are derived from embryonic explants. The data 
from 3- and 7-day cultures of 42-day chicken heart cells in presence of excess RA (66 nM  and 133 
nM) clearly demonstrated a difference between species in TGFβ2 response to the same doses of 
exogenous RA, leading to preliminary suggestion that RA-regulation of TGFβ2 differs from species 
to species and is cell-type specific. We suggest that RA regulation of TGFβ2 is at  the 
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transcriptional level since also in human heart MSCs TGFβ2 gene expression in the presence of 
excess RA mimics that of its total protein level changes in excess RA.
 The expression of six of TGFβ/SMAD regulated genes (Verrecchia et al., 2001) was 
screened in all five human heart  MSC cultures but it was difficult to determine the effects of RA on 
gene expression due to the high standard deviations. The heart MSCs were from five different 
donors that could be an explanation of individual differences among cell samples. While TGFβ2 
gene expression is increased in presence of RA, the expression of FN1 was slightly down-regulated. 
The data of FN1 correlate with results from avian hfr experiments where in the presence of excess 
RA the changes of FN1 expression levels are opposite to TGFβ2 expression levels. According to 
published data, the TGFβ/SMAD regulated genes should respond similarly  to the presence of RA. 
However, this was not the case in the gene expression changes observed here, as most of the genes 
were either insignificantly down-regulated or not altered after 3- and 7-day culturing. By day 14, 
the expression of all genes tested was decreased which is not consistent with the TGFβ/SMAD 
regulation reported previously (Verrecchia et al., 2001). One explanation could be that there is a cell 
type-specific TGFβ signaling, since the data of target genes come from human fibroblast cell 
cultures. We must conclude that due to the high variability among heart MSC donor cells, it is 
difficult to interpret these data; a greater number of samples is required to obtain statistically 
meaningful data.
 HUVEC cells were chosen to test the interaction between RA and TGFβ2 in cells from 
earlier developmental stages. In the MSCs cells from the human adult heart (Fig.3.14 A), TGFβ2 
protein was elevated in the presence of RA at day 3 of culturing, while in the HUVEC cells (Fig.
3.16), the increase in TGFβ2 protein was observed at longer incubation times and the data were not 
consistent. The differences between HUVEC and hMSC results can be explained by cell type 
differences. The mean average amount of total TGFβ2 protein from all cultured samples in human 
MSC control media (2468.7 pg/ml) is similar to HUVEC (2705.7 pg/ml) samples from all time 
points tested. Previous report from Cenni et al. (2001) shows that RA has no effect on expression 
levels of TGFβ1 in HUVEC. Our preliminary data suggest that that RA regulation of TGFβ2 is 
similar in adult  heart MSCs and human umbilical vein endothelial cells. However, more research on 
more HUVEC lines is needed to substantiate this hypothesis.
 Elevation of total TGFβ2 protein in human cardiovascular progenitor cells was observed 
using ELISA kit containing recombinant human TGFβ2. This elevation, however, seems to come 
from the mouse embryonic fibroblasts (MEFs) that are used as feeder layer for embryonic stem 
cells and CPCs. The total TGFβ2 protein levels are almost the same in media from MEFs cultured 
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alone as in media samples taken from CPC cultured on MEFs, suggesting a MEF response to RA, 
but not CPCs. The primers for TGFβ2 gene analysis were human-specific, since no transcripts were 
observed in MEF samples. Expression of TGFβ2 is decreased by  almost 80% (Fig.3.18) in presence 
of smaller RA concentration (10 nM) whereas excess RA (100 nM) leads to 35% decrease in 
TGFβ2 transcript synthesis, leading to suggestion that these cells are more sensitive to 
physiological and excess levels of RA Interestingly, the previously reported (Verrecchia et  al., 2001) 
TGFβ/SMAD target gene, FN1, responds similarly to the presence of RA. This response differs 
from our avian primary cell in vitro data. However, the observed changes of TGFβ2 gene 
expression in presence of RA at physiological levels are in line with the data from avian hfr studies 
obtained from in vivo VAD quail embryos, suggesting that RA-regulated mechanisms are conserved 
among species during early embryonic development. However, the data are insufficient and more 
cell lines need to be tested to confirm these observations. These data also suggest the CPCs as 
potential human cell model for further research of the development of the cardiovascular system in 
vitro.
 In summary, we have made the following observations: that RA regulation of TGFβ2: (i) in 
adult heart cells differs between species; (ii) is similar in adult heart MSCs and human umbilical 
vein endothelial cells; (iii) is cell type-specific and (iv) that TGFβ2 regulation by  RA is likely 
conserved among species during vertebrate early embryonic development.
 Understanding how networks of regulatory signals work during cardiovascular development 
will help  to understand the etiology of congenital cardiovascular malformations, which are the 
major birth defects (August and Suthanathiran, 2006).
 The observed interactions between TGFβ2 and RA could be tested on several disease models 
that involve elevated TGFβ2 levels. One of such is Alzheimers disease (AD). Noguchi et al. (2010) 
discovered that an upregulation of the TGFβ2 level is a common pathological feature of AD brains; 
they  suggest that elevated TGFβ2 may be closely linked to the neuronal death related to AD. 
However, the regulatory mechanisms in absence and in excess RA are different therefore this 
interplay  must be investigated in the involved cell types, since many studies in the field of cancer 
demonstrate the role of excess RA as an inhibitor of malignant cell growth through a positive 
regulation of TGFβ2 (Jakowlew et al., 2000; Singh et al., 2007)
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5. Conclusions
 The vitamin A active form at the gene level is retinoic acid (RA), a strong morphogen 
influencing vertebrate development, including embryogenesis. Deficiency  of vitamin A during 
embryogenesis manifests in abnormalities of cardiovascular development that have been 
demonstrated in several species. However, the function of vitamin A at very early  stages of  heart 
development have not been studied. In this work we have examined the interactions between RA 
and the global growth factor TGFβ2 during early heart morphogenesis. We have made the following 
novel observations:  
 
1. The vitamin A-deficient in vivo model (VAD quail embryo) demonstrates abnormal 
morphological and biochemical changes during heart development, including the closure of 
cardiac inflow tracts, and elevated mRNA levels of N-cadherin and TGFβ2. TGFβ2 transcripts 
are  localized in the heart forming regions of normal and VAD embryos.
2. Administration of TGFβ2 anti-sense to the VAD embryo results in the normalization of inflow 
tract development suggesting that TGFβ2 is involved in IFT morphogenesis. This hypothesis is 
supported by data obtained from normal quail embryos injected with TGFβ2 active protein,  that 
leads to VAD-like abnormalities in early heart development. 
3. In our laboratory in vitro cell culture system has been developed from chicken heart forming 
region cells which can be used as a base for further detailed mechanistic studies of interaction 
between RA and TGFβ2.
4. The expression level of HoxBI in vitro is elevated when RA is administered in both 
concentrations verifying the functionality of RA signaling in the primary cell culture. 
5. Importantly, our studies determined that RA acts as a negative regulator of TGFβ2 in 
cardiovascular cells in vivo and in vitro, validating the use of the cell culture model for further 
studies of the RA/ TGFβ2  interaction.
6. The target genes of TGFβ/SMAD pathway, Fibronectin 1 (FN1) and neogenin (NEO), were 
found to be altered both in the presence of excess RA and when blocking RA signaling in vitro. 
In the presence of excess RA, expression of FN1 is elevated, but blocking of RA signaling does 
not change FN1 expression. NEO is down-regulated in the presence of excess RA, while 
blocking RA signaling leads to a strong up-regulation of NEO expression.
7. The data of increased levels of VEGF transcripts in the presence of RA in our in vitro system 
correspond to the morphological and histological observations from VAD quail embryos in vivo.
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8. Cell cultures from human heart mesenchymal stem cells and from human umbilical vein 
endothelial cells demonstrated a different response in TGFβ2 mRNA expression and protein 
accumulation in response to RA compared to that observed in avian cell cultures, where there 
was a decrease of TGFβ2 mRNA and protein in the presence of exogenous RA.
9. Preliminary  results from human embryonic stem cell derived cardiac progenitor cell line (CPC) 
suggest that these cells can be used as a model system for further studies on RA and its 
regulated molecules since their responses were similar to whose obtained in avian hfr in vitro 
system. 
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6. Defense thesis
1.During early heart development (4-5 ss) the absence of vitamin A in the in vivo VAD quail 
embryo leads to an increased accumulation of TGFβ2 protein (a ligand for many signaling 
pathways) and its mRNA in the heart forming regions and subsequently  in the heart inflow tracts 
during heart morphogenesis. Strict regulation of TGFβ2 gene transcription by retinoic acid at this 
stage is necessary for normal heart development.
2.The effects of RA observed in vivo can be duplicated in the in vitro systems of avian heart 
forming cells and human early cardiovascular progenitor cells. 
 
3.The interaction of TGFβ2 and retinoic acid is time and cell type dependent. Further studies on 
molecular mechanisms and species-specific features can be conducted in either avian or human 
heart forming cells in culture. 
4.The in vitro data of the effect of RA on VEGF and in vivo observations from VAD quail embryos, 
together with data from literature showing lower numbers of endothelial cells in VAD embryos 
suggest that RA is involved in the regulation of endothelial cells during early  cardiovascular 
development.
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Appendix 1
The PCR and real-time PCR oligonucleotide sequences 
Name Sequence (5’- 3’) Product size (bp) Gene Bank ref.nr.
Chick N-cadherin F agccgacaacgaccctacag 70 NM_001001615.1
Chick N-cadherin R tggagccgcttccttcatag
Chick TGFβ2 F caataggaaaaaatacagtgggaagac 84 NM_001031045.2
Chick TGFβ2 R actgggctgttgcgactca
chick-b-actin F ctgaaccccaaagccaacag 214 X00182.1
chick-b-actin R ccagatccagacggaggatg
chick TGFb2 F cagtgggaagaccccacatc 185 X59080.1
chick TGFb2 R tgaatccatttccagccaag
chick FN1 F cgcccctaccactctgacac 175 XM_421868.2
chick FN1 R cagctctgcaacgtcctcct
chick NEO F tccggatagctgccatgact 161 U07644.1
chick NEO R tggagtccagctcaccacaa
chick HoxB1 F aacctctcgccttccctaaa 191 NM_001080859
chick HoxB1 R agctgcttggtggtgaagtt
chick VEGF F gcagagcgcggagttgtc 127 NM_001110355
chick VEGF R gtccaccagggtctcaattgtc
h b-actin F agtgtgacgtggacatccg 207 NM_001101
h b-actin R aatctcatcttgttttctgcgc
h GAPDH F gtcatccctgagctagacgg 171  NM_002046
h GAPDH R gggtcttactccttggaggc
h PGK1 F cttaaggtgctcaacaacatgg 119 NM_000291
h PGK1 R acaggcaaggtaatcttcacac
h TGFb2 F ccggaggtgatttccatcta 221 NM_003238
h TGFb2 R ctccattgctgagacgtcaa
h FN1 F ggagttgattataccatcactg 259 NM_002026
h FN1 R tttctgtttgatctggacct
h NEO F gggacccatgtctgaagctg 149 NM_002499
h NEO R tactgccgctcattggaggt 
h c-Myc F tgacctgaaagaccgaccat 181 NM_001018139
h c-Myc R gccaacctgaatgcagaagt
h b-cat F gcagaaaatggttgccttgc 135 NM_001098210
h b-cat R aaagcttggggtccaccact 
h CD44 F ggctgatcatcttggcatcc 172 NM_001001391
h CD44 R tgagacttgctggcctctcc 
h lam B1 F tccaccacagaacccaacag  193 NM_002291
h lam B1 R ggggtgttccacaggtcatt 
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Appendix 2
PCR  oligonucleotide sequences used for characterization of human MSCs
Name Sequence (5’ - 3’) Product size (bp) GeneBank reference nr.
oct4 F gtggaggaagctgacaacaa 119 NM_002701.3
oct4 R attctccaggttgcctctca
nanog F cctgtgatttgtgggcctg 77 NM_024865.2
nanog R gacagtctccgtgtgaggcat
sox2 F gtatcaggagttgtcaaggcagag 77 NM_003106.2
sox2 R tcctagtcttaaagaggcagcaaac
nestin F gccctgaccactccagttta 220 NM_006617.1
nestin R ggagtcctggatttccttcc
GATA4 F tcatctcactacgggcacag 233 NM_002052.2
GATA4 R gggaagagggaagattacgc
TGF-β1 F gcgtgctaatggtggaaac 275 NM_000660.3
TGF-β1 R cggtgacatcaaaagataaccac
CD90 F ctagtggaccagagccttcg 333 NM_006288.2
CD90 R tggagtgcacacgtgtaggt
CD105 F tgccactggacacaggataa 204 NM_000118.1
CD105 R ccttcgagacctggctagtg
β-actin F tccttcctgggcatggag 207 NM_001101.2
β-actin R aggaggagcaatgatcttgatctt
130
